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Summary
This thesis explores the potential of two prototype (‘marker’) vaccines with 
differential diagnostic capability for improved control of equine viral arteritis. 
The rational for using a sub-unit adjuvanted vaccine and a recombinant live virus 
vaccine, analysis of immune responses they induce and assessment of the 
protection against infection in experimental conditions is described and 
discussed in this thesis. Also, the development of new methods for measuring 
cytotoxic T-lymphocyte responses to EAV is described, increasing the repertoire 
of immunological assays for EAV infections. Finally, attempts to determine the 
antigenic specificity of the cytotoxic T-lymphocyte response have been taken.
The sub-unit vaccination approach developed in this project derives from the 
findings of Dr. Ewan Chirnside et al (1995a). This strategy has been developed 
further. A recombinant protein expressed in E.coli comprising the putative 
ectodomain of the large envelope glycoprotein (G l) of equine arteritis virus 
(EAV) was used as a vaccine in ponies resulting in the induction of virus 
neutralising antibody (VNAb) responses which are comparable in titre to those 
induced by inactivated whole virus vaccines. The protection afforded by this 
vaccine against virulent challenge, which correlated with the pre-challenge 
VNAh titres, was characterised by reduction of nasal virus excretion and 
viraemia.
A second ‘marker’ vaccination strategy for EAV was explored. A recombinant 
live virus containing a deletion of a neutralisation domain on Gl was constructed
by manipulations of the cDNA full length clone of EAV. A synthetic peptide 
(Peptide-1) whose sequence is contained within the deleted fragment is the basis 
of an already developed antibody capture diagnostic ELISA test for EAV. The 
deletion mutant virus (EAV-GlA) showed in vitro slightly slower growth 
kinetics than wild type EAV and when administered by the nasopharyngeal route 
to ponies these experienced an asymptomatic infection, although virus was 
recovered from blood and nasal secretions. Both inoculated ponies developed a 
discriminating antibody response which lacked the Peptide-1 antigen specificity. 
The serum VNAb response was of high titre against EAV-GlA but of low titre 
against wild type EAV. Yet, the EAV-AGl inoculated ponies were highly 
protected against virulent challenge. This novel approach shows great potential 
as a marker vaccine. Safety and duration of immunity need to be investigated. 
The structure of VNAb epitopes and effector mechanisms of immunity 
stimulated by administration of EAV-AGl deserve also attention.
The serum VNAb response that invariably develops in the infected animal lasts 
for many months or years and is believed to play an important role in virus 
clearance. However, very little was known about the cellular immunity against 
EAV due the lack of methods to evaluate these immune responses. Methods to 
detect cytotoxic T-lymphocyte (CTL) precursors in the peripheral blood of EAV 
convalescent ponies are described using a ^^Cr release cytolysis assay. Primary 
equine dermal cells, used as CTL targets, were shown to express MHC-I but not 
MHC-II, retain ^^Cr efficiently and support EAV replication. Peripheral blood 
mononuclear cells (PBMC) collected from EAV convalescent ponies that have 
been incubated with or without live EAV were used as effectors. EAV induced
PBMC cultures showed evidence for expansion and activation of lymphoblasts, 
with an increase in the CD8+/CD4+ ratio in comparison to mock-induced 
PBMC. The cytotoxicity induced by EAV stimulated PBMC was virus specific, 
showed genetic restriction, was mediated by CD8+ T lymphocytes and could be 
detected for periods between 4 months to more than 1 year post-infection. These 
findings and methods will hopefully contribute to understanding of virus-host 
interactions in horses, in particular the mechanisms of virus clearance occurring 
during EAV infection.
The last part of this project described efforts to try to identify proteins serving as 
targets for EAV specific CTL’s. Target cells transiently expressing EAV0RF7 
were used in the standard CTL assay developed during the course of these 
studies (Chapter 4). Cloning of EAV0RF7 into the mammalian expression 
vector pcDNA3 for subsequent expression in different cell lines is described. 
Whilst, expression of EAV N protein in C0S7 and RK-13 cells using plasmid 
transfection techniques was achieved, EDC’s failed to express N efficiently. 
Unlike plasmid transfection, baculovirus transduction appeared to be a suitable 
method to achieve protein expression in a high proportion of EDC. The levels of 
expression of EAV N antigen in transduced EDC, which occurred without the 
loss of their original morphology, suggested a priori that this method was 
adequate to identify CTL targets. Time and resources constraints limited the 
number of experiments performed but sufficient progress was made to indicate 
that this expression technique has good potential for examining EAV CTL 
targets.
In this research project two novel approaches have been used for the generation 
of marker vaccines against EAV and methods to evaluate cytotoxic T 
lymphocyte responses developed. The essential findings of the thesis provide 
new and interesting information about EAV vaccinology/immunology that now 
provide the basis for rational approaches to be undertaken to disease prevention.
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Chapter 1. Introduction
Equine viral arteritis is a systemic disease that affects horses, mules, donkeys and 
zebras worldwide. It was probably first described in the 19^  ^ century with the 
name of ‘pink eye’ (Clark, 1892) or equine influenza (Pottie, 1888) but the 
aetiology was unknown until 1953 when the virus was first isolated from an 
abortion and respiratory disease outbreak in Bucyrus, Ohio (Doll el a l, 1957). 
The virus was then named equine arteritis virus (EAV) for the widespread lesions 
it caused to the vascular system and since then the disease has been reported 
frequently in different parts of the world.
1.1. Equine Arteritis Virus (EAV)
EAV is a single stranded RNA enveloped virus initially classified as a member 
of the family Togaviridae (Cavanagh et a l, 1994; 1997). However, important 
advances in the molecular biology of EAV made in the last 15 years revealed that 
its genome organisation and RNA replication strategies are similar to those of 
Coronaviruses and Toro viruses and therefore these viruses have been reclassified 
in the order Nidovirales (Snijder and Meulenberg, 1998). EAV is the prototype 
of the genus Arterivirus of the family Arteriviridae that includes also porcine 
reproductive and respiratory syndrome virus (PRRSV), lactate dehydrogenase 
elevating virus (LDV) and simian hemorrhagic fever virus (SHFV).
1.1.1. Virus structure
EAV, like other arteriviruses, is an enveloped rounded virus of 50 nm diameter. 
It consists of an isometric core of approximately 25 nm, formed by a single 
protein (the nucleocapsid protein N), containing an infectious single stranded 
positive-sense RNA molecule. The envelope is acquired by budding of already 
formed nucleocapsids into the smooth endoplasmic reticulum and Golgi followed 
by release of enveloped virions from the cell by exocytosis (Wood et al., 1970; 
Magnusson et ah, 1970; Wassenaar et al., 1997). A total of six envelope proteins 
have been characterised for EAV (Gs or GP2b, E, GP3, GP4, GbOr GP5 and M) 
and PRRSV (E, GP2a, GP3, GP4, Gl or GP5 and M), whereas only three have 
been characterised for LDV (VP-3M, VP-3P and M/VP-2) and SHFV (p42, p54 
and M) (de Vries et ah, 1992; 1995a; 1995b; Snijder et al., 1999; Wieringa et al., 
2002; Mardassi et a l, 1996; Meulenberg et al, 1995b; Meulenberg et a l, 1997; 
van Nieuwstadt et a l, 1996; Wu et a l, 2001; Faaberg and Plagemann, 1995; 
Go deny et a l, 1995). The large spikes typical of coronaviruses are absent from 
arteriviruses although ring-like structures (Hylseth et a l, 1973), spicules (de 
Vries et a l, 1994) or ‘Y’ shaped formations (Magnusson et a l, 1970) have been 
observed in EAV virions projecting out of the membrane as determined by 
morphogenesis studies using electron microscopy. A typical feature of 
arteriviruses is the formation of double membrane vesicles during the first few 
hours of infection in the perinuclear region (Breese and McCollum, 1973) where 
the replicase sub-units that contain the replicase and helicase functions are also 
localised (van Dinten et a l, 1996).
1.1.2. Genome organisation, translation and virus replication 
The EAV genome consists of an infectious single stranded RNA molecule of 
12704 nucleotides excluding the poly (A’) tail. Indeed, Breese and McCollum 
(1973) were able to incorporate [3H]uridine into virus particles demonstrating 
the virus contained RNA, and Van der Zeijst (1975) showed that actinomycin D 
did not inhibit EAV replication and obtained virus after transfection of RNA 
purified from virions. The genomic RNA of EAV is polyadenylated at the 3’ end 
(van Berio et a l, 1982). At the 5’ end, the genomic RNA is believed to have a 
type I cap structure similar to that described in SHFV (Sagripanti et al., 1986). 
This structure is thought to be important for infectivity as demonstrated in 
PRRSV (Meulenberg et al., 1998).
The polycistronic arterivirus genome contains two large replicase open reading 
frames that occupy the 5’ three quarters of the RNA and a set of 7 to 10 
dowstream genes which encode the structural proteins (Snijder et al, 1999; de 
Vries et al.,1992; Meulenberg et a l, 1997; Plagemann, 1996). Each ORF has 
sequences at the 5’ and 3’ ends that overlap with neighbouring genes. In EAV, 
ORF’s la  and lb encode the replicase proteins whereas ORF’s 2a, 2b, 3, 4, 5, 6 
and 7 encode proteins E, Gs, GP3, GP4, Gl, M and N respectively. The same 
number of structural genes has been found in PRRSV. The structural nature of 
LDV ORF’s 2a (E), 2b (VP-3M), 5 (VP-3P), 6 (M) and 7 (N) has been 
demonstrated whereas the function of ORF’s 3 and 4 still remain to be 
determined. Interestingly, the SHFV genome encodes 10 putative structural 
genes (ORF’s 2a, 2b, 3, 4a, 4b, 5, 6, 7, 8 and 9) of which a structural function has 
only been assigned for ORF’s 8 and 9.
The coding regions of the arteriviruses genome are flanked by 5’ and 3’ non­
coding sequences of 156-221 and 59-117 nucleotides respectively. In addition to 
the aforementioned ORF’s, an additional ORF upstream of EAV ORFla 
encoding a hypothetical 37 amino acid peptide has been described (Kheyar et al., 
1996). Potentially this could be expressed abundantly since it is contained in the 
leader sequence shared by a set of subgenomic viral m-RNA’s. Indeed, apart 
from the messenger genomic viral RNA, six smaller subgenomic m-RNA’s are 
detected in EAV infected cells (van Berio et al., 1982; 1986a; 1986b). These 
hybridised with cDNA copies derived from the smallest of the sub-genomic 
RNA’s, RNA-7, in Northern blots (van Berio et al., 1986b) indicating that all 
subgenomic RNA molecules possess common sequences. Corroboration of these 
findings was made by de Vries et al., (1990) providing evidence as well that 
these molecules form a nested 3’ co-terminal set and contain a common leader 
sequence of 206 nucleotides at the 5’ end which is fused to the body of the m- 
RNA by the junction sequence 5’UCAAC 3’ (Fig. 1.1). This leader sequence 
derives from the 5’ terminal end of the genome. The subgenomic m-RNA’s 
contain the 3’ terminal end of the genome and extend for various distances 
towards the 5’ end. Part of the sequence of each subgenomic RNA is contained 
within the 3 ’ portion of the next larger mRNA. The existence of the nested set of 
3’co-terminal sub-genomic RNA’s has been described for other arteriviruses and 
coronaviruses (Kuo et ah, 1991; Meulenberg et ah, 1993b; Baric et al., 1983 and 
Spaan et al., 1983) and is what gives the order Nidovirales its name {nidus, latin 
for nest). These subgenomic RNA species are formed during a discontinuous 
transcription mechanism similar to that of coronaviruses (Baric et al., 1983; 
Spaan et al., 1983). In this model, transcription is initiated from the common
leader sequence at the 3’ end of a negative sense genomic RNA. The junction 
sequence could pair with any of the complementary junction sequences of the 
negative RNA strand and extend the leader to complete a subgenomic mRNA. 
However, an alternative nidovirus transcription model has been put forward by 
Sawicki and Sawicki (1995) that explains the existence of subgenomic 
replicative intermediates that are mirror images of the subgenomic mRNA’s. In 
this model, the subgenomic positive RNA strands derive from negative 
subgenomic RNA strands generated by a discontinuous synthesis of the negative 
RNA (Fig. 1.1).
All virus proteins are translated from the subgenomic mRNA’s except the 
replicase proteins encoded by ORFla and ORF lb, which derive from the viral 
genome. The translation of ORF lb requires a frame shift just before the 
translation of ORFla is terminated (den Boon et a l, 1991). The result is the 
generation of ORFla derived and ORF lab derived polyproteins of 1727 and 
3175 amino acids respectively. These are cleaved by three ORFla encoded 
proteases (Snyder et a l,  1992; 1995; 1996) yielding eight non-structural proteins 
from ORFla (nspl-8) and four non-structural proteins from ORF lab (nsp 9-12). 
The nspl and nsp2 are cleaved by internal cysteine autoprotease activities 
whereas the rest of the cleavage sites are mediated by the serine protease nsp4. 
The helicase and polymerase functions are associated with nsp 9 and nsp 10 
respectively (van Dinten et a l, 1999; 1996).
1.1.5. Stmctural proteins and antigens
1.1.3.1. The nucleocapsidprotein N
The small, basic, phosphorylated EAV nucleocapsid protein N is a protein of 12- 
14 kDa expressed from 0RF7 (Zeegers et al., 1976; de Vries et al., 1992). The 
phosphate group is probably acquired after transport of the EAV N protein to the 
nucleus immediately after translation (Timjs et al., 2002). The protein is then 
transported back to the cytoplasm where it is required for virus assembly. Its 
homologues of PRRSV and LDV are also expressed from 0RF7, whereas that of 
SHFV is derived from 0RF9. The N protein is abundantly expressed in EAV 
infected cells and constitutes approximately 40% of the virion mass. The protein 
is highly antigenic and N specific antibodies have been found in EAV 
convalescent horses (Chirnside et al., 1995b; Kheyar et al., 1997; MacLachlan et 
al., 1998). Similarly PRRSV infected pigs develop antibodies to the PRRSV N 
protein (Meulenberg et al., 1995a; Rodriguez et al., 1997). It is therefore a good 
candidate for the development of diagnostic tests. Furthermore, monoclonal 
antibodies have been produced against this antigen (Chirnside et al., 1988; 
Weiland et al., 1999).
1.1.3.2. The matrix protein M
The major envelope proteins of EAV are encoded by ORF’s 5 and 6. The non­
glycosylated M protein, encoded by 0RF6, has a molecular weight of 16 kDa 
and forms disulphide linked homodimers in EAV infected cells and heterodimers 
with the Gl protein (de Vries et al., 1995; Snijder et al., 2003). It appears that 
only the heterodimers are incorporated into virus particles. The protein has a 
short stretch of 18 amino acids thought to be exposed at the virus surface. The M
protein has been shown to be recognised by EAV post-infection equine sera 
using baculovirus or E  coli expression systems (MacLachlan et al., 1998; Kheyar 
et al., 1997). However, to date detailed epitope mapping of this protein has been 
hampered by the absence of MAb’s recognising it, in contrast to the homologous 
protein of PRRSV (Yang et al., 2000; Magar et al., 1997).
1.1.3.3. The large envelope glycoprotein Gl
The expression product of 0RF5, the large envelope glycoprotein of EAV, G l, is 
a heterogeneously glycosylated protein of 28-42 kDa which forms heterodimers 
with the protein M (de Vries et al., 1992; 1995). Its topology has not been 
resolved conclusively but the large hydrophobic domain is predicted to span the 
membrane one or three times leaving the amino-terminal end exposed at the 
surface and the carboxyterminus in the cytoplasm. EAV G l is the 
immunodominant viral antigen and its antigenic features have been studied in 
detail over the last ten years. Balasuriya et al., (1993) demonstrated that MAb’s 
with neutralisation capacity recognised a 29 kDa envelope glycoprotein. 
Subsequently it was shown that these antibodies bound at a region between aa 
99-104 in G l (Balasuriya et al., 1995a). Likewise, Deregt et al. (1994) obtained a 
panel of G l specific MAb’s, neutralising and non-neutralising, one of which was 
still reactive to a deletion mutant lacking amino acids 116 to 211. Also, 
neutralising epitopes mapping to amino acid positions 99 and 100 and 96 and 
113 were reported in a separate study (Glaser et al., 1995). Furthermore, a GST- 
fusion protein and a synthetic peptide comprising aa 55-98 and aa 75-97 
respectively reacted with EAV convalescent equine sera and induced neutralising 
antibodies after intramuscular injection to ponies (Chirnside et al., 1995a).
Pep scan analysis of the Gl protein also demonstrated that the predicted 
ectodomain of Gl is a major immunodominant antigen when EAV specific horse 
antiserum recognised strongly three synthetic 15-mer peptides encompassing aa 
75-90, 79-94 and 83-98 of G l (Kondo el al., 1997). More detailed neutralising 
epitope mapping studies using neutralisation escape mutants, neutralising MAb’s 
and field strains of EAV (Balasuriya et al. 1997) identified four regions in the G l 
ectodomain that participate in the formation of neutralising epitopes. These 
localise around amino acids 49, 61, 67-90 and 99-106. It appeared that the 
peptide 99-104 is a dominant neutralisation epitope. However, mutants 
containing a deletion encompassing amino acid 66 to 112 could still be 
neutralised by equine antisera suggesting the presence of other neutralising 
epitopes not represented by the deleted fragment that can be recognised by the 
equine immune system.
The EAVGl homologues of PRRSV and LDV (GP5 and VP-3P) are 
approximately 60 amino acids shorter than that of EAV. As for EAV, these 
proteins also interact with the proteins encoded by 0RF6, PRRSV M and LDV 
MA/P-2 (Mardassi et al., 1996; Faaberg et a l, 1995); are N-glycosylated at 2 to 
4 positions in the case of GP5 of PRRSV and at only 2 positions in the case of 
LDV VP-3P; and are targetted by post-infection sera. Neutralising epitopes map 
to the putative N-terminal ectodomain (Ostrowski et al., 2002; Wissink et a l, 
2003; L ie/a/., 1998).
It is thought that Gl / M heterodimers are implicated in virus receptor binding 
and membrane fusion since they are relatively abundant in the viral envelope, all
neutralising mononoclonal antibodies bind to the predicted Gl ectodomain and 
Gl contains a large internal hydrophobic domain. However, chimeric viruses in 
which the ectodomain of GLhas been swapped by that of LDV and PRRSV or in 
which the ectodomain of PRRSV M was substituted by that of EAV or LDV 
retained their inactivity to BHK-21 and porcine alveolar macrophages 
respectively (Dobbe et ah, 2001; Verheije et a l, 2002), suggesting G l and M are 
not the main cell tropism determinants.
L 1.3.4. Other envelope glycoproteins
Apart from the two major envelope glycoproteins an additional four have been 
identified for EAV as well as for PRRSV. The approximately 10 kDa non­
glycosylated E protein of EAV is encoded by ORF 2a (Snijder et a l, 1999). Its 
hydropathy profile suggests is an integral membrane protein with an uncleaved 
signal-anchor sequence in the central part of the molecule. Its topology has not 
been elucidated and it could span the membrane one, two or three times. Nothing 
its currently known about the immunogenicity of this protein. Its homologues in 
LDV, PRRSV and SHFV are encoded by ORF’s 2a, 2b and 4a respectively.
The ORF 2b of EAV encodes the Gs protein, a class I integral membrane 
glycosylated protein of 25 kDa which is present in virions as a sialylated 
disulphide-bonded homodimer (de Vries et a l,  1995). The protein is poorly 
immunogenic and very rarely recognised in immunoassays by equine post­
infection sera.
More recently (Wieringa et a l, 2002) it has been demonstrated that the products 
of ORF’s 3 and 4 of EAV encode structural proteins, although the data available
suggests that they represent a very small percentage of the virion mass. GP3 is a 
heavily glycosylated protein in which the signal sequence has not been cleaved 
and that can adopt a type II or type III configuration, being anchored by its signal 
sequence or at both termini respectively. The EAVGP3 protein is antigenic 
(Hedges et al, 1999) like its homologues of other arteriviruses (Faaberg et al., 
1997; Katz et al., 1995). GP4 of EAV is a type I membrane glycoprotein of 28 
kDa which is glycosylated inefficiently although it appears that only the fully 
glycosylated form of the protein is incorporated into virions. The protein has not 
been proven to be antigenic for EAV although for PRRSV, antibodies with 
neutralising capacity react with PRRSV GP4 (Meulenberg et al., 1995b; van 
Nieuwstadt et al., 1996).
1.1.4 Biological properties o f EAV.
EAV infectivity is retained at -70°C for years, at 4°C for > 75 days, at 37°C for 2 
or 3 days and at 56°C for just 20-30 minutes (McCollum, 1961). Low pH, ether, 
chloroform, sodium deoxycholate and phospholipase C inactivate EAV 
infectivity rapidly, as expected for an enveloped virus. Detergents such as Triton- 
X-100 (Zeegers et al., 1976) and Nonidet NP-40 (Horzinek et ah, 1971), and UV 
light also inactivate the virus efficiently (de Vries et al., 1996).
Monocytes, macrophages and vascular endothelial cells are the primary target 
cells of EAV in vivo and arteriviruses in general. However, while EAV can grow 
in vitro in a wide variety of cell lines, the cell tropism of other arteriviruses 
seems much more restricted (de Vries et al., 1996). Thus, EAV has been 
successfully grown in baby hamster kidney cells (BHK-21) (Hyllseth, 1969),
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African green monkey kidney cells (BSC-1) (Crawford et al, 1973), simian virus 
40-transformed equine ovary cells (EO), hamster lung (HmLu) (Konishi et a l, 
1975), canine hepatitis virus-transformed hamster tumour (HS and HT-7) 
(Shinagawa et a l, 1976), cynomolgus monkey kidney (JINET) (Konishi et a l, 
1975), rhesus monkey kidney (LLC-MK2) (Radwan and Burger, 1973 a; b), 
equine dermal cells (NBL-6) (Breese and McCollum, 1970), rabbit kidney (RK- 
13) (McCollum, 1970) African green monkey kidney (VERO C l800) (Konishi et 
a l, 1975; de Vries et al., 1993), primary equine embryonic lung (EEL) (Castillo- 
Olivares et a l, 2001). LDV grows in primary cultures of mouse magrophages, 
but other macrophage cell lines failed to support its replication (Plagemann and 
Moenig, 1992) and PRRSV and SHFV can only replicate in porcine alveolar 
macrophages and peritoneal macrophages respectively as well as in cell lines 
derived from African green monkey kidney such as MA-104, Marc-145, and CL- 
2621 (Benfield e ta l,  1992; Kim et a l, 1993 and Graved et a l, 1986a; b).
EAV infected cells present cytoplasmic vacuoles containing virus particles 
(Breese and McCollum, 1970) and they round up and detach from the tissue 
culture vessel surface allowing easy titration of virus stocks by end-point dilution 
assays (Hyllseth, 1969; van Berio et a l, 1980; Senne et a l, 1985).
1.2. Epidemiology of Equine Viral Arteritis
Various serological studies reveal that EAV has a worldwide distribution 
including reports from various parts of Europe (Akashi et a l, 1976; Burki, 1992; 
Ceccarelli et a l, 1972; Chirnside et a l, 1995; Wood et a l, 1995 de Boer et a l, 
1979; Eichorn et a l, 1995; Gerber, 1978; Hyllseth and Petterson, 1970;
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Klingeborn et al., 1991; McCollum, 1973; McGuire, 1974; Moraillon and 
Moraillon, 1978; Newton et al., 1999; Weiss et al., 1994; Wood et al., 1995), 
America (Hullinger et al., 2001; Lang and Mitchell, 1984; McCollum, 1973 ; 
McCue etal., 1991; McGuire, 1974), Asia (McKenzie, 1988; Akashi etal., 1976; 
Fukunaga et al., 1994), Africa (Himeur et al., 1975; Moraillon et al., 1978; 
Paweska et al., 1994) and Australia (Huntington et al., 1990a; b; McKenzie, 
1988; McKenzie, 1989; McKenzie, 1990). But the prevalence is variable 
between different countries and horse breeds. The ubiquitous distribution of the 
virus contrasts with the relatively few occasions that EAV related disease is 
reported. Indeed, it has been observed that asymptomatic infections are very 
common and on many instances the disease passes unnoticed, although reports of 
abortion and clinical arteritis or foal deaths due to EAV occurred in various 
outbreaks reported from Austria (Nowotny et al., 1992), Canada (Klavano et al., 
1987), Italy (Redaelli et al., 1980), Poland (Golnik et al., 1981, 1986) and 
Switzerland (Burki and Gerber et al., 1966). These have also been described in 
the USA such as those reported by Collins (1987) in a teaching veterinary 
hospital or those described in a trotting race track in Kentucky (McCollum and 
Swerczek, 1978), or in farms at Washington and Virginia in 1997 (Balasuriya et 
al., 1998; 1999a) and Pensylvannia in 1996 (McCollum 1999a). Clinical signs 
were observed too in riding schools in the Netherlands (van Gorkum et al., 1994) 
and Spain (Monreal et al., 1995), and in stud farms in Germany (Eichorn et al.,
1995), Britain (Wood et al., 1995) and France (Zientara et a l, 1995).
Susceptible equines acquire the infection via the respiratory route or venereally 
through infected semen from persistently infected stallions. Indeed, experimental
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infections and field studies have shown that aerosol transmission from 
respiratory secretions of acutely infected animals constitutes a means of 
spreading the infection to a large number of animals (Doll et al., 1957; 
McCollum and Swerczek, 1978; McCollum et al., 1971; Cole et al, 1986), but 
the efficiency of this mode of transmission varies between various epizootics. 
Epidemiological and experimental data indicate that persistently infected 
stallions play a central role in the epidemiological cycle of equine viral arteritis. 
These animals excrete virus in their semen for months or years without 
displaying any symptoms (Timoney, 1987) and can introduce inadvertedly the 
infection into naïve equine populations after mating to susceptible mares, which 
become infected by this route with an efficiency of 85-100 % (McCollum et al., 
1987; Timoney et al., 1987a, 1987b). Therefore, EAV can be easily introduced 
into stud farms via infected semen with subsequent horizontal spread by the 
respiratory route. Artificial insemination with fresh, frozen or extended-frozen 
semen from persistent shedding stallions has been proven as effective as natural 
mating for transmission of EAV infection and has been documented as the origin 
of various outbreaks of EAV (Timoney, 2002). Additionally, EAV can be 
transmitted from urine (Timoney and McCollum, 1993; Neu et a l, 1988; 
Fukunaga et a l, 1981) and other secretions and body fluids such as placenta and 
amniotic fluid from aborted foetuses (Cole et a l, 1986). Other minor sources of 
infection are through contaminated personnel and fomites (Timoney and 
McCollum, 1993).
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1.3. Pathogenesis
EAV, like all the other arteriviruses, infects primarily macrophage / monocytes 
and disseminates throughout the organism via these infected cells and probably 
also as a cell-free virus. The progression of the infection in the horse has been 
studied by analysis of distribution of viral antigen and lesions in horses sacrificed 
at different times after challenge with the Bucyrus strain and in natural infections 
(Del Piero, 2000; MacLachlan et al, 1996; McCollum, 1971; Prickett, 1973). 
These studies showed that the virus first replicates in the respiratory epithelium 
and alveolar macrophages around 24 hours post-infection and then disseminates 
to regional lymph nodes by day 3. From there systemic distribution follows via 
infected macrophages and monocytes and probably cell-free virus with viral 
antigen present in macrophages and dendrite-like cells of lymph nodes. By day 6 
post-infection the virus localizes to the endothelium and medial myocytes of 
blood vessels and mésothélium. Maximum vascular damage occurs by day 10 
post-infection and from this moment virus begins to disappear from all locations 
except the renal tubular epithelium where the virus can persist for another 2 
weeks. Normally, virus is cleared from most sites by day 28 post-infection. 
However, in an important proportion of stallions (30%-60%) the virus establishes 
a persistent infection that is localised to the genito-urinary tract (Neu et al., 1988; 
Timoney, 2002).
The pathogenicity of EAV seems to be exerted via damage of the vascular 
endothelium leading to alterations in the permeability of the blood vessels 
causing edema or in more severe cases hemorrhage. The pathogenicity is 
believed to be dependent on host factors (yet unidentified), environmental
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conditions and virus strains. In this respect, McCollum and Timoney (1999b) 
noted variations in virulence of different EAV isolates according to the severity 
of clinical signs and lesions they produce after infection, with the velogenic Buc- 
53 strain being the most pathogenic virus encountered so far. Moore et al. (2002) 
correlated the virulence of different EAV strains in horses with the virus growth 
characteristics in primary equine endothelial cells. Lymphopenia is a common 
denominator of most EAV infections, although this seems to be an indirect effect 
of the infection since lymphocytes have not been identified yet as virus targets. 
The pathological consequences of monocyte / macrophage infection and effects 
of EAV in the immune system have not been studied in detail. Arteriviruses 
cause a cytocidal effect which occurs by apoptosis and / or necrosis. Apoptosis 
during PRRSV infection, which occurs in the lymphoid tissues and testicular 
germ cells, has been suggested as an explanation for the lymphopenia observed 
in infected pigs (Sirinarumitr et al., 1998). Although the clinical and pathologic 
significance of apoptotic cell death due to EAV infection (Archambault et al.,
1999) remains to be determined, it could explain also the EAV induced 
lymphopenia in the infected equine.
The pathologic mechanism of abortion has not been clearly identified but it is 
speculated that it occurs due to a myometritis (Del Piero, 2000). Reduction of 
blood supply to the foetus due to alterations of vascular tone by inflammatory 
mediators and compression of blood vessels by edema, reduction of progesterone 
production by placenta and release of prostaglandins may all contribute to 
chorionic detachment and foetus expulsion.
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1.4. Persistence
A hallmark of arteriviruses biology is the capacity to establish persistent 
infections in the host (Timoney, 2002; Snijder and Meulenberg 1998, Graved et 
al., 1986a; b Plagemann 1996). In horses, EAV persistent infections have only 
been reported in the stallion, a condition that apparently is dependent on 
testosterone. Indeed, naturally infected persistently shedding stallions stopped 
excreting virus in semen after castration, but this can be maintained by 
administration of testosterone (Little et al., 1992). Likewise, efforts to establish 
persistent infections in colts infected before puberty have been unsuccessful 
(Holyoak et al., 1993). EAV has been isolated from vaginal swabs of mares but 
only during the acute phase of infection (Fukunaga et al., 1981). EAV appears to 
localise to cells of organs of the stallion urogenital tract during persistent EAV 
infections. Thus, virus has been recovered from the epididymis, vas deferens, 
ampulla, seminal vesicle, bulbourethral gland, prostate, urinary bladder and 
proximal urethra in persistently infected stallions necropsied between days 92 
and 148 post-infection (Neu et al., 1988). The mechanisms by which testosterone 
promotes virus persistence are not known but it is hypothesised that the 
immunological barriers operating in the male genital tract, both physical and 
functional, which are androgen dependent, prevent infection being cleared by 
effector cells of the immune system. Also, testosterone maintains accessory sex 
glands ftmctional and active, with cells able to support virus replication. These 
organs become atrophic after castration (Thompson et al., 1980).
An important aspect of EAV persistence is the behaviour of the virus as a 
quasispecies with emergence of genotypic and phenotypic variants during
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persistent infection of stallions (Hedges et a l, 1999). New variants could be 
more adapted to replicate in the respiratory tract and spread rapidly by this route 
causing outbreaks as was suggested by Balasuriya et a l (1999a). The generation 
of genotypic variants has been documented also for SHFV and LDV (Plagemann,
1996).
Alternative anatomic sites of virus persistence may exist since virus has been 
isolated sporadically from blood buffy coat samples collected on days 111 and 58 
after infection from EAV infected stallions (Neu et al, 1988) and up to day 53 
post-infection in geldings (McCollum et a l, 1994).
Other arteriviruses also establish persistent infections in their hosts. PRRSV 
persistent infection in pigs is not restricted to males. Indeed, this virus replicates 
in testicular germ cells of boars and virus is excreted in the semen of these 
animals but virus can be detected in cell culture or by RT-PCR in infected pigs, 
including females, from oropharyngeal scrappings and tonsils (Wills et a l, 1997; 
2003) up to day 251 after infection. Mice infected with LDV invariably develop 
a life long persistent infection (Plageman, 1996). The virus infects a sub­
population of macrophages that is continually renewed in the liver, spleen, lymph 
nodes and skin of the host. Also, viral RNA has been detected in germinal 
centres of lymph nodes and spleen and is associated with polyclonal activation of 
B cells (Anderson et a l, 1995). SHFV causes acute or asymptomatic persistent 
infections in patas monkeys in which the virus can be detected in the blood of 
their hosts for long periods of time (Graved et a l, 1986a; b).
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1.5. Pathology
Gross and histological lesions of experimental (Holyoak et a l, 1993; Prickett et 
al., 1973; McCollum, 1981; MacLachlan et al., 1996) and natural infections with 
EAV (Del Piero, 1997; Lopez et al., 1996; Prickett et al., 1973; Vaala et ah,
1992) have been reviewed recently (Del Piero, 2000). As a result of the damage 
to the vascular system, EAV acute infection causes, depending on the virulence 
of the isolate, generalised edema, congestion and / or hemorrhage of 
subcutaneous tissues, lymph nodes and various organs including the presentation 
of a yellowish exudate in pleural and peritoneal cavities. Aborted foetuses can be 
expelled without premonitory signs and may be either autolysed or well 
preserved.
Microscopic lesions occur primarily in small arteries and venules and lymphatics 
of almost all organs, ranging from perivascular edema with a discrete 
lymphocytic infiltrate and endothelial cell hypertrophy to, in more severe cases, 
loss of endothelium, fibrinoid necrosis of the tunica media accompanied by an 
abundant inflammatory infiltrate in the perivascular space and presence of 
thrombi in the lumen of capillaries. The virus antigen is present in blood vessels 
in endothelial cells, myocytes, pericytes and endothelium associated 
macrophages. In the lungs, EAV infection may cause an interstitial pneumonia 
characterised by macrophage infiltrate and hyperplasia or hypertrophy of 
pneumocytes with virus antigen present in both these cell types. EAV infected 
lymphoid tissues present necrosis, edema and slight hemorrhage with histiocytic 
erytrophagocytosis with viral antigen in macrophages and stromal dendrite-like 
cells. The intestine may present distension of submucosal lymphatics of the large
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intestine with necrosis of the lamina propria. EAV antigen is present in 
enterocytes. Kidneys may be severely affected presenting tubular necrosis, 
lymphocytic interstitial nephritis, glomerular tuft disorganisation and 
hypercellularity. Viral antigen may localize to tubular epithelial cells, glomerular 
endothelium and mesangial cells. Skin may be affected as well, presenting 
dermatitis and thrombosis associated with vasculitis. The central nervous system 
is rarely affected.
In the aborted foetus the lesions are normally mild and are only detected 
occasionally being perivascular lymphocytic infiltrate and interstitial pneumonia. 
Antigen can be localised in allantochorion, thymus epithelium, splenic reticular 
cells, endothelial cells of blood vessels and enterocytes.
1.6. Clinical signs
Symptoms of equine viral arteritis vary widely in severity and range of 
symptoms displayed by affected animals. This variability depends on the virus 
strain, environmental factors, age, breed and immune status of the host (Timoney 
and McCollum, 1993). Thus, infected horses may or may not present any 
combination of the following clinical signs: fever (which may last up to 6 or 7 
days and reach up to 41°C); depression; lethargy; anorexia; weakness; congestion 
or petechiation of mucosal membranes; palpebral, periorbital or supraorbital 
edema; conjunctivitis; edema of mammary glands, prepuce, ventral abdomen and 
legs; urticarial skin rash; ataxia; respiratory distress; rhinitis with serous nasal 
discharge; diarrhoea and abortion in the pregnant mare. The range of clinical 
signs vary between outbreaks and even between individuals in the same 
outbreak. The breed appears to be an important factor in determining what
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symptoms can be displayed by the infected animal. It is worth noting that 
although susceptibility to infection is the same for Standardbreds and 
Throroughbreds, clinical disease is less frequently reported in the former, which 
is an interesting fact considering the high sero-prevalence in this breed. 
Serosurveys in US and Australia for example demonstrated that 60-90% of 
Standardbred stallions and mares are positive compared to only 2-3% of 
Thoroughbreds (McCue et al., 1991; Huntington et al., 1990a; b). Furthermore, 
experimental infection in donkeys with a moderately virulent strain such as 
Kentucky-84 failed to induce significant clinical signs (McCollum et al., 1995) 
suggesting the genetic background of the host might play a role in pathogenicity. 
The virus strain is a factor determining the outcome of the infection as noted in 
the pathogenesis section. McCollum and Timoney (1999b) summarised the 
severity of clinical signs induced by different virus isolates. Thus, the VB-53 
strain, derived from the original 1953 Bucyrus outbreak by serial passages in 
horses, produced severe signs of disease. Others like the KY-84, ARIZ-87, Nebr- 
89 and 111-93 strains produced moderately severe signs, whereas KY-63, PA-76, 
KY-77 and the vaccine strain ARVAC produced sub-clinical infections. 
Similarly, host factors and virus strain appear to be important in determining the 
outcome of SHFV infection. Macaques are severely affected displaying a 
hemorrhagic syndrome which is often fatal, whereas patas monkeys experience 
mild and subclinical chronic infection or an acute infection depending on the 
strain they are infected with (Graved et a l, 1986a).
Infection of pregnant mares can result in abortion, which has a serious economic 
impact for the horse breeding industry. It usually occurs 10-33 days post-
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infection and can occur without the mare displaying any clinical signs (Timoney, 
2002). Abortions have been reported in mares between 3 to 10 months of 
gestation. Mares do not appear to suffer fertility problems after EAV infection 
but stallions experience a reduction in the quality and quantity of the sperm 
during the acute phase of the disease but no fertility problems have been 
observed in persistent carrier stallions (Timoney, 2002). A proportion of stallions 
become chronically infected with EAV after the acute phase and can continue to 
excrete virus in the semen for months or years without displaying any signs of 
disease. The virus is excreted in the sperm rich fraction.
1.7. Diagnosis
Due to the asymptomatic nature of many natural infections and the fact that 
several of the clinical signs which may be presented are non-specific, it is always 
necessary to confirm suspected EAV cases by the laboratory.
1.7.1. Virus detection
Virus isolation from clinical specimens has been performed successfully using 
various cell lines such as LLC-MK2, Vero, BHK-21 and primary equine dermal 
cells, but it appears that the most sensitive cell line and the most commonly used 
is RK-13 (Timoney, 2000). It appears that the passage number affects the 
sensitivity of this particular cell line with the technique being more successful 
when the cells are of low passage. Clinical specimens can include heparinised 
blood, serum, nasal swabs and conjunctival swabs collected during the acute 
phase of the infection, homogenates of various tissues, in particular lymph nodes, 
when biopsy samples are available and placental tissues and fetal fluids from
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abortion cases. Also, virus isolation can be attempted from semen samples of 
persistently infected stallions. Confirmation of the presence of the virus in the 
clinical sample is made by observation of CPE in cells, which is characterised by 
rounding up and detachment from the vessel surface. Isolations have been 
successful with or without using a carboxymethylcellulose overlay (Timoney,
2000). Sometimes the CPE is not evident after the first passage and two or three 
blind passages are necessary before considering a sample negative. This is 
applicable in particular to semen samples. Identification of the isolates is made 
by a one-way virus neutralisation test, RT-PCR or by immuno-staining using 
monoclonal or rabbit polyclonal antibodies specific for EAV antigens, eg G l and 
N (Balasuriya et al., 1993; 1995a; Glaser et al., 1995; Deregt et al., 1994; 
Weiland et al., 1999) as exemplified in a recent study (Balasuriya et al., 2002b). 
Antibodies with these specificities have been used successfully to confirm the 
presence of viral antigen in tissues (MacLachlan et al., 1996; Wada et al., 1994; 
Lopez et al., 1996). Isolation of EAV from clinical material is not always 
possible and is time consuming, in particular for semen samples. Failures to grow 
the virus from samples collected during the acute phase of the disease have also 
been reported (Monreal et al., 1995). Detection of persistently infected virus 
shedding stallions can also be made indirectly by test-mating. The suspected 
stallion is mated to two seronegative mares on two consecutive days and 
detection of a rise in VNAb titre of the mares is taken as an indication of the 
shedding status of the stallion. These method, however is laborious and 
expensive and results are not available for at least 21 days.
22
Due to these inconveniences, molecular diagnostic methods have become 
increasingly popular in the last 10 years for the detection of EAV from clinical 
samples. The potential of these techniques for EAV diagnosis was demonstrated 
by Chirnside and Spaan (1990) who amplified in a single round RT-PCR 
reaction, single-stranded cDNA fragments from three conserved regions of the 
EAV genome. This technique had a sensitivity to detect 60 PFU / 100 pi from 
EAV positive semen samples. Since then, modifications of these procedures and 
new developments on PCR based diagnostic techniques have been reported. St 
Laurent (1994) compared the sensitivity of various primer pairs and obtaining 
best results with primers from the ORF lb region and reached a sensitivity of 2 
and 20 TCID50 of virus per lOOpl of culture fluid and semen respectively. The 
introduction of nested amplification procedures using 0RF7 specific primers 
(Belak el a l, 1994) improved the sensitivity of virus detection by RT-PCR and 
even traces (<0.007 PFU / pi) of EAV could be detected from semen and other 
clinical samples. The value of molecular diagnostic methods has been 
documented further (Gilbert et al., 1997; Sekiguchi et al., 1995; Ramina et a l, 
1999). More recently the introduction of real-time PCR methods to molecular 
diagnosis of viral diseases, which are capable of monitoring the progress of the 
PCR reaction, has enabled the quantification of the viral load in the samples and 
facilitated high sample throughput minimising cross contamination (Leuteneger,
2001). In these methods, an oligonucleotide probe labelled with a fluorogenic 
dye and a quencher molecule, anneals to the target DNA in a position between 
the amplifier primers. As the reaction progresses, the 5’-3’ nuclease activity of 
the thermostable polymerase cleaves the dye producing a fluorescent signal 
which is proportional to the amount of PCR product. A real-time TaqMan
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diagnostic test for EAV has been described recently (Balasuriya et al., 2002b) 
capable of detecting 200 copies of viral RNA from semen samples and tissue 
culture grown virus.
1.7.2. Serological diagnosis
Retrospective diagnosis of EAV infection is made by detection of virus specific 
antibodies in serum from convalescent horses. Early serological diagnostic 
methods were based on plaque reduction neutralisation assays (Burki, 1965; 
Hylseth, 1969; McCollum, 1970) and complement fixation tests (Fukunaga and 
McCollum, 1977; Fukunaga et al., 1993). The former assays, although sensitive 
and specific, are laborious and not suitable for screening of large numbers of 
samples and therefore they are not routinely used today. Complement fixation 
tests using live virus antigen and formalin inactivated antigen have proved useful 
for diagnosis. These are less sensitive than virus neutralisation tests and it 
appears that CF antibodies disappear rapidly from serum after infection. These 
observations have been perceived as a drawback of the CF test for diagnosis of 
EAV, however this tests could be useful for detection of recent infections.
By far, the most widely used serological test used today and the one that is 
prescribed for international trade by the Office International des Epizooties 
(OIE), is the virus neutralisation test performed on microtitre plates as described 
by Senne et al. (1985). This test is best performed using RK-13 as indicator cells 
and guinea pig or rabbit complement to enhance test sensitivity. Virus 
neutralising antibodies (VNAb) are detectable in equine serum as early as day 7 
post-infection and persist for months or years. Therefore it is necessary to take
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acute and convalescent serum samples to diagnose recent EAV infections using 
this test. The test, although widely used and suitable for large sample screening 
and automation, can present problems in its performance and discrepant results 
have been obtained by different laboratories. This problem was recognised and 
addressed by the EAV OIE reference laboratory in Europe through an 
harmonisation programme on diagnostic procedures for EAV to identify the 
sources of variability of results produced by various laboratories (Edwards el a l, 
1998). The two main factors identified affecting test variability were the use of 
rabbit or guinea pig complement and the virus strain. The CVL-Bucyrus strain, 
as held by the European EAV OIE reference centre (CVL, Addlestone, Surrey, 
UK), was found to increase the sensitivity of the test.
Due to the inconveniences of the VN test, alternative diagnostic procedures have 
been investigated. Enzyme-linked immunosorbent assays (ELISA) using antigen 
preparations derived from tissue culture grown virus have been developed (Lang 
and Mitchell, 1984; Cook el a l, 1989) and used in serosurveys, but in both cases 
false positive reactions occurred due to antibodies directed against tissue culture 
components present in sera of horses vaccinated with tissue culture derived 
preparations. Diagnostic ELISA procedures for EAV were further refined by the 
use of EAV N and Gl antigens expressed in E  coli as recombinant glutathione-S- 
transferase (GST) proteins and used as the antibody capture component of the 
procedure (Chirnside et a l, 1995a; c). The GST-Gl (aa 55-98) based ELISA 
presented sensitivity and specificities of 99.6 % and 90.1 % respectively when 
compared to the VN test indicating that it is a useful diagnostic tool for primary 
screening of samples. Some of the field samples tested positive by ELISA but
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negative by the VN test, but similarly sera collected from horses vaccinated with 
the killed vaccine showed a higher proportion of positives by ELISA than VN 
test, suggesting that the discrepant results could be due to higher sensitivity of 
the ELISA test. One of the inconveniences of the use of GST fusion proteins as 
antibody capture antigens was that some sera recognised this antigen non 
specifically. Thus, other Gl based antigens not comprising the GST molecule 
were evaluated as diagnostic antigens (Nugent et ah, 2000) in comparison to the 
GST-Gl protein. These studies demonstrated that a G l derived synthetic peptide 
(aa 81-106) conjugated to ovalbumin presented less background reactivity than 
the other two antigens when used in an ELISA and that using a panel of 800 sera 
the G l-O VA ELISA gave sensitivity and specificity values of 96.75 % and 95.6 
% respectively. Similar tests based on G l derived peptides have been used 
(Kondo et al., 1998). Alternatively, baculovirus expressed N, M and G l proteins 
have been demonstrated to be useful diagnostic tools either in immunoblotting 
(MacLachlan et al., 1998; Kheyar et al., 1997) or ELISA tests (Hedges et al., 
1998).
1.8. Immune responses to EAV infection
All the knowledge about the immune response to EAV, prior to studies of this 
thesis, was concerned with the development of virus specific antibodies which 
can be measured by VN test, CF test or ELISA. Experimental infections indicate 
that neutralising antibodies in serum appear within the first week after infection 
(Fukunaga and McCollum, 1977; Fukunaga e/a/., 1981; McCollum, 1969, 1970, 
1986; Paweska et al., 1995) peaking on the second or third week and remain 
usually at high levels for months or years. These findings obtained from
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experimental studies are confirmed by field data showing that horses in endemic 
areas maintain a high antibody titer over years, although this could be due to 
repeated infections as antibody titers correlate with the age of the animal (Burki 
et al., 1992). Likewise, antibodies can be detected by ELISA soon after infection 
and are still detectable a long time after. Several data indicate that VNAb’s play 
an important role in protection against and recovery from infection. Thus, the 
presence in serum of VNAb coincides with clinical recovery in experimentally 
infected animals (Fukunaga et al., 1981); passively acquired maternal antibodies, 
which last between 2 to 8 months in foals (McCollum, 1976; Hullinger et al., 
1998) prevented or moderated EAV infection; and horses vaccinated with the 
formalin inactivated vaccine show various degrees of protection which correlated 
to the VNAb at the time of challenge (Fukunaga et al., 1990, 1992). Infection 
with EAV results in a long-lasting, if not life-long, immunity. However, although 
recovered horses do not show signs of disease, they are rarely protected from re­
infection, and sterile immunity is difficult to achieve in every circumstance with 
either inactivated or live vaccines (Doll et al., 1968; Harry and McCollum, 1981; 
McCollum 1969a and 1969b, McCollum et al., 1986, 1987; Fukunaga et ah, 
1990; 1992; 1997). The mechanisms by which EAV specific antibody neutralises 
virus infectivity were addressed by three studies (Radwan and Burger, 1973a; b; 
Radwan and Crawford, 1974) showing this was mediated by physical 
interference of virus entry at high antibody concentrations and lysis of antibody 
coated virions by complement.
To date, very little is known about cell-mediated immune responses against 
EAV. In contrast, cellular immunity has been studied in other equine viral
27
infections like equine influenza, equine herpesvirus and notably equine infectious 
anemia contributing to gain further understanding of their pathogenesis and 
immunity. Thus, CTL precursors have been demonstrated in blood of equine 
influenza infected ponies after secondary stimulation in vitro in the presence of 
low concentrations of exogenous IL-2 (Hannant and Mumford 1989). Similarly, 
CTL assays have been developed to study EHV-1 immunity (Allen et ah, 1995) 
demonstrating that MHC-I restricted CD8+ T lymphocytes could be detected 
from the peripheral blood of convalescent horses and probably play an important 
role in controlling EHV-1 infections. This assay was modified later (O’Neill et 
al., 1999) to determine the frequency of CTL precursors in peripheral blood 
demonstrating that high CTL precursor frequencies increase in ponies after 
infection with EHV-1. Equine infectious anemia virus infections have been the 
subject of extensive cellular immunology studies and methods to assess CTL 
responses and lymphoproliferation assays are well developed (McGuire et 
a/., 1994; 1997; 2000; Zhang et al., 1998; Lonning et a l 1999a; 1999b; 
Hammond et a l 1997; 1998). The role of CTL’s in control of virus infection was 
suggested after finding that activated CD8+ T lymphocytes could be detected in 
blood of EIAV infected horses and disappear from the circulation once the initial 
virus replication and plasma viraemia cease (McGuire et al., 1994). However, 
CTL memory cells can still be detected from these animals, with Env or Gag/Pr 
proteins identified as the predominant CTL targets recognised. Fine mapping of 
viral protein targets for CD4+ and CD8+ CTL lymphocytes demonstrated that 
proteins p i5 and p26 from the Gag viral protein contain peptides frequently 
recognised by EIAV infected horses opening the possibility of designing 
synthetic peptide vaccines against this disease, although it was also demonstrated
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that it is unlikely that all horses recognise the same CTL peptide antigens due to 
differences in MHC-I haplotypes.
Similarly, immunological research of other arteiiviruses has progressed more 
rapidly than that of EAV and, in particular for PRRSV and LDV, aspects of 
humoral, cellular and innate immunity have been addressed. Thus, pigs infected 
with PRRSV develop VNAb’s after infection but the kinetics are somewhat 
different to those described in EAV. These VNAb’s do not appear in serum until 
4 weeks post-infection, although virus specific IgG are readily detectable by 
ELISA by day 7 post-infection (Murtaugh et al., 2002). Cellular immune 
responses have been demonstrated in PRRSV infections in pigs and a role in 
final virus clearance can be attributed to these responses. Thus, Samson et al. 
(2000) observed an increase in CD4- / CD8+ T lymphocytes in lungs of PRRSV 
infected pigs, PRRSV-specific T-lymphoproliferative responses have been 
detected in blood 4 weeks after infection (Lopez Fuertes et ah, 1999) and IFN-y 
secreting T cells have been detected in lungs, lymph nodes and PBMC of 
PRRSV infected pigs (Lopez Fuertes et al., 1999). However, persistent infections 
occur and pigs finally eliminating virus from oropharynx up to 150 days after 
infection have been observed. The mechanisms of immune evasion have not been 
elucidated for PRRSV but the findings of Suradhat et al. (2003) in peripheral 
blood collected from PRRSV infected pigs demontrating an upregulation of IL- 
10 expression suggest that the virus might utilise the immunosuppresive effects 
of this cytokine to avoid an effective cellular immune response that would have 
otherwise cleared the infection faster. Consistent with this hypothesis is the 
observation that the frequency of IFN-y secreting cells in PRRSV infected pigs
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ranged from 50 to 100/10^ PBMC at 13 weeks post-infection or at 8 weeks post­
vaccination whereas frequencies > 400 ! \&  PBMC have been observed just 2 
weeks after administration of a pseudorabies vaccine (Murtaugh et al., 2002). 
Indications of a protective role for cytotoxic T lymphocytes in arterivirus 
infections have been obtained indirectly by experimental infection studies 
performed with SHFV in monkeys. Persistently infected patas monkeys can clear 
a subsequent infection with a different strain that is not neutralised by sera from 
these monkeys (Gravell et al., 1986a). In contrast, LDV infection of mice 
induces a CTL response that has been reported to disappear by day 30 post­
infection (Even et al., 1995) or that persists up to day 250 post-infection (van den 
Broek et a l, 1997) which cannot prevent the establishment of a life-long 
persistent LDV infection. This virus seems to also evade the antiviral actions of 
innate immune defense mechanisms mediated by NK cells which become 
activated, showing increased expression of IFN-y and cytolytic activity, but 
failed to alter the early and rapid LDV replication (Markine-Goriaynoff et a l,
2002). Another example of arterivirus interference of natural immunity is 
provided by the fact that IFN-a, which inhibits in vitro growth of PRRSV, is not 
produced during PRRSV in vivo infection (Albina et a l, 1998) and that PRRSV 
superinfection of coronavirus infected macrophages prevent these from 
producing EFN-a.
1.9. Current vaccines for Equine Viral Arteritis
1.9.1. Equine antiviral vaccines
Induction of immunity against viral diseases by traditional vaccination protocols 
is based in general in the inoculation of a virus which has been attenuated by
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repeated passage in cell culture or laboratory animals, or by intramuscular 
injection of a virus inactivated by physical (usually high temperature) or 
chemical (formalin, p-propiolactone) methods and often formulated with an 
adjuvant.
As with other viral diseases of humans and other domestic animals, vaccination 
has often contributed to improve the health of horses worldwide. For example, 
inactivated vaccines were first developed to prevent equine influenza and have 
been used extensively for more than 30 years. These vaccines are formulated 
with oil or polymer adjuvants such as carbopol (Wood et al., 1983; Mumford et 
al., 1994b), or more recently with the adjuvant Quil A to form 
immunostimulating complexes (ISCOM’s) (Mumford et al., 1994) and provide 
different degrees of protection against infection and disease, which correlated 
with the pre-infection antibody levels measured by single radial hemolysis 
(Wood et al., 1983; Mumford et al., 1988). However, the antibody response is 
short-lived and frequent revaccinations are required to sustain an acceptable 
degree of immunity. Antigenic variation is another factor affecting the efficacy 
of vaccination procedures for equine influenza and it is important to update the 
antigenic content of the vaccines by incorporating the strains currently 
circulating in the field. Modern approaches for vaccination against equine 
influenza try to mimic the immune responses of natural infections, which confer 
long term protection which is not dependent on circulating antibody. Thus, cold- 
adapted live influenza vaccines have been studied and shown to have great 
potential for prophylaxis against this disease (Youngner et al., 2001). Also, the 
growing understanding of the mucosal immune system (Hannant et al., 2002) 
and the demonstration of a mucosal immune response following natural infection
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(Nelson et al., 1998) directed research towards mucosal vaccination. Thus, 
intranasal vaccination with inactivated equine influenza virus and the mucosal 
adjuvant CTB (the non-toxic B chain of cholera toxin) induced virus-specific 
IgA and neutralising antibody in the nasopharynx as well as serum IgG (Hannant 
e ta l,  1999).
EHV-1 induced respiratory disease and abortion has been prevented by using live 
vaccines which were derived from the hamster adapted strain (Rac-H strain) 
which was subsequently passaged in equine cells (Mumford and Hannant, 1993). 
Live vaccines, used extensively in Europe and America, were useful in 
preventing abortion but reports of posterior paresis in horses vaccinated with 
attenuated EHV-1 vaccines (Liu et al., 1977) indicated that virulence could be 
restored. Due to the difficulties in obtaining a safe attenuated vaccine vaccine 
research focused on the development of inactivated EHV-1 vaccines. Early 
studies with formalin inactivated EHV-1 vaccines formulated with complete 
Freund adjuvant demonstrated the potential of this strategy (Thompson et al., 
1978). However, this adjuvant is unsuitable for use in horses and killed vaccines 
formulated with other adjuvants did not prevent completely clinical signs or virus 
excretion. Nevertheless, inactivated vaccines dominate the market and there are 
reports that their use in a wide scale reduced the number of abortions due to 
EHV-1. These vaccines often include inactivated EHV-4 virus. Modern 
vaccination strategies for EHV-1 and EHV-4 infections include the use of sub­
unit vaccines, often formulated as ISCOM’s (Cook et a l, 1990; Hannant et a l,
1993), use of thymidine kinase deletion (TK ) mutants (Cornick et a l, 1990) and 
recombinant vaccinia virus encoding single EHV-1 proteins (Guo et a l, 1989;
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1990), which has served to elucidate the protective role of individual virus 
components.
Prevention of African Horse Sickness has relied upon the use of live attenuated 
vaccines, by virus adaptation in mouse brain or in tissue culture. These vaccines 
are effective for protection against homologous strains but concerns have been 
raised about their safety. Thus inactivated vaccines have also been developed 
(vanDijk, 1999).
Other examples of conventional vaccines for horses are those developed for the 
prevention of arboviral encephalitides caused by members of the family 
Flaviviridae such as Japanese encephalitis virus or West Nile virus (Monath, 
2001) or by members of the family Togaviridae such as Eastern equine 
enchephalitis, Venezuelan equine encephalitis and Western equine encephalitis 
(Ostlund, 2000). Inactivated vaccines are generally preferred and these vaccines 
are prepared by growing the virus in tissue culture or mouse brain which is 
subsequently inactivated with formalin or monoethylamine.
1.9.2. Vaccines fo r  EAV
Available EAV vaccines have been developed by classical methods. Currently 
there are two commercially available vaccines for the prevention of equine viral 
arteritis. The live attenuated vaccine was developed in the early sixties when 
techniques to cultivate EAV in tissue culture were established (McCollum, 
1961). The virus was passaged serially in primary horse kidney cells (HK) and it 
was not found avirulent until passage 46. The virus was passaged further in HK
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cells, primary rabbit kidney cells (RK) and equine dermal cells to optimise the 
safety and immunogenic properties of the virus for use as a vaccine. Thus, 
modified viruses with different passage histories have been used in different 
studies to evaluate these two properties. Most viruses studied were passaged 131 
times in HK cells followed by 80 or 111 passages in RK cells. The last versions 
of the modified virus had 10, 16 or 25 extra passages in equine dermal cells. The 
commercial live vaccine Arvac is HK-131 / RK-111/ ED-24 passage virus.
It has been shown consistently over the years that inoculation of horses with 
tissue culture passaged viruses induce a transient leucopenia and mild febrile 
responses (Doll et al., 1968; McCollum 1969; McCollum 1981; Harry and 
McCollum 1981; McColluml986; Fukunaga etal., 1981; McKinnon etal., 1986; 
Timoney et al., 1988). Furthermore, virus has been detected in the blood of 12 
out of 19 (Timoney et al., 1988) and in 4 out of 9 (Fukunaga et al., 1981) horses 
inoculated with the live vaccine, and from cervical lymph nodes of every animal 
up to day 8 post-vaccination (McCollum, 1981). However, these results contrast 
with those of McKinnon et a/.(1986) who failed to detect virus from the buffy 
coat from a group of 16 vaccinated stallions. Isolations from nasal and rectal 
swabs have also been reported (Fukunaga et al., 1981). The virus titres of the 
vaccination isolates were generally very low and considered insufficient to result 
in aerosol transmission. Indeed, earlier studies by Doll and colleagues (1968) 
showed that seronegative ponies in contact with vaccinated horses failed to 
develop an immune response and that five sequential passages in horses of the 
vaccine virus failed to restore pathogenicity. The vaccine virus is considered safe 
for use in stallions since these animals do not excrete virus in semen and no
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alterations in fertility have been observed (Timoney et al., 1988). In contrast, its 
use in the pregnant mare is not recommended since earlier attenuated versions 
inoculated into foetuses in utero induced abortion and virus could be isolated 
from various foetal tissues (Doll et ah, 1968). More recently, Moore et al. (2003) 
described a virus with an identical sequence to the modified Bucyrus vaccine 
strain that was derived from an aborted fetus whose dam was vaccinated a few 
days earlier with the live vaccine.
The immune responses following vaccination are characterised by appearance in 
serum of VNAb which are of low titre and can decline rapidly (Fukunaga et ah, 
1981; McKinnon et al., 1986; Timoney et al., 1988) and therefore revaccination 
is recommended to sustain a protective degree of immunity. The anamnestic 
response after challenge is very good and clinical protection and reduction of 
duration of viraemia and virus nasal shedding against challenge has been 
demonstrated even after several months post-vaccination. However, sterile 
immunity is not always achieved even in efficacy studies where ponies were 
infected shortly after vaccination. Thus, horses challenged at 3, 6, 12, 18 and 24 
months after vaccination with the HK-131 / RK-111/ ED-16 virus showed mild 
or no clinical signs, but challenge virus was recovered from the nasopharynx of 
almost all vaccinees and also on various occasions from the buffy coat 
(McCollum et al., 1986). In another study, mares infected with semen from a 
persistently shedding stallion 19 days after vaccination with Arvac were 
clinically protected against equine arteritis but displayed febrile responses and 
virus was isolated from the nasopharynx and from the buffy coat for a few days 
(McCollum et al., 1988). Similar results were obtained with horses challenged 8 
weeks after being immunised with lyophilised preparations of HK-131 / RK-111
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/ ED-16 virus (McCollum et ah, 1981). These apparent drawbacks have not 
prevented the use of Arvac successfully for the control of EAV in the states of 
Kentucky and New York (Timoney and McCollum 1988; Timoney, 1992). 
Prevention of PRRSV by use of a live modified vaccine has proved problematic 
since the vaccine virus could be excreted and transmitted to non-vaccinated 
animals giving rise to new genetic variants restoring virus pathogenicity 
(Oppriesnig et al., 2002).
The discussed drawbacks of the EAV live vaccine, stimulated efforts to develop 
an inactivated vaccine which could be more suitable in non-endemic countries. 
Polyethylene glycol concentrated virus, produced in an equine dermal cell line 
and subsequently inactivated with 0.1 % formalin was demonstrated to be 
immunogenic in horses after two intramuscular inoculations in the absence of 
adjuvant (Fukunaga et al., 1984). The animals receiving two doses 4 weeks apart 
develop VNAb titres as high as 1280 and 5120 one week after the second dose 
and were still seropositive (VNAb titres of 40 and 80) six months later. It was 
demonstrated in later studies that the duration of immunity, assessed by VNAb 
titre in serum, was improved by supplementary administration of the vaccine 
carried out 2 or more months after the basal dose regime (Fukunaga et al., 1990). 
Clinical protection against challenge in these horses appeared to depend on the 
antibody titre at the time of challenge rather than on time after the last 
vaccination and it was concluded that the mean protective dose was 1: 43 and 
that 1: 80 was the 100% protective dose. This vaccine could be useflil to prevent 
the carrier state since horses challenged two weeks after vaccination presenting 
VNAb titres > 1; 80 did not develop a viral infection of the reproductive tract
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(Fukunaga et al., 1992), and to prevent disease following venereal infection 
(Fukunaga et al., 1997) and EAV abortion (Fukunaga et al., 1996). A 
commercial inactivated vaccine (Artervac, Fort Dodge) is available in the UK 
although very limited data about efficacy and duration of immunity exists. The 
vaccine claims to stimulate VNAbs after two doses but some field studies and 
experimental observations showed that detectable titres are not achieved after 
three or more inoculations (Castillo-Olivares et al. unpublished observations; 
Cardwell et al., 2002).
1.10. Control of Equine Viral Arteritis
As with many other diseases of domestic animals control relies on combining 
serological surveillance, vaccination and sound animal management practices. 
For EAV, special emphasis is put on prevention of the carrier state, detection of 
persistent shedding stallions and prevention of EAV induced abortion. However, 
the policies to successfully achieve this goal vary between different countries, 
these differences motivated in great part by the differences in disease incidence 
and seroprevalence. Thus, the American Horse Council Protocol on EAV base its 
recommendations for the control of EAV on the extensive use of the live vaccine, 
permitting the breeding of mares to shedding stallions under special 
circumstances. The key aspects of this protocol are: a) vaccination of 
seronegative mares at least 21 days prior to breeding and if the stallion is 
shedding virus the mare should be isolated for at least 21 days; b) no vaccination 
of pregnant mares; c) revaccination annually of seropositive mares; d) testing all 
seropositive stallions for virus shedding: e) vaccination of seronegative stallions 
and annual revaccination but they should not be used for breeding for 30 days
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after vaccination; e) seropositive shedding stallions can be used for breeding 
under the circumstances detailed above; f) seropositive non-shedding stallions 
with written certification of their seronegative status prior to vaccination need 
not be tested for virus shedding and should be revaccinated annually.
The live virus vaccine has not been used in Europe or Japan. Instead, the 
inactivated adjuvanted vaccine (Artervac, Fort Dodge) or the formalin 
inactivated preparation are available for the prevention of equine viral arteritis. 
The control measures implemented in the UK, an area of very low prevalence, 
contrast to those observed in the United States. In the UK, under the Equine Viral 
Arteritis Order 1995, EAV is a notifiable disease when a stallion is suspected of 
being infected or when a mare becomes infected after insemination (either by a 
stallion or by artificial insemination). Shedding stallions are not allowed to be 
used for breeding. The Horserace Betting Levy Board recommendations for the 
control of EAV are based on thorough serological screening of mares and 
stallions every year before the breeding season to restrict breeding practices to all 
seronegative animals and those séropositives demonstrated to be non-infectious. 
Seropositive stallions are tested by virus isolation from their semen or by test 
mating and only allowed for covering if negative. Seropositive mares need to 
show stable or declining VNAb titres with respect to previously tested samples in 
order to be regarded as non-infectious. The commercial inactivated vaccine can 
be used under an Animal Test Certificate on stallions. Therefore it is of 
paramount importance that the serological monitoring of every animal and 
stallions in particular is accurately recorded to determine whether a positive VN 
result is due to vaccination or infection.
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None of the vaccines described above permit serological discrimination of 
infected from vaccinated animals. Such discrimination would allow the use of 
vaccination without compromising serological surveillance in non-endemic 
areas, such as the UK, that are at risk of infection due to constant movement of 
animals or would be usefiil in the implementation of eradication programmes 
should the disease becomes endemic. Disease eradication programmes based on 
the use of marker vaccines for Aujeszky’s disease of pigs or bovine infectious 
rhinotracheitis have been applied in Germany and the Netherlands (van Oirschot,
2001).
1.11. Alternative approaches to conventional vaccines for the prevention of 
viral diseases.
The advent of molecular biology and recombinant DNA technologies permitted 
the advance of medicine, immunology, virology and opened new avenues for the 
generation of safer and more efficacious vaccines and facilitated the design of 
marker vaccines. These lack an antigen that is present in the pathogen causing 
the disease they intend to prevent, or contain an additional antigen absent from 
the pathogen in its natural form. The result is that naturally infected animals 
develop an antibody response of different specificity to that resulting from 
vaccination (for reviews see Babiuk, 1999; van Oirschot, 2001; Collet, 1989).
1.11.1. Sub-unit vaccines
These vaccines are based on a single or a discrete number of proteins from the 
pathogen identified as relevant for immune protection. These can be produced by 
conventional means as is the case for the production of tetanus toxoid by
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growing the bacteria in fermenters and subsequent purification and inactivation 
of the toxin. But also these vaccines can be produced by chemical synthesis of 
polypeptides or by using recombinant DNA technology by cloning the desired 
gene into the appropriate vector for subsequent production of the immunogen in 
an expression system. Various expression systems have been used for the 
production of sub-unit vaccines, from bacteria {E coli, Bacillus spp), yeast 
{Saccharomyces spp, Piscchia spp) or baculovirus (Autographa californica 
nuclear polyhedrosis virus) to mammalian cells. Bacterial systems, in particular 
E coli, have been used extensively since they are well characterised and large 
quantities of the protein can be produced and purified. However, the general 
view is that they may not be the best choice for the production of viral proteins 
whose tridimensional conformation is essential for maintainance of their 
antigenic properties, since bacteria do not modify the proteins post- 
translationally. Therefore an eukaryotic cell system might be preferred. 
Expression in yeast has the advantage of cost since there is extensive experience 
in growing yeasts in an industrial setting and the expression levels are very high 
compared to mammalian expression systems. This system has not been widely 
used for the production of veterinary vaccines but the first sub-unit vaccine 
against Hepatitis B was and is still produced in yeast (Valenzuela et al., 1982). 
The baculovirus expression system offers the advantage that the desired genes 
can be cloned into the virus genome under the control of very a strong promoter 
such as that of the polyhedrin protein, a non-essential protein which is expressed 
abundantly in baculovirus infected cells. However, production is difficult to scale 
up. The system has been used extensively as a vaccinology research tool and in 
some cases good prospects exist for the commercial use of baculovirus expressed
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immunogens as is the case for African Horse Sickness (Martinez-Torrecuadrada 
et al., 1994; 1996; Roy et al. 1996; du Plessis et al., 1998; Scanlen et al., 2002).
Mammalian expression systems are often the best option for producing correctly 
folded proteins. In these approaches, the desired gene, cloned downstream of an 
appropriate promoter, is introduced into mammalian cells via a viral vector (e.g. 
vaccinia, herpesvirus, adenovirus, Sindbis, polio) which then is translated and the 
protein produced, purified and used as an immunogen. These systems are often 
difficult and costly to scale up in an industrial setting because the cells are lysed 
by the virus or need to be lysed to release the protein from the cell. This means 
the recombinant immunogen need to be purified away from cell proteins and 
viruses. Furthermore, some proteins have toxic effects to the cells. For these 
reasons, alternative systems have been developed for the production of sub-unit 
vaccines in mammalian cells. These are based on the generation of cell lines 
stably transfected with genes controlled by induceable promoters that encode 
proteins that can be secreted into the medium therefore simplifying purification 
steps. Thus, Kowalski et al. (1993) cloned the gB gene of bovine herpesvirus-1 
devoid of the transmembrane region under the control of a strong promoter such 
as bovine HSP70. The cells are scaled up first and then the temperature is 
switched to 43 °C to drive the expression of gB which is secreted in the medium 
facilitating its purification.
Synthetic peptide vaccines have also been used as sub-unit vaccines. Since these 
molecules are very small they are normally coupled to large carrier molecules 
such as keyhole limpet hemocyanin (KLH) or ovalbumin in order to provide
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sufficient T helper epitopes to stimulate a strong immune response across a wide 
range of MHC antigens in a population. Promising efficacy data were obtained 
with experimental synthetic peptide vaccines against various animal virus 
diseases including foot-and mouth disease (Bittle et al., 1992) although these did 
not meet the requirements for the existing classical vaccine. The main problems 
are associated with antigenic variation and mimicking conformational epitopes of 
antigens. More success has been obtained with vacination against canine 
parvovirus infection of dogs using a synthetic peptide based on a linear and 
conserved B cell epitope of the virus coat (Langeveld et al., 1994).
Sub-unit vaccines therefore have the advantages of safety, stability, being 
chemically defined and importantly having ‘marker’ capacity. The main 
disadvantages are their low immunogenicity and rapid degradation in vivo. It is 
often necessary to incorporate adjuvants in their formulation as with inactivated 
vaccines. .
Adjuvants are chemical compounds which combined with the immunogen of 
choice enhance the immune response after administration. The modes of action 
of adjuvants can be classified, according to Cox and Coulter (1997), into the 
following categories: a) Immunomodulation: refers to the capacity of the 
adjuvant to direct the immune response towards either a Thl or Th2 type 
response; b) Presentation: refers to the way cells of the immune system recognise 
the antigen; c) Induction of CTL; d) Targetting: the adjuvant affects the way the 
antigen is taken up by antigen presenting cells; e) Depot generation: slows down 
the in vivo degradation of the antigen. A vast number of different compounds 
have been used as adjuvants although only very few have been licensed for use in
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commercial human and veterinary vaccines. Thus, aluminium hydroxide, has 
been for a long time the only licensed product for use in human vaccines, is a 
safe, inexpensive gel-like particulate adjuvant which possesses good targetting 
properties inducing a strong Th2 type response with elevated antibody 
production, moderate depot effect and stimulating very poor cellular immunity. 
Freund’s complete and incomplete adjuvants, used extensively in monoclonal 
antibody production, are water-in-oil emulsions. These are microdroplets of 
water stabilised in a continuous oil layer (mineral oil, squalene, squalane or 
metabolizable oil). The targetting and presentation are poor whereas the CTL 
induction and depot effects can be strong. Oil-in-water emulsions are oil 
microdroplets stabilised by surfactants in a water phase which can contain 
immunomodulators such as muramyl-dipeptide or block copolymers. They are 
suited for amphipatic molecules and have good presentation properties. 
Immunostimulating complexes (ISCOM’s) are cage-like structures resulting 
from the interaction of saponins with cholesterol and phospholipids and induce 
strong Thl and Th2 responses with good CTL and excellent presentation. They 
have been used in veterinary vaccines and their use in human vaccines is 
currently being considered. Other type of adjuvants include liposomes, nano­
particles, muramyl dipeptide and derivatives, non-ionic block copolymers, 
saponins, cytokines, and CpG motifs.
L I  1.2. Recombinant live virus vaccines.
Advances in recombinant DNA technology allow with relative ease the 
manipulation of viral genomes for the generation of vaccines. The viral genomes
43
can be modified to produce an attenuated virus (by deletion of virulence 
determinants) to immunise against the disease caused by the original virus or to 
deliver heterologous genes encoding the protective immunogens of other viruses. 
Thus, genes encoding the thymidine kinase (TK) or the glycoproteins gE, gG or 
gC of Aujeszky’s disease and infectious bovine rhinotracheitis viruses were 
deleted or rendered inactive to generate attenuated virus vaccines (Kit et ah, 
1985; Mettenleiter et ah, 1994). A step further in the development of this type of 
vaccines is the deletion of an essential gene rendering the virus unable to 
replicate in the host and therefore increasing vaccine safety. For the production 
of such deletion mutants it is necessary to supply the essential gene by a helper 
virus or by infecting a cell line stably transfected with the gene in question. This 
type of defective single cycle virus has been described for herpesvirus infections 
(Farrell et ah, 1994). With the development of reverse genetics, the 
manipulations described above have been possible for positive sense RNA 
viruses too, and thus full length cDNA clones of flaviviruses (Monath et ah, 
2001), coronaviruses (Ortego et ah, 2002), alphaviruses (Pushko et ah, 1997), 
pestiviruses (Moorman et al., 1996; van Gennip et ah, 2002) and arteriviruses (de 
Vries et ah, 2000; 2001; van Dinten et ah, 1997; Verheije et ah, 2001) have been 
created enabling the generation of vaccines for the diseases the parental viruses 
produce or against other diseases.
Indeed, attenuated viruses obtained either naturally, by conventional means or by 
recombinant DNA technology can be used as gene delivery vectors. The most 
extensively used virus vector is vaccinia virus. There are vast numbers of 
immunology, virology and vaccinology studies describing expression of
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heterologous genes using the vaccinia virus (for a review see Paoletti, 1996) and 
only a few examples are cited here. Thus, the glycoprotein G of rabies virus was 
inserted into the thymidine kinase site of the Copenhagen vaccinia virus strain to 
generate a rabies vaccine which has been used successfully in the field for the 
prevention of wild-life rabies (Pastoret and Brochier, 1996). Other poxviruses 
have been used as vaccine vectors such as canarypox for the prevention of feline 
leukemia (Tartaglia et a l, 1993; Poulet et a l, 2003), equine influenza or EHV-1 
infections (Minke et al., 2000) or fowlpox virus to prevent rabies in dogs (Taylor 
etal., 1995).
Examples of other attenuated viruses as vectors are bovine herpesvirus 1 
encoding capsid epitopes of foot and mouth disease, human adenovirus 5 
encoding the spike protein of porcine transmissible gastroenteritis and yellow 
fever 17D strain carrying the prM or E genes of Japanese enchephalitis virus 
(Monath et al., 2001). All these recombinant virus vaccines have most, if not all, 
the advantages of a live virus vaccine, providing cellular as well as humoral 
immunity and long duration of immunity. Additionally, they are safer and have 
the capacity to discriminate between vaccinated and infected animals.
Recombinant virus vaccines for EAV have also been devised. Thus, use of 
alphavirus replicon particles based on Venezuelan equine enchephalitis virus has 
been documented for the in vivo expression of G l and / or M of EAV (Balasuriya 
et al., 2000; 2002a) in mice and horses resulting in the stimulation of VNAb’s 
when both proteins were expressed together but not when either protein was 
expressed alone. The immune responses generated in GL / M vaccinated horses 
conferred clinical protection, reduced virus excretion and prevented viraemia
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against intranasal challenge infection. These levels of protection were slightly 
lower when the vaccinates were challenged by intra uterine virus inoculation.
The generation of a cDNA infectious clone of EAV will allow the deletion or 
insertion of genes to modify the replication properties, tissue tropism and/or 
antigenic specificity of the antibody response of EAV infection to generate 
improved EAV vaccines. Furthermore, a cDNA clone derived virus, has been 
found to be infectious, avirulent and genetically stable after inoculation in horses 
(Balasuriya et al., 1999b) demonstrating the vaccine potential of this approach.
1.11. S. DNA vaccines
DNA vaccines are composed of bacterial plasmid DNA encoding the desired 
genes under the control of appropriate mammalian expression regulatory 
sequences. The DNA vaccines are administered to the animal by the intradermal 
or intramuscular route and these are taken up by various cells resulting in the 
expression in vivo of the immunogen which then can be presented to T 
lymphocytes via MHC-I and MHC-II molecules, and be recognised by B cells in 
the surface of the cell membrane or in soluble form if the protein is secreted. This 
approach has been tried in many veterinary species including cattle, pigs, cats, 
dogs and horses. The main disadvantage of this approach is the high dose of 
DNA required to achieve sufficient expression levels in the host. Often, 
potentiation of the immune response has been tried by incorporating cytokine 
genes, CpG motifs or classical adjuvants. Another issue is safety with regards to 
integration of the foreign DNA into the host genome.
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DNA vaccination has been explored for EAV. Thus, immunisation protocols 
involving five inoculations in mice of 100 pg of plasmid DNA encoding 0RF7, 
0RF5 or 0RF5 ectodomain of EAV or a combination of plasmids endoding 
0RF2, 0RF5, 0RF5 ectodomain, 0RF7 and equine IL-2 administered four times 
to horses were reported to stimulate neutralising antibodies (Tobiasch et al., 
2001; Gieseetal., 2002).
1.12. Aims of the thesis
The main objective of this research work was to explore the potential of two 
vaccination strategies to generate a marker vaccine for EAV as well as to 
develop an assay to measure cytotoxic T lymphocyte responses, which will assist 
in future determination of the contribution of CTL’s to protective immunity and 
the efficacy of EAV vaccines.
Based on the findings by Chirnside et al. (1995a; 1995c) identifying a major 
immunodominant region on the EAV Gl protein containing sequences that 
stimulate a VNAb response in ponies after intramuscular inoculation, I have 
explored further the potential of the G l sub-unit vaccination approach. 
Modifications of the vaccination protocol,used by Chirnside et a l (1995a), in 
particular changes in the amino acid composition of the immunising protein, 
were introduced in an attempt to increase the duration and strength of the 
antibody responses. The protective efficacy of these responses against a virulent 
challenge was evaluated.
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An alternative ‘marker’ vaccination strategy based on a genetically modified 
mutant EAV virus was evaluated. The in vivo properties of an EAV Gl deletion 
mutant, the immune responses stimulated and their protective efficacy against a 
virulent challenge were studied.
Although VNAb titres in serum appear to be a correlate and an effector 
mechanism of immunity for EAV, nothing is currently known about cellular 
immune responses and the role they play in protection and virus clearance. 
Development of methods to measure CTL responses is described.
Attempts to identify viral proteins targetted by CTL’s will assist the development 
of future vaccines and would help to elucidate whether CTL responses alone are 
sufficient to provide protection against infection. A gene delivery system based 
on a baculovirus expression vector was developed in order to express EAV genes 
(using N as a model) in equine primary dermal cells and to test whether this 
system could be used to identify CTL targets.
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Figure 1.1. Schematic representation of two models of discontinuous EAV RNA 
transcription. Synthesis of m-RNA 4 and m-RNA 7 are illustrated. A) Representation of 
the genomic RNA. B) In this model the positive sense genomic RNA is transcribed to 
generate a full length negative strand which serves as a template for the generation of 
more genome length positive strands and the sub-genomic m-RNA’s from which the 5’- 
most ORF is translated. The leader sequence, once transcribed, ‘jumps’ to any of the 
negative junction sequences of the template via base-pairing of the positive and negative 
sense junction sequences to prime the transcription of the sub-genomic RNA. C) The 
positive genomic RNA strands transcribed from the anti-sense genomic RNA are the 
template for anti-sense subgenomic RNA synthesis. In this case, transcription of the 
negative subgenomic RNA’s is interrupted at the junction sequences and the body of the 
RNA jumps to the leader sequence of the positive genomic strand to complete the 
transcription generating the anti-sense leader sequence. The anti-sense subgenomic 
RNA’s serve as templates for the synthesis of the sub-genomic m-RNA.
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Chapter 2. Immunogenicity of EAVGl ectodomain based 
polypeptides.
2.1. Introduction
The potential of EAV G l ectodomain derived antigens to be used as a sub-unit 
vaccine for EAV has been demonstrated in previous studies in which serum 
VNAb were stimulated in ponies after intramuscular injection of Carbomer-PD 
adjuvanted vaccines (Chirnside et ah, 1995a). These comprised a synthetic 
peptide (aa 75-97) conjugated to keyhole limpet hemocyanin (SP25-KLH) and a 
glutathione-S-transferase fusion recombinant protein FP5RsaI (aa 55-98). 
However, peak VNAb titres varied between individuals and disappeared from 
serum relatively rapidly. In an attempt to increase duration and levels of serum 
VNAb antibodies after vaccination, various adjuvants, different doses and 
different EAVGl based immunogens were tested. In addition to FP5RsaI and 
SP25-KLH, the following antigens were used: Pep 1-KLH (aa 81-106), which 
included a neutralising antigenic site absent from previously tested polypeptides 
(aa 99-106), Pep2-KLH (aa 81-98) and a bacterially expressed polyhistidine 
tagged protein, 6hisGLCCto (aa 18-122), which includes all regions identified as 
targets for neutralising antibodies (Balasuriya et a l, 1997; Chirnside et al., 
1995a).
2.2. Materials and Methods
2.2.1. Synthetic Peptides and Recombinant Proteins
All synthetic peptides and recombinant proteins used as immunogens in this 
study derive from the Gl amino acid sequence of the Bucyrus-Utrecht strain (den
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Boon et al., 1991). The GST fusion protein FP5RsaI (aa 55-98) and the keyhole 
limpet hemocyanin (KLH) conjugated synthetic peptide SP25 (aa 75-97) have 
been described previously (Chirnside et al., 1995a). In addition, new 
immunogens were prepared. Peptide-1 (aa 81-106) and Peptide-2 (aa 81-98), 
obtained from Chiron Mimotopes (Victoria, Australia), were synthesized 
including an extra cysteine residue at the carboxy-terminus to allow coupling to 
KLH via the maleimide cross-linking moiety of sulfo-SMCC (V-succinimidyl 4- 
(V-maleidomethyl)cyclohexane-1 -carboxylate). The Imject Activated 
Immunogen Conjugation Kit (Pierce, Rockford, IL, USA) was used for this 
purpose. In addition to the above peptides an N-terminally polyhistidine tagged 
recombinant protein covering the entire Gl ectodomain (aa 18-122), denoted 
6hisGLCCto, was also used. A batch of this protein was kindly supplied by Dr 
A.A.F. de Vries at the University of Utrecht. Cloning, expression and antigenic 
analysis of the 6-hisGLCCto protein are described elsewhere (Nugent et al 2000). 
Briefly, the EAV0RF5 gene fragment encoding the predicted N-terminal 
ectodomain of Gl (i.e. without the predicted signal sequence) was cloned into the 
pQE9 (Qiagen) expression vector, thereby fusing an N-terminal 6-His motif to 
the Gl ectodomain. Bacteria {E. coli strain M l 5) transformed with both pREP-4 
and pQE9/GLCCto were cultured in Terrific Broth medium containing 100 pg /ml 
ampicillin and 50 pg/ml kanamycin. Protein expression was induced by addition 
of IPTG to a final concentration of 2 mM after 1 hour incubation at 37°C. 
Following 5 hours induction, bacteria were pelleted, subjected to lysozyme 
digestion in the presence of protease inhibitors, treated with DNAse and RNAse 
and insoluble protein was pelleted by centrifugation (6000g, 15 min, 4 °C). The 
pellet was washed in distilled water and resuspended in 6M guanidine
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hydrochloride, 20mM sodium phosphate, pH 7.8, 500 mMNaCl. The solubilized 
protein was then applied to a charged affinity column (ProBond™ column, 
Invitrogen) and subsequently eluted with 8M urea, 250 mM imidazole, 0.1 
NaH2P0 4 , 0.01 M Tris pH 6.0. The protein solution was stored in the dark at 4 
°C until used.
All the vaccines were prepared in 2 ml doses and administered by the 
intramuscular route. The antigen stock solution was diluted in 1 ml of phosphate 
buffered saline (PBS) to the required concentration. Then, 1 ml of proprietary co­
polymer adjuvant (Solvay-Duphar / Fort Dodge, Holland) was added. The doses 
of the GST-fijsion protein FP5RsaI vaccine were calculated taking into account 
the molar ratio of the Gl antigen to the whole protein (5/32). The dose of the Gl 
antigen on the KLH-conjugated peptide vaccines were calculated considering 
that the 1: 1 KLH : peptide (mass) reaction occurred with an efficiency of 100%.
2.2.2. Analysis o f Gl recombinant proteins by polyacrylamide gel electrophoresis 
(SDS-PAGE) and immunoblotting.
The purified 6hisGLCCto and FP5RsaI proteins were diluted in 2x sample buffer 
(250 mM Tris-HCl, 2% SDS, 10% glycerol, 20 mM DTT, 0.01% bromophenol 
blue) and heated at 95°C for 4 minutes. The pre-stained SDS-PAGE Standards 
Broad Range (BioRad) was used as the molecular weight marker (MWM) 
according to manufacturer's instructions. The protein samples were run for 30-45 
min at 160 Volt on 12.5% SDS-PAGE mini-gels inmersed in Running Buffer 
(25mM Tris, 192mM glycine, 0.1% SDS, pH 8.3) 
and stained with Coomasie blue solution (50% methanol, 10% acetic acid, 0.25%
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Coomasie blue R-250). Gels were finally destained in destaining solution (40% 
methanol, 10% acetic acid).
Proteins on acrylamide gels were electroblotted onto nitrocellulose membranes 
(Hybond) previously wet on transfer buffer (25 mM Tris-HCl, 19.2 mM glycine, 
20% methanol) applying a current of 7 Volt for 15 min. The membranes 
containing the electroblotted proteins were blocked overnight in 2% NFM PB ST 
[PBS, 2% non-fat milk (BioRad), 0.05% Tween 20 (BDH)]. After washing in 
PB ST, the membranes were incubated with anti-Gb specific antibodies a-SP25 
(Chirnside et al. 1995a) or a-6hisGLCCto, obtained by repeated intramuscular 
immunisation of a pony with this protein. These primary antibodies were diluted 
1/1000 in 2% NFM PB ST and incubated with the membranes for 1 hour at 37°C. 
After another wash in PB ST, horseradish peroxidase (HRPO) conjugated anti­
horse IgG (Pierce) or anti-rabbit IgG (DAKO) antibodies diluted 1/500 or 1/1000 
were added to the membranes and incubated for another hour at 37°C. A final 
wash in PB ST was performed and the membranes were incubated for 2 min with 
the HRPO chromogenic substrate TMB. The reaction was stopped with 0.18M 
H2SO4.
2.2.3. Measurement o f Antibody Responses
Serum samples were collected regularly from the ponies and VNAb titres were 
determined according to Senne et al. (1985). Briefly, serial two-fold dilutions of 
heat treated serum (56°C, 30 min.) were carried out in microtitre plates (25 
pl/well) from a starting dilution of 1/2. The diluent was MEM [minimum 
essential medium Eagle with Earle’s salts (Sigma, M2279) supplemented with
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100 ru  of penicillin per ml, 10 pg of streptomycin per ml, non-essential amino 
acids, L-glutamine to a final concentration of 2 mM and 200 mM HEPES] 
supplemented with heat inactivated foetal bovine serum to a final concentration 
of 5 %. Then 25 pi of a virus suspension (100 TCID50) in medium containing 
10% guinea pig complement was added to each well. The virus used (CVL 
Bucyrus) is a derivative of the Bucyrus strain obtained from the OLE Reference 
Laboratory, Weybridge, UK. This virus, a standard reagent for the VN test, has 
been evaluated in trials and found to give high sensitivity (Edwards el al., 1998). 
Three control equine sera and a titration of the virus dose were included in each 
test. After 1 hour incubation (37 °C, 5% CO2), rabbit kidney (RK-13) cells (100 
pl/well, 1.2 X 10^  cells/ml) were added, the plates sealed and the results read after 
a 48 hour incubation period. Wells showing more than 50 % cytopathic effect 
were recorded as positive. Titres were calculated using the Karber formula 
(Karber, 1931) and expressed as logio VNso-
Anti-Gb specific antibody responses were measured using the Peptide-1 based 
diagnostic ELISA test described by Nugent et al. (2000).
2.2.4. Experimental infections
Virus LP3A, provided by Mr David Westcott at the Veterinary Laboratories 
Agency, Surrey, England, is a large plaque variant derived from a pleural fluid 
isolate collected from a horse which died after being infected with the 14^  ^horse 
passage of the original Bucyrus strain (McCollum et ah, 1971). Plaque 
purification and growth of virus stocks were carried out in primary equine 
embryonic lung (EEL) cells . All challenges were performed in a controlled 
environment building. Two vaccinates and an unvaccinated control pony were
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used in each challenge. The ponies entered the building 1 week before the 
challenge to acclimatise to the new environment and remained in contact 
thereafter for 21 days. The ponies were examined twice a day every day while 
within the building. Infection with EAV was by instillation into the ponies’ 
nasopharynx of 1.0 ml virus suspension containing 10  ^ TCID50 using a flexible 
tube with spray attachment. Symptoms and rectal temperatures were recorded 
from the day of challenge for a period of 14 days. Nasopharyngeal swabs 
collected over the 14 day period were stored into standard virus transport 
medium and frozen at -70 °C. Heparinised blood samples were processed 
immediately for virus detection.
2.2.5. Virus isolation
Swabs collected from experimentally infected ponies were thawed, squeezed and 
the resulting extract used for virus isolation. White blood cells from 8 ml of 
plasma collected from unclotted blood samples were pelleted by low speed 
centrifugation and resuspended in 2 ml of MEM. Procedures to isolate EAV 
were performed essentially as described previously (Paweska et al., 1996). 
Volumes of 0.5 ml of nasal swab extract or white blood cell suspension were 
inoculated into 25 cm  ^flasks of confluent monolayers of RK-13 cells. The flasks 
were incubated for 1 hour at 37 °C, 5 % CO2 and overlaid with 5 ml of MEM 
supplemented with 2% bovine serum (2 % MEM). The following day the 
medium was discarded, fresh medium added and the flasks incubated for 5-6 
days. Confirmation of isolated virus was made by indirect immunofluorescence 
using a mixture of two monoclonal antibodies to the nucleocapsid protein kindly 
supplied by Dr Cordioli (Istituto Zooprofilattico Sperimentale, Brescia, Italy).
55
Samples were recorded as negative after failure to isolate EAV on a second 
passage. Nasal swab extracts were titrated as follows. Serial dilutions (0.5 logio) 
were made in quadruplicate in 96 well trays using a volume of 150p.l. Then, 100 
|il of 2 % MEM containing 10"^  RK-13 cells were added to each well and 
incubated at 37 °C, 5 % CO2 for 4 days. Wells presenting cytopathic effect were 
recorded as positive and virus concentration calculated according to Karber and 
expressed as TCED50 / ml of swab extract.
2.2.6. Statistical analysis
Six variables have been used for the statistical analysis of the data: a) duration of 
pyrexia (rectal temperature >38.5 °C), b) maximum temperature, c) duration of 
viraemia (number of days virus was isolated from blood samples) d) duration of 
nasal excretion of virus, e) maximum virus excretion in one day and f) total virus 
excretion, calculated as the arithmetic sum of virus excretion values over the first 
ten days post-infection. The study was a standard randomized block 
experimental design (with challenge groups as blocks), with the vaccine 
treatment applied to two ponies and the control treatment to one pony in each 
group. For this experimental design the appropriate analysis of variance 
(ANOVA) model is: Xÿ = p + Gi + Tj +eÿ , where Xÿ = the observed variable 
value for the pony in i-th Group receiving j-th treatment, p = overall mean value, 
Gi = i-th Group effect, Tj = j-th Treatment effect, and Cÿ = random error term 
assumed to have normal distribution with mean = zero and constant variance. For 
each variable studied, the mean and standard deviation were calculated as well as 
the ANOVA to test the null hypothesis of no difference in the effects of the two 
experimental treatments (vaccination versus no vaccination), on the variable
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concerned. The test for the null hypothesis Ho: Ti = T2 where Ti = control and T2 
= vaccine, used the standard variance-ratio F-test with 1 and 11 degrees of 
freedom. Details of the ‘Randomized Blocks’ experimental design and analysis 
may be found in the following textbooks (Cochran & Cox, 1957; Scheffe, 1959; 
Steel & Torrie, 1980). The effect of pre-challenge VNAb titres upon subsequent 
virus shedding by the ponies was assessed using both correlation and regression 
relationship between pre-challenge titre values and total virus excretion.
2.3. Results.
2.3.1. Selection o f  6hisGL^cto as a potential sub-unit vaccine candidate
2.3.L I. Experiment!
Four experimental vaccine preparations containing either Pep-l-KLH or 
FP5Rsal, adjuvanted with either Carbopol or Amplimune-Alhydrogel were 
tested in ponies. Two doses of 160 pg of each EAV Gl antigen, equivalent to 1 
mg of FP5Rsal and 320 pg of Peptide-1-KLH, were administered four weeks 
apart by intramuscular injection to four ponies and antibody responses measured 
by the Peptide-1 ELISA (Nugent et al., 2000) and the VN test.
All ponies responded to the first vaccine dose, developing antibodies to the 
Peptide-1 antigen (Figure 2.1). The serum antibody levels increased after the 
second vaccination, remaining at high levels up to week 8 and then declined 
progressively. There were little differences in the peak O. D. values of the 
ELISA antibody response between pony groups or between individuals. In 
contrast, differences in VNAb were more pronounced and only the Fp5Rsal / 
Carbopol preparation induced measurable titres, which peaked one week after 
the second vaccination and then declined rapidly to undetectable levels by week
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10. These results are consistent with Chirnside’s studies with the FpSRsal / 
Carbopol vaccine, despite the different vaccination regimes (v2 was given on day 
28 instead of day 56) and doses (120 pg instead of 160 pg of EAV antigen). 
Interestingly, the FP5RsaI recombinant protein did not induce VN antibodies 
when it was used in combination with Amplimune / Alhydrogel. Further 
vaccination experiments were performed with Carbopol adjuvant only. In 
contrast to the results obtained by Chirnside et a l, (1995a) showing a VNAb 
response following vaccination with SP25-KLH, in the present experiment 
ponies receiving the Peptide-1-KLH vaccine did not mount a VNAb response. 
The dose (160 pg), amino acid composition of the Peptide-1 (GLaa 81-106) and 
method to conjugate the peptide to the KLH carrier molecule (malic anhydride 
linkage) were different to those used by Chirnside (60 pg, G l aa 75-97, 
glutaraldehyde conjugation) and could have contributed to these results.
We tested fiirther the potential of synthetic peptide vaccination for EAV by 
comparing the immunogenicity of the original SP25-KLH antigen preparation 
used by Chirnside with Peptide-1-KLH and Peptide-2-KLH.
2.3.1.2. Experiment II
Three groups of two ponies were vaccinated by the intramuscular route with 
Peptide 1-KLH, Peptide 2 -KLH or SP25-KLH on weeks 0, 4 and 11 using 62 pg 
of Gl antigen (124 pg of peptide-KLH conjugate), which was formulated with 
Carbopol. Antibody responses were analysed by the VN test and the Peptide-1 
ELISA (Figure 2.2). All ponies developed a rapid IgG antibody response to 
Peptide-1 antigen, which remained very high throughout the study period for the 
Peptide-1-KLH and Peptide-2-KLH vaccinated groups. The intensity of the
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antibody response of SP25-KLH vaccinates was weaker than in the other groups, 
especially after the first two immunisations. Sera began to show low levels of 
virus neutralising activity after the second dose but significant titres (>0.6) were 
not reached after the last boost on week 11. The Peptide-2-KLH vaccine group 
presented the highest tires (1 and 0.9). Neither the use of a shorter and less 
hydrophobic peptide (Peptide-2), different dosage nor administering the peptide 
vaccines three times produced higher peak serum VNAb titres than those 
obtained with the FPSRsal / Carbomer-PD vaccine. As in the previous 
experiment, all three synthetic peptides elicited low titre VNAb’s despite anti- 
Peptide-1 antibodies being easily detected, suggesting that conformation of the 
Gl protein plays an important role in preserving neutralising epitopes.
To investigate the influence of immunogen tertiary structure in virus 
neutralisation and the antigenic resemblance of vaccine neutralising epitopes to 
native Gl epitopes, anti-Peptide-2 specific antibodies were depleted from a 
serum sample collected from a naturally infected horse. The serum samples 
before and after antibody depletion were analysed for their reactivity to the 
Peptide-2 antigen by ELISA and for their virus neutralisation capacity in the VN 
test. For this, 10 ^g of biotinylated Peptide-2 were incubated with streptavidin 
coated paramagnetic beads, used in excess (1.5 mg) to maximise Peptide-2 
binding (binding capacity of beads is 10 p,g peptide/mg of beads). Then 1/4 and 
1/100 dilutions of the serum were incubated with the beads.
The depletion assay results (Figure 2.3) show that Peptide-2 specific antibodies 
were effectively removed from the samples since the ELISA absorbance readings 
for all serum dilutions from the depleted samples (both dilutions) were very low
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in comparison to the undepleted ones. However, the antibody depletion 
procedure did not produce a decrease in VNAb titres, supporting the hypothesis 
that Peptide-2 does not mimic neutralising epitopes or that virus neutralisation 
depends on antibodies binding to other epitopes outside the Peptide-2 amino acid 
sequence.
The above results, the known conformational nature of certain virus neutralising 
epitopes in EAV Gl (Deregt et ah, 1994; Balasuriya et al, 1997) and the 
presence of some of these epitopes in regions of Gl not included in either 
Peptide-1, Peptide-2 or SP25 led us to investigate the immunogenicity of a 
polyhistidine tagged recombinant protein, 6hisGLecto, expressed in E  coli which 
comprised the whole ectodomain of Gl.
2.3.1.3. Experiment III
The antigenicity of the 6hisGLCCto protein has been demonstrated previously in 
solid phase format immunoassays (Nugent et a l, 2000). A new batch of this 
protein produced specifically for immunisation experiments was kindly supplied 
by Dr de Vries. Analysis by SDS-PAGE (Fig 2.4.a.) showed that the protein 
solution was virtually free of contaminant proteins. Also, 6hisGLecto was 
recognised by an anti-SP25 specific rabbit polyclonal anti serum but not by 
normal rabbit serum in an immunoblott assay (Fig 2.4.b).
The immunogenicity of 6hisGLecto was compared to Peptide-2-KLH and 
FPSRsal by administering 160 pg of each EAV antigen (160 pg of 6hisGLecto, 1 
mg of FPSRsal, 320 pg of Peptide-2-KLH respectively), with Carbopol as 
adjuvant, to 2 ponies by intramuscular injection on weeks 0, 7 and 13 and 
monitoring antibody responses by the Peptide-1 ELISA and the VN test. Figure
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2.5 displays the serology results which show, consistent with previous 
experiments, good ELISA antibody responses by all ponies soon after 
vaccination. In contrast, two or three doses were necessary in order to induce a 
measurable VNAb response. Peptide-2-KLH induced low titre VNAb’s only 
after the third dose was given. FP5RsaI vaccinated ponies sera presented low 
titres (0.22 and 0.45) 2 weeks after the second dose which increased further after 
the last boost (0.6 and 2.2). The highest titres (2.6 and 2.3) were obtained after 
the third vaccination with the 6hisGLCCto protein, which rose from 1.125 and
1.05 respectively on week 7. These results indicate that 6hisGLCCto presents 
neutralising epitopes more efficiently than the other antigens tested.
To test the presence of VNAb’s with anti-6hisGLecto specificity in EAV 
convalescent horse sera, a panel of serum samples were depleted of anti- 
6hisGLecto antibodies and analysed by the VN test and 6hisGLCcto ELISA before 
and after the antibody depletion. For this purpose Ni^^ NT A beads coated with 
75 pg of the recombinant protein were incubated with 0.5 ml of equine sera 
diluted 1/10 in MEM. The serum samples included a number of EAV VNAb 
positive field sera, 2 samples from EAV experimentally infected ponies (C65 p i. 
and 37Cp.i.) and one sample from a 6hisGLecto vaccinated pony collected 2 
weeks after receiving the third dose (B6A p.v3). As controls, the B6Ap.v3 and 
37C p i samples were also incubated with uncoated beads. The results displayed 
in Table 2.6 show that incubation with 6hisGLCCto coated beads reduced 
completely the ELISA absorbance values of all samples from EAV infected 
animals but only partially of B6A p.v3 (6hisGLecto vaccinated pony), whereas 
incubation with uncoated beads did not reduce the anti-Gb reactivity. However, 
VNAb titres from control samples (B6A p.v3 and 37C p.i.) incubated with
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uncoated beads showed a small decrease (0.3 and 0.4 respectively) after antiGb 
antibody depletion. The VNAb titre reduction was considered significant only 
when this reduction in VNAb titre was twice the value of that observed for the 
control depleted sample 37C (i.e. 0.8). A significant decrease in VNAb titre was 
observed in some samples but not in others despite efficient depletion of anti- 
6hisGLCCto antibodies. This suggests that ôhisGiecto resembles better than Pep- 
2-KLH (Experiment II) the tertiary protein structure of VNAb antigenic domains 
and that the incomplete reduction of the VNAb titre in all the samples, except 
B6A p.v3, is possibly due to the presence of VNAb’s which bind epitopes not 
mimicked by ôhisGLCCto. The fact that the VNAb titre could be reduced in 
sample c65 p.i., which showed low antiGb reactivity before applying the 
procedure, is difficult to interpret. However, it is noted that a previous assay 
showed a high ELISA absorbance value for this particular sample.
The antibody response following immunisation with bhisGiecto and the results 
of the depletion assay showing the capacity of this protein to bind VNAb’s in 
vitro prompted continuing the investigation of this protein as a potential sub-unit 
vaccine for EAV. Specifically, VNAb induction after 6hisGLecto vaccination 
using three different doses, duration of the antibody response and protection of 
the immunised ponies against experimental infection were studied.
2.3.2. tihisGiecto stimulates VNAb responses and provides protection against 
experimental infection.
2.3.2.1. Antibody responses to bhisGiccto.
The ability of different doses of the prototype sub-unit vaccine to elicit VNAb 
was evaluated in three groups of Welsh Mountain Ponies, each group comprising
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one yearling colt and three 2-year old geldings. Group A (pi, p2, p3 and p4). 
Group B (p5, p6, p7 and p8) and Group C (p9, plO, p ll  and p i2), were 
vaccinated initially (VI) with 6hisGLecto doses of 140, 70 and 35 pg 
respectively (administered intramuscularly with Carbopol). The results (Figure 
2.7.) show that following the priming vaccination, a weak VNAb response was 
observed in Groups B and C but not in Group A. A second dose (V2) on week 5 
(140pg for Group A, 70 pg for Group B, 35 pg for Group C) boosted the 
antibody response in all ponies, with the highest titres observed for individuals 
from Group B (VNAb titres 2.3 to 3.1). Five weeks following V2, two ponies 
from Group A and an unvaccinated control pony were infected with EAV 
(challenge 1, described in more detail below). Protection was observed despite 
moderate VNAb titres for both vaccinates. A third vaccine dose (V3) was 
administered to all ponies on week 13 (140 pg for Group A, 70 pg for Group B, 
35 pg for Group C). This induced another peak in the antibody response after 
which the two remaining ponies from group A were challenged on week 15 
(challenge 2, described below). In this case, both vaccinates displayed a high 
degree of protection. The remaining ponies (Groups B and C) were sampled 
over a period of 40 weeks to determine the duration of the antibody response. 
VNAb declined gradually, being still detectable in all ponies on week 27, but 
undetectable by week 53.
The kinetics of the anti-Gb antibody response measured by ELISA were broadly 
in line with the VNAb response (Fig. 2.8) although they show a slower rate of 
decline. In particular, the ELISA values remain at a high level for several weeks 
after V3. This could be due to the high sensitivity of the ELISA and the high 
anti-Gb specific antibody concentration of the serum samples. In order to test
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whether ELISA antibody titres may decline at a similar rate to VNAb’s, various 
dilutions (1/100, 1/400, 1/1600 and 1/6400) of sera from ponies p9, plO, p l l  and 
pl2 collected on weeks 5, 6, 8, 10, 13 and 15 were analysed. The results confirm 
that the ELISA antibody response show very similar kinetics to the VNAb 
response (Fig. 2.9).
Following determination of the kinetics of VNAb induction and decline, the 
remaining ponies received a fourth vaccination (V4), comprising 35 pg of 6his 
Gbecto, on week 53. This dose was administered to all remaining ponies since it 
appeared as effective as the other higher doses used previously. Following V4, 
VNAb responses were monitored and a series of EAV challenge infections 
performed, in order to establish the protective efficacy of vaccination across a 
range of VNAb titres. The results of these challenges are described below.
2.3.2.2. Protection against experimental infection
Previous challenge infections in naïve ponies with LP3A virus indicated that 
intranasal administration of this virus (10^ TCID50) resulted in reproducible 
clinical signs, virus shedding from the nasopharynx and cell-associated viraemia 
(Hannant D, Westcott D and Castillo-Olivares J, unpublished observations).
The results of each of the six experimental challenge infections of the present 
study are displayed in Fig. 2.10. a -  f. and summarised in Table 2.11. For each 
challenge, two vaccinates and one control pony were used. In all challenges, the 
control ponies became infected presenting a syndrome characterised by pyrexia 
lasting 6 to 11 days (maximum temperatures 40 -  40.5 °C), viraemia (detected 
for 6 or 7 days) and virus shedding from nasal secretions for 8 to 11 days. All 
controls seroconverted to EAV by the neutralisation test (seroconversion defined
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as an increase in VNAb titre of at least fourfold). Depression, mild 
conjunctivitis, sub-mandibular lymph node swelling, nasal discharge and 
diarrhoea were observed in some ponies.
Preliminary analysis of the challenge data indicated that vaccinated ponies 
showed a range of clinical and virological outcomes. It is clear that for challenge 
2 (Fig. 2.10. b), vaccinated ponies are strongly protected against infection, with 
negligible pyrexia, viraemia or virus shedding in comparison with the control 
pony. Even for the vaccinates with undetectable VNAb (challenge 6, 19 weeks 
after V4), partial protection was observed, as judged by reduced severity and 
duration of pyrexia and substantially reduced virus shedding (Fig. 2.10. f). 
Protection against infection in vaccinated ponies was quantitatively evaluated 
according to objective and measurable variables consistently reproduced in the 
control ponies, namely the intensity and duration of pyrexia, duration of 
viraemia, duration of virus excretion, maximum virus excretion, total virus 
excretion [nasal swab samples with virus concentration below the detection limit 
(10^^^ ) were assigned a value of (mean of 0 and 10^^  ^ )] and
seroconversion (Table 2.11). Protection was maximum in ponies p6, p i and p4 
which had VNAb titres above 1.95 at the time of challenge. These ponies did not 
seroconvert to EAV, febrile reaction and viraemia were totally prevented and 
virus excretion was absent or limited to a single day (<10^^^ TCID50 /ml nasal 
swab). The other vaccinated ponies displayed varying levels of protection. All 
ponies with a VNAb titre <1.95 seroconverted to EAV, but pyrexia duration and 
intensity were reduced compared with the controls, with only one vaccinate 
(plO) having a peak of temperature above 40 °C and only one vaccinate (p5) 
with pyrexia for 6 or more days. Furthermore, the vaccinates displayed a
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reduction in the duration of viraemia and nasal virus excretion, and reduced virus 
titres from nasal swabs. Even those vaccinates with negligible VNAb titres at the 
time of challenge (19 weeks after V4) were partially protected, with a substantial 
reduction in virus shedding (over 100 fold) compared with the corresponding 
control pony (Table 2.12).
In order to determine the significance of protection against each of these 
variables statistical advice was sought from Ken H. Lakhani who performed an 
Analysis of Variance. The results of this analysis (Table 2.12) indicate that the 
6his-Giecto sub-unit vaccine provided significant protection (p<0.01) against 
EAV infection as judged by a reduction of pyrexia, cell-associated viraemia and 
virus shedding from the nasopharynx. The correlation between VNAb titre at the 
time of challenge and total virus excretion was found to be significant as the 
results of linear regresion analysis performed by Ken H. Lakhani show (Figure 
2J3J.
2.4. Discussion
The work described in this chapter represents a follow up of previous studies 
demonstrating the potential of G l derived antigens to serve as sub-unit vaccine 
against EAV (Chirnside el a l, 1995a). We found that although all the antigens 
tested were effective at inducing anti-GL responses as assessed by a GL-specific 
ELISA, the virus neutralising capacity of the antibodies induced by the synthetic 
peptides was poor as compared with the VNAb induced by bacterially expressed 
antigens, of which the 6hisGLecto antigen induced the highest titres. Analysis of 
the nucleotide sequences of the 0RF5 of a wide range of EAV isolates and of 
mutant viruses escaping neutralisation by GL-specific monoclonal antibodies
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identified four regions in the Gl protein where neutralising epitopes occur 
(Balasuriya et a l, 1997). Of the antigens tested in this study, the 6hisGLCCto 
recombinant protein includes all four of these antigenic sites. The anti-Peptide-2 
antibody depletion experiments described in the present study suggested that 
either epitope conformation or number of neutralising epitopes present in the 
antigen could play an important role in VNAb induction after vaccination. 
Similar experiments performed with 6his-GL ecto indicated the presence of 
VNAb binding epitopes in this recombinant protein, but it was not possible with 
this protein to deplete completely the VN activity of post-infection sera. This, 
together with the fact that some VN positive sera have low reactivity to Gl as 
measured by Peptide-1 or 6hisGLCCto ELISA (Nugent et al., 2000) suggests that 
there could be additional neutralising epitopes not presented correctly by the 
6hisGLecto or which lie outside the ectodomain itself. Previous studies have 
indicated that both linear and conformational epitopes are recognised by 
neutralising antibodies (Deregt et al., 1994; Balasuriya et al., 1997). It is 
uncertain whether the antibodies induced by the 6hisGLCCto antigen are restricted 
to recognition of linear rather than conformational epitopes. It is possible that 
the use of protein expression procedures in eukaryotic systems to produce 
glycosylated 6hisGLecto, combined with less stringent purification methods, 
might improve induction of neutralising antibodies. Balasuriya et al. (2000) 
reported that when full length Gl is expressed in eukaryotic cells, co-expression 
of M is required for induction of neutralising antibodies in mice. Protective 
immunity in horses is also higher when both envelope proteins are expressed 
(Balasuriya et al., 2002a). It is clear from our studies that the recombinant Gl 
ectodomain alone, expressed in bacteria, does form epitopes required for
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induction of neutralising antibodies. It would be interesting to determine whether 
the Gl ectodomain expressed in eukaryotic systems is similarly able to elicit 
VNAb.
Having identified the 6hisGLecto protein as the antigen of choice we conducted 
an extensive vaccination study using 18 ponies. Three doses of the antigen were 
compared to provide an indication of optimum antigen dose. We found that the 
medium (70 pg) and low doses (35 pg) performed similarly and, unlike the high 
dose (140 pg), induced detectable VNAb titres after the first vaccination. All 
animals developed VNAb after subsequent booster vaccinations, peaking 1 to 2 
weeks after each vaccination and reaching titres > 1 . 8  at their peak. The 
medium dose induced the highest VNAb titres following the second vaccination, 
with 3 ponies exhibiting titres >2.5. Two preliminary challenge infections were 
carried out, using ponies from the high dose vaccination group, to establish 
whether the VNAb responses induced by vaccination were protective (described 
later). The results of the challenges indicated that vaccination was protective, 
justifying continuation of the study to monitor the duration of VNAb responses 
and determine levels of protection in the remaining ponies.
Following three vaccinations, the VNAb titres in the medium and low dose 
groups were monitored for 40 weeks. For both groups, titres peaked 2-3 weeks 
after V3, but then declined gradually until week 53, when neutralising activity 
had become undetectable in all vaccinates. However anti-GL antibody was still 
present as assessed by ELISA. The sensitivity of the peptide-1 ELISA and the 
good correlation with VN test would allow a quick and reliable estimation of the
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immunity elicited after vaccination with the éhis-Giecto protein. The kinetics of 
VNAb development of horses vaccinated with formalin inactivated virus 
(Fukunaga et a l, 1984; Fukunaga et al., 1991) are similar to those observed 
during this study. High titres were achieved two weeks after two vaccine doses 
administered four weeks apart, which then progressively declined. A third dose 
boosted the antibody levels, which then persisted for 6 months. Similarly, studies 
performed with the modified live vaccine showed that after a single vaccine dose 
the VNAb levels were relatively low and transient (Fukunaga et al., 1981; 
McKinnon et al., 1986; Timoney et a l, 1988) but supplementary vaccine 
administration resulted in a good anamnestic response with titres maintained for 
9 to 12 months.
In order to evaluate the protective capacity of the immune responses generated 
by the bhisGbecto protein we challenged vaccinated and control ponies with 
LP3A virus derived from the virulent Bucyrus strain. The challenge virus was 
found to consistently reproduce clinical signs and virus shedding/viraemia in 
EAV naive ponies (as described here and unpublished observations). With the 
exception of pyrexia the clinical signs observed in the control ponies were mild. 
The relatively mild symptoms were not entirely unexpected since the virulent 
pleural fluid isolate of the Bucyrus strain (derived by sequential in vivo passage) 
has been shown to lose its virulence rapidly after passage in tissue culture 
(McCollum, 1970; McCollum e/fl/., 1961).
Until recently (Chapter 4) there were no methods to evaluate cellular immunity 
against EAV, but serum VNAb are considered to be a good correlate of
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immunity (Fukunaga et al., 1991; Fukunaga et al., 1990; McCollum, 1976). In 
this study we have experimentally infected 18 ponies having different levels of 
VNAb at the time of challenge and observed a correlation between the level of 
protection and the pre-challenge VNAb titre. The three ponies with titres >1.95 
showed maximum protection. None of these animals seroconverted and all were 
negative for viraemia. No significant virus shedding was detected (nasal swab 
titres <10^^^ TCID50 /ml), and although two of the ponies were positive for virus 
shedding, this occurred on a single day in each case. It is therefore unlikely that 
an EAV infection had been established. These results are similar to those 
reported previously in horses vaccinated with formalin inactivated virus inducing 
VNAb titres > 1: 320 (equivalent to 2.3) (Fukunaga et al., 1990), although in this 
case seroconversion to EAV after challenge was observed despite the lack of 
viraemia or clinical signs. Varying levels of partial protection were observed in 
the rest of the 6hisGLCcto vaccinates. All ponies with intermediate and low 
antibody levels, even those vaccinates with undetectable serum neutralising 
antibodies at the time of challenge, showed a reduction of pyrexia, nasal virus 
shedding and viraemia in comparison to the control ponies infected at the same 
time. Similar results have been described by Fukunaga et al. (1991) in his 
evaluation of the efficacy of a whole virus killed vaccine, where vaccinated 
horses with VNAb titres > 1: 80 (equivalent to 1.9) showed complete clinical 
protection against EAV. It was interesting to observe that after challenge, pony 
p5 became febrile by day five and virus began to be isolated from nasal swab and 
peripheral blood samples collected after that day. This apparent increase in the 
incubation period may indicate that this animal resisted the initial challenge but 
became infected subsequently as a consequence of exposure to virus shed by the
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control pony. ‘In contact’ transmission of EAV from experimentally infected to 
susceptible seronegative mares has been reported previously (McCollum et ah, 
1987). This phenomenon raises the question of whether protection would have 
been better if controls and vaccinates had been kept separate after challenge. In 
our study all unvaccinated ponies excreted large amounts of virus after challenge 
every day for 7 to 10 days.
In this study we have assessed the protection afforded by the experimental 
vaccine against intranasal challenge. By analogy with previous studies we 
anticipate that this vaccine has the potential to protect against venereal challenge, 
since efficacy studies performed with an inactivated whole virus vaccine showed 
similar results independent of the route chosen to challenge the vaccinated 
animals (Fukunaga et al., 1997; Fukunaga et al., 1990). In the case of ponies 
with VNAb titres < 1.95 (the threshold for complete protection), viraemia was 
generally observed. Whether under such conditions there will be protection 
against abortion, or the establishment of persistent infection in stallions, is 
uncertain. However, the significant reduction in the duration and titre of virus 
shedding observed in vaccinates, even when VNAb titres were no longer 
detectable, suggests that sub-unit vaccination could provide significant 
protection against respiratory spread of infection for at least five months 
following a boost.
We have used in the present study three viruses derived from the prototype 
Bucyrus strain: Utrecht Bucyrus for preparation of the recombinant antigen, 
CVL for the VN test and LP3A for challenge. Plasmids for expression of
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recombinant G l were derived from cDNA from the Utrecht Bucyrus strain, 
which had been used to determine the complete genomic sequence of EAV (den 
Boon et al., 1991). The CVL strain has been developed as a standard reagent for 
EAV VN tests and was therefore utilised for determination of VN Ab titres in 
this study. Both the above strains have been passaged in non-equine cells and 
were not considered suitable for use in experimental challenges. Hence the third 
strain (LP3A), derived from the original Bucyrus isolate by in vivo passage 
(McCollum et al., 1971) followed by plaque purification and passage exclusively 
on equine cells (Westcott et a/., unpublished data), was utilised as the challenge 
virus. As noted previously, LP3 A had been observed to produce consistent virus 
shedding, viraemia and pyrexia upon infection of naïve ponies. Alignment of the 
Gl amino acid sequences of the three viruses used is shown in Figure 2.14. 
Within the ectodomain region of the vaccine, two amino acid differences are 
observed between the vaccine sequence and the challenge virus and five amino 
acid changes between the vaccine sequence and the neutralisation test virus. 
Notably, the LP3A virus has preserved the potential N-linked glycosylation site 
(aa 81-83) of the original Bucyrus isolate (also found in the majority of field 
isolates: Stadejek et al, 1999), which is lost (Ngi-D) in the other two isolates. 
Despite these changes, equine sera raised against the Gl ectodomain of the 
Utrecht Bucyrus isolate neutralised effectively in vitro the CVL Bucyrus and in 
vivo the LP3A isolates. Thus, any antigenic differences that may exist between 
the Gl of the vaccine and the viruses used to detect VN Ab and for challenge did 
not prevent virus neutralisation. A single serotype of EAV is recognised and 
previous studies (Balasuriya et al, 1997) demonstrated that four different post­
infection equine sera were able to neutralise a wide range of different EAV
72
isolates, although at varying titres. In view of the observed sequence variation of 
G l, fiirther studies are required to evaluate the potential of G l vaccination to 
protect against heterologous isolates of EAV, representative of naturally 
occurring field isolates.
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Figure 2.1. Virus Neutralising Antibody (open circles) and Peptide-1 specific antibody 
(closed boxes) responses of 4 groups of 4 ponies vaccinated on week 0 and week 4 with 
either FPSRsal (a, c) or Peptide-1-KLH (b, d) formulated with either Carbopol (a, b) or 
Amplimune-Alhydrogel (c, d).
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b) VNAb responses of ponies vaccinated with Synthetic Peptides.
Pony/Vaccine Tim e in W eek s
0(V1) 1 2 3 4(V2) 5 6 7 11 (V3) 12 13 14
D77/Pep1-KLH 0 0 0 - - - 0.3 0 0 0.45 0.75 0.7
B63/Pep1-KLH 0 0 0 - - - 0 0 0 0.4 0.45 0.3
019/Pep2-KLH 0 0 0 - - - 0.45 0 0 1 1 0.7
BOD/Pep2-KLH 0 0 0 - - - 0.23 0 0 0.45 0.9 0.45
268/SP25-KLH 0 0 0 - - - 0 0 0 0 0 0.45
87A/SP25-KLH 0 0 0 - - - 0.37 0 0 0,45 0.4 0
Figure 2.2. Peptide-1 specific and VNAb responses of three groups of 2 ponies 
vaccinated with Gi -derived synthetic peptides formulated with the adjuvant Carbopol. 
Vaccinations were administered on weeks 0, 4 and 11.
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Figure 2.3 Reactivity to Peptide-1 antigen by ELISA (a and b) 
and VNAb titres (c) of an EAV positive horse antiserum (CM) 
before and after depletion of anti-Peptide-2 specific antibodies
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Figure 2.4 a) Electrophoretic mobility of the 6hisGLCcto (lane 2) and FPSRsal 
(lane 4) proteins on a 12.5% SDS-polyacrylamide gel. Lane 3 was empty, b) 
Immunoblots of 6hisGLCCto and FPSRsal with anti-SP25 rabbit antiserum (left 
panel) and normal rabbit serum (right panel). Lanes 1 in all the figures correspond 
to a pre-stained Molecular Weight Marker.
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vveek13(\/3) neg neg 0.45 0.5 1.6 1.3
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Figure 2.5. Antibody responses of ponies immunised with Carbopol adjuvanted 
Girderived vaccines measured by the Peptide-1 ELISA and Virus Neutralisation 
test
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Incubation with GL coated beads
Serum sanpl es
Previous results EUSAO.D. VN Ab Titre VN Ab Titre 
reductionEUSAO.D. VN titre Preinc Post inc Preinc Post inc
600112 1 0.3 3.1 0.5 0.1 3.2 1.8 1.4
603217 2 0.1 1.8 0.1 0.1 1.7 1.2 0.5
610356 3 0.3 2.0 0.3 0.1 2.1 1.4 0.7
506246 4 0.1 1.2 0.1 0.1 1.6 1.2 0.4
608194 5 0.1 1.5 0.1 0.1 2.1 1.5 0.6
713225 8 2.6 2.4 2.1 0.1 2.5 1.0 1.5
713459 9 2.9 2.3 2.9 0.1 2.3 1.3 1.0
710831 10 2.3 2.0 1.6 0.1 2.3 2.0 0.3
710326 11 1.3 1.9 0.6 0.1 1.8 1.1 0.7
B6A p.V3 12 2.8 2.3 3.5 1.5 2.3 <0.70 >1.6
C65p.i. 13 1.5 1.5 0.2 0.1 2.0 1.0 1.0
37Cp.i. 14 0.5 2.2 0.1 0.1 2.1 1.5 0.6
Incubation with uncoated beads
37Cp.i. 15 0.5 2.2 0.1 0.1 2.5 2.1 0.4
B6Ap.V3. 16 2.8 2.3 3.5 3.4 2.6 2.3 0.3
Table 2.6. Reactivity by the Peptide-1 ELISA and the VN test of selected horse sera 
previously tested positive by the AHT virology diagnostic services and of sera collected 
from EAVUK93 experimentally infected ponies before and after depletion of bhisGb 
specific antibodies.
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Figure 2.7. VNAb responses of ponies vaccinated with 140 (a), 70(b) or 35(c) pg of 
bhisGLCCto. Vaccines were administered (open arrows) on weeks 0, 5, 13 or 53. 
Selected individuals were challenged (closed arrows) at weeks 10, 15, 55, 59, 65 and 
72 (Ch 1 to Ch 6 respectively).
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Figure 2.8. Peptide-1 specific antibody responses by ELISA of ponies 
vaccinated with 140 (a), 70(b) or 35(c) pg of bhisGLCCto. Vaccines were 
administered (open arrows) on weeks 0 ,5 , 13 or 53. Selected individuals were 
challenged (closed arrows) at weeks 10, 15, 55, 59, 65 and 72 (Chi to Ch6 
respectively). Sera were analysed by ELISA only until week 62.
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Figure 2.9. Anti-Peptide-1 specific antibody responses and VNAb titres of sera collected 
from ponies p9, plO, p ll  and pl2 on weeks 5, 6,8, 10, 13 and 15. The sera was tested in 
the ELISA at 1/100, 1/400, 1/1600 and 1/6400 dilutions.
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Figure 2.10. Rectal temperatures, virus excretion and viraemia of 
dhisGhecto vaccinated (ponies p i-p i 2) and control (ponies cl-c6) over 
14 days following exposure to virulent challenge virus LP3A. Two 
vaccinees and one control pony were challenged on weeks 10(a), 15(b), 
55(c), 59(d), 65(e) and 72(f).
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CHALLENGE 6 
Rectal Temperatures
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Pony" VNAbtitre*^
Pre post Seroc.
Pyrexia'  ^
days max Temp
Viraemia'*
days days
Virus shedding 
Nasal sN3bs 
max titre Total oorj nd.
ainical Signs  ^
Ins dep others
P2(1) 1.30 230 + 1 38.64 4 1 <175 1.45 + - - + -
1.10 260 + 3 39.60 2 0 0 0 — - — — -..... ___________
C1(1) - 1.90 + 8 4Q18 6 11 3.75 4.16 + - - + -
p4(2) 225 233 - 0 38.44 0 0 0 0 - - - - -
p1(2) 1.95 210 - 0 38.æ 0 1 <1.75 1.45 - - + - -
c2(3 - 200 + 6 40.44 6 8 3.20 3.63 + ++ + + -
p6(^ 230 220 - 0 38.46 0 1 <1.75 1.45 - - - - -
...... ................ 1.40 3.80 + 7 39.72 5 3 1.75 205 - — - — -
c3(3) - 220 + 7 40.50 7 11 3.10 3.70 + + + + -
p7(4) 1.30 275 + 0 38.12 0 2 1.75 1.92 - - - - -
p10(4) 0.70 3.40 + 5 40.70 3 6 200 250 + + — - -
o4(4) - 200 + 6 40.50 7 8 3.00 350 - ++ + - - -
P8(5) 0.97 3.15 + 5 39.40 1 5 200 250 + - - - -
p12(5) 0.75 240 + 2 39.08 3 7 4.25 4.25 + - + — -
c5(5) - 1.95 + 11 4Q00 6 9 5.00 520 -H- + ' - -
m - 3.20 + 4 39.60 4 7 240 262 + + - + -
p11(6) - 270 + 1 39.50 1 8 280 294 + - - + -
- 250 + 7 4Q40 7 11 4.70 ' ^ 7 + + + ++ diarrhoea
Table 2.11. Clinical and vifological results of experimental EAV infections performed in 
unvaccinated and ôhisGiecto vaccinated ponies, a) Pony identification number; b) Neutralising 
antibody titres on days 0 (pre) and day 14 post-infection (post); seroconversion (seroc.) defined 
as a fourfold increase in VNAb titre between pre and post titres; c) Number of days temperature 
was over 38.5°C and maximum temperature recorded; d) Number of days virus was isolated from 
blood samples; e) Number of days virus was isolated from nasal swabs, log 10 maximum virus 
excretion values of each sample and total virus excretion (arithmetic sum of virus titres of 
samples collected during the first 10 days post-infection) expressed as log 10; samples which were 
virus isolation positive, but with virus concentrations below the titration detection limit (<10  
1.75) were given a value of 10 1.45 (mean of 0 and 101.75 ); f) Absence (-) or presence of 
various clinical signs of low (+) or moderate (++) severity observed after infection, namely 
conjunctivitis (conj), nasal discharge (n.d.), lymph node swelling (Ins), depression (dep); an 
isolated case of diarrhoea is also noted.
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Variable___________ Mean ± standard deviation____________ Significance
Control Vaccine F-ratio probability
Pyrexia (days) 7.50 ±1.87 2.33 ±2.42 20.77 0.0008
Pyrexia (max. temp. °C) 40.35 ± 0.20 39.13 ±0.78 11.55 0.0060
Viraemia (days) 6.50 + 0.55 1.92 ±1.83 31.54 0.0002
Vims nasal excretion 
(days)
8.83 ±0.75 3.42 ±3.00 36.57 <0.0001
Vims nasal excretion 
(max.)
3.80 ±0.86 1.78 ±1.14 28A8 0.0002
Vims nasal excretion 
(Total)
4.24 ± 0.79 1.93 ±1.19 39.33 <0.0001
Table 2.12. Summary of statistical analysis comparing the effects of no vaccination 
(Control: n = 6) and vaccination (Vaccine: n = 12) for several variables indicative of 
severity of infection and disease following EAV infection. The means ± standard 
deviation for each of the variables are shown. Statistical significance was assessed 
using analysis of variance (ANOVA): the F-ratio (1 and 11 degrees of freedom) to 
test the null hypothesis of no difference between control and vaccine treatments and 
the significance probability assessed by this test are shown.
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Figure 2.13. Observed relationship between total virus excretion (log of the 
arithmetic sum of virus titres of nasal swabs over days 1 to 10 post-challenge) 
and pre-challenge values of VNAb titre. Open circles show six control ponies, 
closed circles show twelve vaccinated ponies. The fitted linear regression model 
is Y = 3.83 -  1.45 X (pre- challenge titre) and highly significant (r = 0.78, p < 
0 .0001).
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Figure 2.14 Amino acid sequence alignment of the Gl protein of EAV Bucyrus U trecht, EAV 
Bucyrus CVL and EAV Bucyrus LP3A. Dots indicate the same amino acid as in the top aligned 
sequence. Amino acid substitutions are specified. N-Glycosylation sites are indicated in the 
boxes.
92
Chapter 3: Biological properties in vivo and immunogenicity of 
an EAV G l deletion mutant
3.1. Introduction
Previous results demonstrated that recombinant proteins and synthetic peptides 
based on the EAV Gl ectodomain have the potential to serve as marker vaccines 
for EAV. The bhisGbecto protein, like most sub-unit vaccines, is an inactive 
single component stimulating an effective antibody response with restricted or 
limited antigen specificity, which makes differential diagnosis of infection 
possible through detection of antibodies reactive to any of the rest of the virus 
antigens. In the case of EAV, prototype diagnostic procedures based on N or M 
antigens have been developed. The VNAb responses elicited after bhisGLCCto 
vaccination are strong and conferred different degrees of clinical protection and 
reduction of virus excretion and viraemia relative to prechallenge VNAb titres. 
However the duration of the VNAb response is short as with other sub-unit 
vaccines and, although cell-mediated cytotoxic responses have not been 
measured, it is unlikely that they were stimulated with the Gl sub-unit vaccine. 
Another strategy for generation of an EAV marker vaccine is explored by using a 
genetically modified EAV virus, made through manipulations of the full length 
cDNA clone of EAV.
The generation of cDNA full length clones of RNA viruses has enabled the 
manipulation of viruses genomes to insert or delete DNA fragments representing 
genes or part of them to modify biological properties such as tissue tropism, 
antigenicity or replication, therefore facilitating the design of live marker virus 
vaccines. This approach for marker vaccination offers the advantages of more
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complete immune responses and longer duration of immunity. However, the 
requirements for demonstration of safety and attenuation are higher than those 
for killed or sub-unit vaccines. In the case of EAV, full-length clones of EAV 
have been constructed and manipulated to study fundamental aspects of EAV 
biology (van Dinten, et al., 1997; de Vries et al., 2000, 2001; Molenkamp et al., 
2000; Dobbe et al., 2001). These manipulations included the production of single 
point mutations, deletions of various sizes or insertions of foreign DNA.
The principle of using a live marker vaccine for EAV using a deletion mutant 
virus generated through manipulation of the full-length clone of EAV is explored 
next. This work was performed in collaboration with the Department of 
Infectious Diseases and Immunology of the University of Utrecht under the 
direction of Professor Peter Rottier. This group performed all the molecular 
cloning work and generated the recombinant virus. Some of its in vivo properties 
and immunogenicity have been examined to test whether this virus could be used 
as a live marker vaccine.
The genetically modified virus used in our experiments, denoted as EAV-GlA, 
was created through manipulation of the plasmid pEAN515. This plasmid is a 
derivative of the EAV infectious cDNA clone pEAV030-5g/ll KO (de Vries et 
al., 2000; van Dinten et al., 1997), in which the cryptic transcription termination 
signal at position 8941-8956 has been removed by site directed mutagenesis 
while simultaneously creating a Mscl site (mutations: A8941C, T8945A, 
C8946G, T8947C, T8950C, and G8956G). To construct pEANGiA, a PCR 
product was synthesized using the oligonucleotides 983 (5’-
GAGAATTCACGGCCATACCAACAGGTTTTACTGGCGGAAC-3’) and 984 
(5’- CTTGCGTGCAAGTGGTTG-3’) and pEAN515 as the DNA template. The
94
resulting PCR fragment (724 nt) was treated with BgM  and EcoRl, and the 638 
bp digestion product was cloned into BgBl + EcoBJ digested pEAN515 and 
sequenced. EAV RNA was transcribed in vitro from pEANGlA, and BHK-21 
C l3 cells were transfected with the synthetic RNAs by electroporation 
essentially as described by de Vries et al, (2000). The resulting EAV-GlA virus 
presents a deletion of 138 nucleotides of the 0RF5, encoding amino acids 66 to 
112 of the putative ectodomain of EAVGl (Fig. 3.1). This virus was constructed 
considering: a) that an EAV mutant virus presenting this deletion retained its 
infectivity in vitro (Balasuriya et al., 1997) and although it escaped neutralisation 
by murine monoclonal antibodies it was effectively neutralised by equine 
polyclonal EAV specific antisera; b) that a fiill-length cDNA clone derived virus, 
EAV030H, was infectious, avirulent and genetically stable in horses (Balasuriya 
et ah, 1999b) and c) that the Peptide 1 antigen (aa 81- 106), which forms the 
basis of an already developed diagnostic ELISA test (Nugent et ah, 2000), is 
contained within the deleted sequence, theoretically permitting the serological 
discrimination of vaccinated from infected animals. It is difficult to predict 
however, how the absence of G l neutralising epitopes, contained within the 
deleted Gl fragment, will affect the capacity of the deletion mutant virus to 
induce VNAb or protective immunity in ponies. To study the replication features 
of this virus in vivo and the protective efficacy and antigenic specificity of the 
immune responses stimulated, two ponies were infected with EAV-GlA and six 
weeks later challenged, together with two EAV seronegative ponies, with the 
virulent EAV LP3A+ strain.
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3.2. Materials and Methods.
3.2.1. Cells
Primary equine embryonic lung cells (EELs, fibroblastoid) were obtained from 
an established in-house cell line prepared from an aborted foetus. This cell line 
was tested to be free of mycoplasma or equine viruses. The cells were maintained 
in minimum essential medium Eagle with Earle’s salts (Sigma, M2279) 
supplemented with 100 lU of penicillin per ml, 10 pg of streptomycin per ml, 
non-essential amino acids, L-glutamine to a final concentration of 2 mM and 
10% heat inactivated foetal bovine serum (10% MEM). The continuous cell line 
RK-13 was used for the virus neutralisation test.
3.2.2. Viruses
The EAV LP3A+ virus stock, a single passage derivative in EEL cells of LP3A 
was used for challenge infection of ponies as well as for serological testing 
together with the Bucyrus CVL EAV strain (Edwards et al., 1998). These two 
viruses differ at some positions in the Gl coding sequence (Fig. 2.14) but show a 
high degree of antigenic cross-reactivity.
The Gl deletion mutant EAV-GlA was obtained from Dr Roeland Wieringa in 
Professor Rottier’s laboratory. This virus was generated through manipulations 
of the cDNA infectious clone of EAV as indicated above. This virus stock was 
raised in BHK-21 cells.
3.2.3. RT-PCR
RNA was purified from tissue culture fluid of infected EEL cells or RK13 cells 
using the High Pure PCR Template Prep. Kit (Roche Molecular Biologicals)
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following the manufacturer’s instructions. Briefly, 200 pi of tissue culture fluid 
were mixed with 200 pi of ‘Binding Buffer’ (6 M guanidine-HCl, 10 mM urea, 
10 mM Tris-HCl, 20% Triton-X-100, pH 4.4) and 40 pi of Proteinase K and 
incubated for 10 min at 72°C. After the addition of 100 pi isopropanol, the viral 
RNA was bound to a glass fiber filter and washed twice with 500 pi of washing 
buffer (20 mM NaCl, 2 mM Tris-HCl, 80% ethanol, pH 7.5). Finally the RNA 
was eluted with 200 pi of 10 mM Tris-HCl, pH 8.5. As a control, RNA was 
similarly purified from culture fluid of RK13 cells infected with the CVL 
Bucyrus strain of EAV. Reverse transcription of viral RNA and subsequent 
amplification of cDNA of EAV 0RF5 were performed in one step reaction using 
the rTth DNA Polymerase and EZ Buffer (Perkin Elmer) in the presence of 
manganese acetate Mn(0Ac)2 with primers JVl 
(TTACGACTGGTACGTTGGG) and JV2 (GATACTCACCTAAAATCCCG). 
Purified viral RNA (5 pi) was included in a 50 pi PCR reaction containing 300 
pM of each dNTP’s, 0.1 units/pl of the enzyme, 0.4 pM of each primer and 2.5 
mM Mn(0Ac)2 diluted in EZ buffer. Virus present in blood from infected ponies 
was checked similarly for its 0RF5 deletion by RT-PCR of tissue culture fluid 
from infected RK l3 cells.
3.2.4. Vaccination and challenge infections o f ponies.
The EAV-GlA inoculum was prepared by infecting EELs at an m.o.i. of 
approximately 0.002 with BHK-21-derived virus and incubation for 72 h at 
37°C. The tissue culture fluid was then harvested, freeze-thawed, cell debris was 
removed by centrifugation and aliquots of the supernatant were stored at -70°C.
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Procedures for EAV inoculation of ponies have been described previously 
(Chapter 2). Two year-old castrated male Welsh Mountain Ponies (5062, 697b, 
7b69 and 07d41), seronegative to EAV, were used in this study. Ponies 7b69 and 
07d41 were stabled in a contained environment facility and inoculated with 10  ^
TCID50 of EAV-GlA by the intranasopharyngeal route and monitored closely for 
28 days. Nasopharyngeal swabs, heparinized blood and serum samples were 
collected at regular intervals and analyzed for virus and antibody as described 
below. After infectious virus could no longer be detected the ponies were 
released from containment to an isolated barn. Forty-six days after the 
immunisation ponies 7b69 and 07d41 and EAV seronegative ponies 5062 and 
697b were inoculated with 1 0 ^^  TCID50 of EAV strain LP3A+. All four ponies 
were clinically inspected twice a day and serum, heparinized blood and 
nasopharyngeal swabs collected at regular intervals until the end of the study. 
The ponies were released to a third isolated barn when they were regarded as 
non-infectious, prior to then being transferred 2 weeks later to an isolated 
paddock for 4 weeks before they were allowed to have contact with any other 
equines.
3.2.5. Virus isolation and serology.
Virus isolation from blood and nasopharyngeal samples and virus neutralising 
antibody assays were conducted as previously described (Chapter 2). The virus 
neutralization test was performed using three different EAV strains; LP3A+, 
Bucyrus CVL and EAV-GlA. In addition to the serum samples collected from 
the ponies used in this study a panel of EAV-specific horse antisera collected 
from various experimental infections conducted at the AHT with various EAV
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isolates was used. Antibody responses to two Gl derived antigens were analysed 
by ELISA following the procedures described by Nugent et al (2000) with minor 
modifications. The antigens chosen were Peptide-1 (aa 81-106), a region deleted 
in EAV-GlA, and 6 hisGLCCto recombinant protein comprising the complete Gl 
ectodomain (residues 18-122).
3.3. Results
3.2.1. Preparation o f an EAV-GlA virus stock for intranasal administration to 
ponies.
The intranasal route was chosen for immunisation / infection of the ponies with 
the deletion mutant virus, a route which has been used successfully over the 
years with various EAV stocks prepared in primary equine embryonic lung cells 
(EEL’s). Since the recombinant virus EAV-GlA supplied to us by our colleagues 
in Utrecht was generated in non-equine cells, this virus was passaged once in 
EEL’s in order to prepare a stock for immunisation. Monolayers of EEL’s were 
infected with EAV-GlA at an m.o.i. of approximately 0.002 and incubated for 72 
h at 37°C. At this point CPE was widespread and 80% of the cell sheet was 
destroyed. The tissue culture fluid was then harvested, freeze-thawed, cell debris 
was removed by centrifugation and aliquots of the supernatant were stored at - 
70°C. The titre in EEL’s of the new virus stock was 1 0 ^  ^TCED50 / ml, similar to 
other virus stocks of EAV used successfiilly for intranasal infection of ponies.
The EAV-GlA virus stock was analysed by RT / PCR, using EAV specific 
primers flanking ORE 5 to confirm that it comprised virus with a Gl deletion.
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As shown in Figure 3.3, the EAVGlA RT / PCR product is smaller than the wild 
type ORF 5 product from the CVL Bucyrus strain.
Growth curves of the parental EAV-GlA virus in BHK-21 cells, performed in 
Utrecht (not shown) and of EAV-GlA in EEL cells, performed at the AHT by 
Miss Emma Weston (Fig 3.2) indicate that the recombinants possess a slower 
replication rate than wild type EAV viruses.
3.3.2. Clinical, virological and serological responses to EAV-GlA virus 
inoculation.
Once a suitable virus stock for immunisation was obtained and the deletion of the 
Gl fragment confirmed, an experimental infection of two EAV seronegative 
ponies was conducted to study the virus replication features in vivo, clinical signs 
and immunogenicity induced by EAV-GlA.
Ponies 7b69 and 07d41 were inoculated with 1ml of EAV-GlA by the 
intranasopharyngeal route, as indicated in the materials and methods section, and 
monitored for clinical signs for a period of two weeks. Nasopharyngeal swabs 
and blood samples were collected regularly for virus isolation until three 
consecutive samples gave a negative result.
Infection with EAV-GlA did not induce clinical signs in ponies 7b69 and 07d41. 
However, cell associated viraemia and nasopharyngeal virus excretion were 
observed in both ponies (Table 3.4.). Viraemia was first detected on days 4 and 6 
from ponies 7b69 and 07d41 respectively and lasted until day 14 in both animals 
(viraemia was not detected on days 16, 19 and 21, data not shown). Virus 
excretion from the upper respiratory tract occurred between days 1 and 7 but the
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infectivity was below 10^ '^  TCIDso/ml except for the sample collected on day 5 
from 07d41 (10  ^  ^ TCIDso/ml). This contrasts with high titres obtained in nasal 
swab extracts from ponies infected with the wild type virus LP3A (Chapter 2). 
RT / PCR analysis of viral RNA extracted from the virus isolated from a blood 
sample collected from pony 7b69 on day 4 post-inoculation confirmed that the 
recovered virus carried the expected internal deletion of ORF5 (Fig. 3.3). Both 
ponies developed serum VNAb’s against the immunising virus reaching high 
titres by day 21 post-inoculation. In contrast, the serum VNAb titres against two 
wild type EAV strains, LP3A+ and CVL Bucyrus, measured on the same day 
after infection were 2 logio lower. The antigenic specificity of the antibody 
responses was further characterised and described below in section 3.3.4.
3.3.3. Clinical, virological and serological responses to EAV LP 3A+ challenge 
To evaluate the immunity against EAV infection provided by previous exposure 
to EAV-GlA, ponies 7b69 and 07d41, together with two EAV seronegative 
controls (ponies 697b and 5062), were infected with 10 TCID50 of the virulent 
LP3A+ virus by the intranasopharyngeal route, and clinical signs, virus excretion 
and duration of viraemia compared between both groups of animals (Fig 3.5). 
Both control ponies developed evident clinical signs of EAV which included 
pyrexia, depression, anorexia, conjunctivitis, nasal discharge and ataxia in 
contrast to ponies 07d41 and 7b69 which remained asymptomatic during the 
study period. Control ponies presented cell-associated viraemia lasting up to day 
21 post-infection whereas virus was detected only on day 8 from both vaccinated 
ponies. Virus was excreted from the upper respiratory tract from day 1 to day 12
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in the case of 697b or day 1 to day 9 in the case of pony 5062. For the controls, 
virus infectivity of the nasal swab extracts was high (>10^ TCIDso/ml) between 
days 2 to 9 (697b) or 2 to 7 (5062), reaching maximum levels (>10^ TCIDso/ml) 
on days 4 and 5 (5062) or 5 and 6 (697b). In contrast, virus was only isolated on 
one or two occasions from 7b69 and 07d41 respectively, and the nasal swab 
extract infectivity was <10 TCID50.
3.3.4. Serology
The results of the analysis of the antibody responses after EAV-GlA infection 
and LP3A+ challenge are displayed in figures 3.6 and 3.7. After inoculation with 
the deletion mutant virus, ponies 7b69 and 07d41 developed a low titre VNAb 
response against the wild type EAV strains, Bucyrus CVL and LP3A+. Thus, by 
day 14 post-infection, VNAb’s could only be detected in pony 07d41 against the 
LP3A+ strain. These VNAb titres against the wild type EAV strains increased 
slightly until the day of the challenge on day 46 when the titres for the two 
viruses were detectable in both ponies. Interestingly, the VNAb responses were 
stronger against EAV-GlA, reaching titres of 1.35 and 0.8 by day 14, and 2.2 and 
2.8 on day 21 post-infection (for ponies 7b69 and 07d41 respectively). At the 
time of challenge, VNAb titres for both immunised ponies were at least ten times 
higher against EAV-GlA than against the wild type strains, suggesting that the 
deletion mutant virus differs antigenically from wild type EAV.
After challenge, both immunised ponies responded with a rapid increase in 
neutralising antibodies to all three viruses, with titres being generally higher 
against EAV-GlA. The control ponies showed a typical VNAb response after 
EAV infection against both wild type viruses, with titres detectable by day 6 and
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increasing rapidly to reach high values by day 14. In contrast, the titres against 
the EAV-GlA virus were very low, which is consistent with the antigenic 
difference between the viruses.
Examination of the antibody responses to the Gl ectodomain derived antigens by 
ELISA (Fig. 3.7) showed an undetectable response to the Peptide 1 antigen (aa 
81-106) by ponies 7b69 and 07d41 after immunisation with the deletion mutant 
virus, consistent with the absence of this antigenic peptide from the EAV-GlA 
virion. A weak reaction to this antigen was observed with serum collected from 
pony 7b69 collected 14 days after experimental infection with LP3A+. In 
contrast, both EAV-GlA immunised ponies developed an antibody response to 
6hisGLCCto (aa 18-122) which was subsequently boosted after challenge 
becoming at least three-fold higher than that those against Peptide-1. Both 
control ponies developed antibody responses against the two antigens after 
challenge which, in contrast to the pre-immunised ponies, were at similar levels 
for both antigens.
To study further the antigenic differences exhibited in the VN test by the deletion 
mutant and wild type viruses, a panel of sera collected from experimentally 
infected ponies was analysed in a cross neutralisation test against CVL Bucyrus 
and EAV-GlA viruses (Table 3.8). These ponies were infected with one of the 
following viruses; LP3A, LP3A+, UK93 (a second passage in BHK-21 of a 
semen isolate collected from the UK outbreak in 1993), pf (a pleural fluid isolate 
of velogenic Bucyrus), sp (a small plaque variant of pf obtained by three cycles 
of plaque picking) and ‘vero-adapted’ (a derivative of pf obtained after 30
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passages in Vero cells). The results show that, with the exception of samples 
from the vero-adapted and EAV-GlA infected ponies, all the antisera neutralised 
efficiently the wild type CVL Bucyrus presenting VNAb titres above 2. 
Conversely, only EAV-GlA post-infection sera neutralised at a high titre the 
EAV-GlA virus. Interestingly, the VNAb titres against the deletion mutant virus 
of vero-adapted sera were low too. These data altogether supports the hypothesis 
that EAV-GlA differs antigenically from wild type EAV strains. This might be 
the case as well for the vero-adapted EAV strain.
3.4. Discussion
In the work presented above, the potential of a genetically modified EAV virus 
presenting a deletion in the immunodominant region of the Gl ectodomain as a 
marker vaccine has been explored. As a live marker vaccine this virus should 
present the following features:
a) expression in vivo of those proteins relevant for the induction of immune 
response; b) safety for the individual, therefore non-pathogenic, and safety for 
the environment; c) induction of an immune response allowing serological 
distinction from natural infection and d) induction of protective immunity against 
infection.
In this pilot study we have performed for the first time an infection of ponies 
with EAVGlA to evaluate how well this potential marker vaccine complies with 
the above mentioned requirements. In particular, the study was designed to test 
whether the virus retained its infectivity and determine the outcome of the 
infection in terms of pathogenicity and immunogenicity.
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The administration route and virus dose used are known to infect ponies reliably 
using other EAV strains and both ponies inoculated with EAVGlA became 
infected. The experiment showed, consistent with experiments performed in vitro 
in RK-13 cells and EDC, that despite deletion of parts of Gl, the virus conserved 
its infectivity in vivo since virus was isolated repeatedly from nasal swabs and 
blood from the ponies. This is consistent with a recent study showing that 
chimeric EAV viruses in which the Gl ectodomain was replaced by that of 
PRRSV or LDHV were still infectious to BHK-21 and RK-13 cells (Dobbe et al, 
2001).
Despite being infected with EAVGlA virus, the animals remained asymptomatic 
during the infection and the levels of virus excretion were low, suggesting the 
possible attenuation of this virus. However, the present experiment did not 
permit the assignment of this apparent attenuation to the genetic manipulation 
introduced since virus derived from the full length Gl plasmid pEANSlS was not 
tested in parallel with EAVGlA virus. Comparison with the results of an 
experimental infection of horses with the virus derived from the full length clone 
pEAV030 (Balasuriya et al, 1999b) does not provide a conclusive answer since 
duration of viraemia and nasal excretion were similar to those described for 
EAVGlA virus infected ponies but, unlike our study, both ponies became febrile 
albeit mildly. Furthermore, EAV often occurs asymptomatically in the field and 
experimental infections with some isolates (McCollum and Timoney, 1998; 
Castillo-Olivares, unpublished observations) produced no remarkable clinical 
signs. Both ponies infected with EAVGlA presented viraemia and therefore there 
is a potential for causing abortion in the pregnant mare. Also, the fact that EAV-
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GlA can be excreted from the upper respiratory tract, although at lower titres 
than wild type EAV strains, and is infectious by the natural route could be 
undesirable features of this virus as a vaccine. Continuous transmission of EAV 
in horses could result in the generation of novel genetic variants with increased 
pathogenicity. The generation of new genetic variants has been described in 
persistently infected stallions and this has been identified as the origin of an 
outbreak (Balasuriya et al., 1999a). Also the attenuated live PRRSV vaccine has 
been demonstrated to be transmitted from vaccinated pigs to susceptible animals 
with the appearance of novel genetic variants which are more pathogenic 
(Nielsen et al., 2001). Further studies are required to evaluate attenuation in more 
detail. In particular, with regards to the abortigenic potential of the recombinant 
virus, reversion to virulence and capacity to establish persistent infections in 
stallions.
The present study allowed us to evaluate the immunity against EAV infection 
provided by exposure to the deletion mutant virus. Both ponies inoculated with 
EAV-GlA mounted an immune response to EAV as evidenced by the detection 
of antibodies in serum to whole Gl ectodomain and by the demonstration of 
VNAb to wild-type EAV. Complete clinical protection against the virulent 
LP3A+ virus was observed accompanied by only occasional isolation of 
challenge virus from nasal swabs and blood in the vaccinated ponies. This level 
of protection was unexpected in the light of the relatively low VNAb titres (1.2 
and 0.8) against LP3A+ at the time of challenge. These VNAb’s were stimulated 
after EAV-GlA infection and boosted after challenge despite the Gl ectodomain 
being partially deleted from the immunising virus. Consequently, these
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antibodies must either recognise epitopes in the modified G l polypeptide 
(antigenic sites A and B as identified by Balasuriya et a l (1997) are still present 
in the deletion mutant virus) or be directed to - yet unidentified - neutralising 
epitopes lying outside the Gl protein. However, it seems unlikely that VNAb 
alone can have provided the levels of protection observed. Previous studies 
(Chapter 2) showed that ponies vaccinated with a recombinant protein 
comprising the entire Gl ectodomain presenting titres around 1.0 at the time of 
challenge were only partially protected, despite these ponies showing a strong 
anamnestic response after infection. More likely, the intranasal administration of 
a replicative immunogen may have stimulated a wide range of immune effector 
mechanisms, not dependent upon the deleted region of the Gl protein. Thus, 
strong VNAb responses directed to epitopes outside the Gl(66 -112) region may 
have been elicited efficiently, particularly at the natural port of virus entry in the 
nasal mucosa. Alternatively, cell-mediated immunity may have contributed to the 
protection against challenge infection. Antibody-dependent cell-mediated 
cytotoxicity (ADCC) and cytotoxic T lymphocytes have been described in the 
horse (Allen et a l, 1994; O’Neill et a l, 1999; McGuire et a l, 1997). Recently, 
methods for the detection of EAV specific cytotoxic responses have been 
developed and the induction of CD8+ CTL responses following wild-type EAV 
infection has been demonstrated (Chapter 4). These and other methods should 
enable us to characterise the immune effector mechanisms that are stimulated 
after immunisation with EAV-GlA and to evaluate the relative importance of 
antibody- versus cell-mediated mechanisms.
The serology results indicate that the deletion mutant virus stimulates an 
antibody response that would allow differential diagnosis with natural infection
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making it a potential marker vaccine. Following EAV-GlA immunisation, 
antibody responses were detectable but were different to those following wild 
type infection. Thus, VNAb was preferentially directed against the deletion 
mutant virus rather than wild type EAV, and anti-Peptide 1 responses could not 
be detected by ELISA. In contrast, all post-challenge sera reacted to the Peptide- 
1 antigen and neutralised very efficiently wild type EAV viruses. The different 
antigenic properties shown by the serology results of the four ponies used in this 
study were confirmed by analysis of the virus neutralisation capacity of a panel 
of post-infection antisera. The poor neutralisation of wild type EAV by EAV­
GlA antisera and conversely poor neutralisation of EAV-GlA by wild type EAV 
antisera suggests that there are no other VN epitopes apart from those in Gl and 
that the deletion in this protein has resulted in the formation of a new antigenic 
site targetted by the immune system that results in virus neutralisation in vitro.
The use of the full-length clone has proved to be a very valuable tool to construct 
a potentially efficacious marker vaccine and can be used to dissect the effector 
mechanisms of the adaptive immune response and understanding their role in 
protection.
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Figure 3.1. Schematic representation of the EAV virion. The regions of the Gl ectodomain 
that contribute to form neutralising epitopes are indicated by the white boxes. The size of 
deletion in the Gl ectodomain which was made to generate EAV-GlA is indicated by the 
two vertical lines. The two Gl derived antigens used to analyse the antibody responses of 
ponies to EAV-GlA and EAVLP3 A+ inoculation is indicated by the red lines. The putative 
signal sequence is indicated by the hatched box.
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Figure 3.2. Low multiplicity of infection (m.o.i. = 0.001) virus growth 
curves of LP3A+ (blue line) and EAV-GlA (red line) viruses
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Figure 3.3. RT-PCR analysis of 0RF5 from EAV-GlA inoculated into 
and retrieved from ponies. RT-PCR amplification of ORE5 was carried 
out on tissue culture fluid, using primers JVl and JV2. The presence of 
the deletion in ORE5 was checked both of the input virus and of virus 
present in the blood of one of the ponies (#7b69) at day 4 after 
inoculation with EAV-GlA. Lane 1: EAV-GlA inoculum virus 
prepared in EEL cells; lanes 2 and 3: wild type EAV strain CVL 
Bucyrus grown in RK13 cells; lane 4; uninfected RK13 tissue culture 
fluid; lane 5: virus recovered in RK13 cells from EAV-GlA infected 
pony (#7b69); lane 6: challenge virus (LP3A+) prepared in EEL cells. 
On the left the positions and sizes of marker DNA fragments are 
indicated (in nucleotides).
I l l
days 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
virus isolation from swab + + + + + + neg neg neg
Pony 07d41virus isolation from hep neg neg + + + + +
Recta! Terrpe rature 37.8 37.9 37.4 37.6 37.7 38.1 37.8 37.9 38 38 37.8
virus isolation fromswab + + + + + + neg neg neg
Pony7b69virus isolation from hep neg + + + neg + +
Rectal Terrperature 37.6 37.9 37.4 37.8 37.9 38.1 37.95 38.1 37.7 38 38
Table 3.4. Pyrexia, virus nasal excretion and viraemia from ponies 7b69 and 07d41 over a 
14 day period following intranasal infection with EAVGlA .
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Fbny 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1 19 21
07d41 neg neg neg + neg neg neg I
7b00 neg neg neg + neg neg neg |
5062 + + + + + + + @ +• +
eOTb + + + + + + + 1 + +
Figure 3.5. Rectal temperature (a), nasal virus excretion (b) and cell associated viraemia 
(c) of pre-vaccinated (7b69 and 07d41) and control ponies (5062 and 697b) following 
intranasopharyngeal challenge with EAV LP3A+ strain. Shadowed boxes indicate 
samples not taken.
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Time of VN A b titres
Pony ID Challenge virus sampling CVLBucyrus GLdeletion mutant
7b69 GLdeletion mutant 21 <0.6 2.2
07d41 GLdeletion mutant 21 0.6 1.9
6d2c LP3a 28 2.4 0.75
3566 LP3a 28 2.3 0.75
1757 Pf 29 2.9 0.9
2dSe Pf 29 2.5 0.7
0350 vero adapted 28 0.6 1.05
3227 vero adapted 28 0.75 0.8
6540 sp 7 month 2.55 1.05
3d1a sp 7 month 2.5 1.05
2970 LP3a 14 1.95 <0.6
chnt LP3a 14 2.25 1.05
37c uk93 40 2.5 <0.6
gp uk93 33 2.8 0.75
bp uk93 33 2.8 <0.6
7378 LP3a+ 30 2.85 0.75
5d66 LP3a+ 30 3.4 1.4
027a LP3a+ 30 2.85 1.05
Table 3.8. VNAb titres (expressed in loglO) against CVL Bucyrus and EAV-GlA of a 
panel of sera collected from ponies experimentally infected with different EAV strains.
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Chapter 4: Detection of EAV-specific Cytotoxic T Lymphocyte 
Responses from EAV Infected Ponies.
4.1 Introduction
Virus neutralising antibodies (VNAb) are believed to play an important role in 
the immunity against equine viral arteritis (Fukunaga et a l, 1981; McCollum, 
1969). Their appearance in serum coincides with clinical recovery and reduction 
of virus excretion, passive transfer of colostrum antibodies from immune mares 
to foals was found to moderate or prevent equine viral arteritis (McCollum, 
1976) and protection in animals immunised with inactivated (Fukunaga et al., 
1984, 1990) or GL-sub-unit vaccines (Castillo-Olivares et al., 2001, Chapter 2) 
correlated with VNAb titres at the time of challenge. Currently, nothing is known 
about cell mediated immunity (CMI) to EAV such as the role it plays in 
clearance of virus infection and whether it would be desirable to stimulate such 
immunity by vaccination. However, virus specific cytotoxic lymphocytes have 
been detected in mice infected with the arterivirus LDV (Even et al., 1995, van 
den Broek et al., 1997) and there are some indications that CMI plays an 
important role in clearance of SHFV infections since persistently infected patas 
monkeys with low titre VNAb’s can clear subsequent acute infections caused by 
a different strain (Gravel! et al., 1986a). Furthermore, EAV-GlA immunised 
ponies with low VNAb titres against LP3A+, were highly protected against this 
strain, suggesting the involvement of immune effector mechanisms in addition to 
VNAb’s in protection from EAV (Chapter 3).
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Animals that recover from EAV infection develop a long lasting immunity 
against the disease (Gerber et al., 1978) although not always against reinfection 
(McCollum, 1969). However, EAV replication in chronically infected stallions, 
which is restricted to cells of the accessory sex glands, persists for several 
months or years despite high levels of circulating VNAb’s. EAV is able to 
establish persistent infections in the reproductive tract of the stallion and the cell 
associated viraemia that occurs soon after infection lasts from one to several 
weeks after serum VNAb’s become detectable (Neu et al., 1987; Castillo- 
Olivares, Unpublished observations). The role that immune effector mechanisms 
other than VNAb’s play in viral clearance during acute or chronic infections is 
largely unknown due to the lack of methods to study these responses.
The aim of the following work is to determine whether EAV induces cytotoxic 
CMI responses and to examine some of their features in the natural host. To do 
this work, cell targets (targets) were collected from experimentally infected 
ponies and the activity of EAV-specific cytotoxic cells (effectors) was measured 
using a standard ^^Cr release assay. In order to study cytotoxic T lymphocyte 
(CTL) responses to EAV, the following ponies were used:
• ponies 7378, 027a and 5d66 (infected with LP3A+ to validate this virus stock 
as a suitable challenge virus for vaccine efficacy studies)
• ponies 697b, 5062, 7b69 and 07d41 (used to evaluate the immunity provided 
by the EAV-GlA virus - chapter 3).
Skin biopsies were taken from the ponies before infection with EAV to prepare 
primary cell lines to be used as targets in CTL assays and blood samples were 
collected at various times after infection to isolate PBMC’s for use as ‘effectors’.
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4.2. Materials and Methods
4.2.1. Animals
Seven two-year-old castrated male ponies were used to obtain peripheral blood 
mononuclear cells (PBMC) and equine dermal cells (EDC). Both types of cells 
were used in assays to detect EAV-specific CTL responses. Ponies 7378, 027a, 
5d66, 5062 and 697b were infected intranasally with 10^  ^ TCID50 of the EAV 
LP3A+ strain and ponies 07d41 and 7b69 were immunised with EAVGLA and 
subsequently challenged with EAVLP3A+. Clinical signs and antibody responses 
of ponies 7b69, 07d41, 697b and 5062 to EAVGlA and / or EAVLP3A+ 
infections have been described previously (Chapter 3). EAVLP3A+ infections of 
ponies 7378, 5d66 and 027a resulted in a moderate-severe acute EAV syndrome 
characterised by pyrexia, anorexia, lethargy, weight loss, mild ataxia and 
conjunctivitis, similar to those described for ponies 5062 and 697b. Virus was 
isolated from nasal secretions for the first week of infection and from blood up to 
day 21 post infection. VNAb were first detected in serum by day 6 post infection, 
rose to titres of 1/100 and remained stable for more than a year.
4.2.2. Viruses and cells
A derivative of the EAV strain LP3 A (Chapter 2) was used for in vitro infections 
and for the experimental infection of ponies. This virus, designated EAV LP3A+, 
was obtained by a single passage of EAV LP3A in equine embryonic lung cells 
(EEL) using a low multiplicity of infection. The Diagnostic Virology Laboratory 
of the Animal Health Trust supplied this primary cell line, obtained from an 
aborted foetus. The cell line was tested to be free of mycoplasma or equine
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viruses. The cells were maintained in MEM [minimum essential medium Eagle 
with Earle’s salts (Sigma, M2279), 100 lU of penicillin per ml, 10 |ig of 
streptomycin per ml, non-essential amino acids, L-glutamine to a final 
concentration of 2 mM ] and supplemented with 10% heat inactivated fetal 
bovine serum (10% MEM). Equine dermal cells (EDC) obtained from the ponies 
used in this study via skin punch biopsies were maintained in 10% MEM or 20% 
MEM.
4.2.3. Radiolahelling o f EDC
EDC monolayers, prepared as described in section 4.3.1., were washed twice 
with PBS and then trypsinised. Once detached, the cells were resuspended in 
10% MEM and centrifuged for 5 min. at 475 g. and resuspended in 20% MEM at 
4 X 10^  cells / ml. The cells were inoculated with EAV LP3A+ at a m.o.i. of 0.3 
TCIDso / cell or left uninfected. Then, Na^^Cr0 4  (Amersham) was added to each 
cell suspension to a final concentration of 1-1.5 p,Ci / 4xl0"  ^ cells before 
distributing volumes of lOOpl into 96 well flat bottomed plates. The plates were 
incubated at 37°C, 5% CO2 for 24 hours.
4.2.4. Secondary stimulation o f in vivo primed PBMC (effectors)
The induction of cytotoxic cells from PBMC was conducted essentially as 
described for detection of EHV-1 specific CTL by Allen et al. (1995) with minor 
modifications. Briefly, whole venous blood was collected at various times after 
infection into vacuum tubes containing 1 lU of sodium heparin in PBS / ml of 
whole blood, and then the mononuclear cell fraction isolated by Ficoll-Hypaque
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density gradient centrifugation. PBMC were collected from the interface, washed 
3 times in PBS to reduce the number of platelets and resuspended in either 
freezing medium (10% dimethylsulfoxide, fetal bovine serum) or induction 
medium [1:1 vol/vol mixture of AIM-V (Gibco) / RPMI 1640 (Sigma) 
supplemented with 2mM L-glutamine, minimal essential medium non-essential 
amino acids (0.05 mM each), 0.5 mM sodium pyruvate, 2-mercaptoethanol (55 
|xM), gentamicin (50 |ig/ml) and equine serum (7% - collected from the ponies 
before EAV experimental infection and inactivated at 56°C for 40 min)]. The 
PBMC were incubated in induction medium for 7 days in upright 75 cm^ tissue 
culture flasks at 1.1 -  2.0 x 10  ^ cells / flask / 40 mis in the presence or absence 
(for preparation of mock-induced effector cells) of 10^  ^TCID50 of EAV LP3A+.
4.2.5. Measurement o f cytolytic activity o f ‘ in vitro ’ stimulated PBMC. 
EAV-induced and mock-induced PBMC cultures were centrifuged at 800 g, 
20°C, 10 min, without brake, the supernatant was discarded and cell pellets 
resuspended in CTL medium (RPMI 1640 containing 10% heat inactivated 
equine serum). Both cultures were adjusted to contain the same concentrations of 
viable cells (determined by trypan blue exclusion) and diluted appropriately in 
CTL medium to obtain different effector: target ratios when added to the 
overnight grown fibroblasts. Target cells (24 hr after addition of ^^Cr, +/- EAV 
infection) were washed 3 times with RPMI 1640 using 125 |il / well in each wash 
before the addition of either the effectors, a CTL medium control or cell lysis 
solution (2% Triton-XlOO in PBS). The plates were incubated for 4 hours at 
37°C, 5% CO2 after which the supernatants were harvested (Supernatant
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Harvesting System, Skatron, Newmarket, Suffolk) for quantitation of ^ ^Cr release 
by gamma counting. The lytic activity of each PBMC culture dilution was 
assessed against 4 - 6  replicates of EAV infected and uninfected autologous or 
allogeneic radiolabelled targets. The percentage of specific ^^Cr release was 
calculated according to the formula: [{e -  sp) /  (t -  sp) ] xlOO, where e is the 
experimental ^^Cr release in the presence of effectors, sp is the spontaneous ^^Cr 
release in the presence of CTL medium, and t is the total ^^Cr release from 
targets incubated with cell lysis solution.
4.2.6. Indirect immunofluorescence
Equine dermal fibroblasts or cytospins of PBMC were fixed in acetone or 4% 
formaldehyde, 0.4% Triton-X 100 in PBS for 15 min at room temperature. After 
washing in PBS, an anti-EAV nucleocapsid (N) specific rabbit polyclonal 
antiserum (de Vries et al., 1992) diluted 1/100 in PBS A (2% bovine serum 
albumin, PBS) was applied to the cells and incubated for 1 hour at 37°C. After 
washing in PBS, the samples were incubated for 1 hour at 37°C with an anti­
rabbit IgG FITC conjugated antibody (DAKO, Denmark) diluted 1/40 in PB SA, 
washed again in PBS and observed using a fluorescence microscope.
4.2.7. Flow cytometry
Equine dermal cells were pre-treated before immunostaining procedures in 
suspension were carried out. Confluent monolayers of EDC were trypsinised, 
washed in 20% MEM, resuspended in 20% MEM and incubated at 37°C, 5% 
CO2 for 2 hours. In vitro induced effectors and pre-treated targets were washed in
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PBSG (0.5% normal goat serum, 0.01% sodium azide, PBS) 3 times and 2x10*^  
cells resuspended in PBSG containing monoclonal antibodies (MAb) (2 |ig / ml) 
specific for equine lymphocyte antigens (Lunn et al., 1998). Cells were incubated 
with MAb H58A, H42A, HT14A or HB61-A (VMRD Inc., Pullman, USA) 
specific for MHC-I, MHC-II, CD8 and CD4 antigens respectively. Background 
staining was determined using an IgGl isotype control MAb (DAKO, Denmark). 
After 1 hour incubation on ice, the cells were washed with ice cold PBSG and 
resuspended in goat anti-mouse IgG FITC conjugated antibody (DAKO, 
Denmark) diluted 1/40 in PBSG and incubated for 1 hour in ice. After a final 
wash in PBSG the cells were fixed in 2% formaldehyde and analysed on a 
FACScalibur flow cytometer (Beckton Dickinson). Dead cells were identified 
using propidium iodide staining at a concentration of 20 pg / ml.
4.2.8. Separation o f CD4+ and CD 8+ T cells from induced PBMC cultures 
Biomagnetic separation of effector cells was performed using the MACS Goat 
anti-mouse IgG microbeads and MS Separation Columns (Miltenyi Biotec, 
Germany) following essentially the manufacturer’s recommendations. Briefly, 
after 7 days incubation, the PBMC cultures were centrifuged, the supernatant 
discarded and the cells washed twice in separation buffer (PBS, 0.5% BSA, 2mM 
EDTA). The stimulated PBMC were then incubated for 1 hour at 4°C in 
separation buffer with or without 2pg/ml of either anti-equine CD4 MAb HB61A 
or anti-equine CD8 MAb HT 14A. The cells were washed twice in separation 
buffer and incubated with the anti-mouse IgG conjugated microbeads for 1 hour 
at 4°C before being washed again in separation buffer and applied to the 
separation columns. Both enriched and depleted cell fractions were collected,
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centrifuged and the cell pellets resuspended in CTL medium to obtain equivalent 
concentrations of effectors. The cells were then assayed for cytotoxic activity as 
described above.
4.3. Results
4.3.1. Preparation o f cytotoxic cell targets.
4.3.1.1. Establishing Primary Equine Dermal Cell (EDC) lines from skin 
biopsies.
Primary EDC lines were established for each pony used in the study. Skin punch 
biopsies were performed under aseptic conditions, the epidermal portion of the 
sample removed and the dermal plug inmersed in 20% MEM and transported to 
the laboratory for immediate processing. The dermal plug was sliced with the 
help of sterile scalpel blade and forceps and each slice laid on a well of a 6 well 
flat bottomed plate. Fresh 20% MEM was added to each well and the plates 
incubated at 37°C, 5% CO2 for five days. Once islets of fibroblasts were 
observed growing, the inoculum was removed and fresh 20% MEM was added 
and incubation continued at 37°C, 5% CO2 until a confluent monolayer was 
formed. Then the cells were passaged to a 25 cm^ tissue culture flask, expanded 
and finally resuspended in 10% DMSG in foetal calf serum (FCS) for 
cryopreservation in liquid nitrogen. All the experiments were performed with 
cells between passages 5 and 14.
4.3.1.2. Infection o f Equine Dermal Cells with EAV.
EDC’s can support EAV replication, but in order to use them in a cytotoxicity 
assay, a high proportion should be viable and express viral antigen at the time
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they are incubated with the effectors. Virus titration of EAV in EDC’s and other 
cell lines indicated that at certain virus dilutions the cell sheets did not show 
cytophathic effect until 48 hours post-inoculation, retaining their normal 
morphology for the first 24 hours. To check the proportion of cells expressing 
viral antigens at this time post-infection, EDC suspensions in 10% MEM infected 
with LP3A+ at different multiplicities of infection were seeded on a flat 
bottomed 96 well plate at 4x10"^  TCID50 / well. After a 24 hour incubation period, 
the cells were washed and fixed with fbrmaldehyde-Triton-X-100 (4% 
formaldehyde, 0.4 % Triton-X-100, PBS) and EAV N antigen expression 
checked by immunofluorescence. The results indicated that at a m.o.i. of 0.3, 
antigen expression was observed in a high proportion of cells and the cells 
conserved their normal morphology (Fig 4.1).
4.3.1.3. Expression ofMHC-1 andMHC-Il on the surface o f ED C s  
Cytotoxic T lymphocytes recognise non-self antigens through interaction of their 
T cell receptor and co-receptor (CD4 or CD8 ) with processed peptides displayed 
by MHC-I or MHC-II molecules on the surface of cells. With a few exceptions, 
such as neurons, MHC-I molecules are present in all nucleated cells, although the 
levels of expression vary between different tissues. In contrast, expression of 
MHC-II is restricted to endothelial cells and various cells of the immune system. 
To check whether EDC’s express MHC-I or MHC-II after being processed in the 
laboratory, cell suspensions were subjected to immunofluorescence staining with 
specific MAb’s and flow cytometry scanning. The results (Figure 4.2) showed 
that EDC’s express MHC-I but not MHC-II, indicating they could be used as
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targets recognised by CD8+ CTLs, but not by CD4+ lymphocytes restricted by 
MHC-II.
4.3.1.4. Retention of^^Cr
Standard ^^Cr release cytolysis assays are based in the property of viable cells 
taking up Cr in the form of Na2^^Cr0 4 , which is then released very slowly to the 
extracellular medium. When cell damage occurs, the isotope complexes are 
released and the y-radiation emitted by the extracellular medium can be 
measured as an indication of cell lysis. In order to test whether EDC’s could 
absorb and retain ^^Cr, two sets of EDC suspensions in 20% MEM containing 
4x10^ cells/ml were labelled with 10 p,Ci/ml of Na2^^Cr0 4 . One was infected 
with EAV LP3A+ at a m.o.i. of 0.3. The other was left un-infected. Both sets of 
cells were dispensed in 12 wells of a flat bottomed 96 well plate and incubated 
for 24 hours at 37°C, 5% 02. After incubation, the plates were washed 3 times 
with 150 p,l / well of serum-free MEM and the cells from each set were incubated 
for 4 hours with 100 p,l / well of either 2% Triton-X-100 solution or MEM 
containing 10% of inactivated normal autologous equine serum (CTL medium). 
The liquid contents of each individual well were harvested and radioactivity 
measured. The results (Table 4.3) show little variation between wells containing 
the same type of cells and a percentage spontaneous ^^Cr release of 18.5% and 
15.3% for the EAV infected and un-infected cells respectively.
These studies showed that EDC’s expressed MHC-I molecules and that 24 hours 
EAV infection at an m.o.i. of 0.3 the majority of cells expressed EAV antigen 
and retained normal morphology. Moreover, these cells were successfully
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labelled with and showed sufficiently low spontaneous release of isotope to 
function as viable targets for CTL.
4.3.4. Induction o f cytotoxic cells (effectors) from PBMC o f EAV convalescent 
ponies.
Peripheral blood mononuclear cells obtained from EAV infected ponies were 
used as the source of EAV-specific cytotoxic cells. PBMC’s were obtained by 
standard methods and were stored in liquid nitrogen or used directly for 
stimulation with EAV. Stimulation of CD8+ cytotoxic cells against EHV-1 has 
been achieved by incubation of PBMC’s with virus for 6 days without the 
addition of external cytokines (Allen et al., 1995). This procedure was used to 
induce EAV-specific cytotoxic cells.
First attempts to detect EAV specific cytotoxicity were performed using 
cryopreserved PBMC’s. After thawing, the PBMC’s were centrifuged to remove 
the DMSO and were resuspended in Induction Medium. The PBMC’s were split 
into 2 sets, one of which was inoculated with LP3A+ virus. EAV-induced and 
mock-induced PBMC cultures were processed as indicated in 4.2.5. and 
incubated with EAV-infected and uninfected targets. Radioactivity of each 
individual well was measured and the percentage specific lysis calculated.
A cytolysis assay, performed with cryopreserved effectors derived from pony 
5d66 PBMC collected 21 days post-infection and autologous targets (Table 4.4), 
showed very low levels of specific lysis for the 4 combinations of effectors and 
targets used. In a second assay, cryopreserved PBMC’s collected 42 days post­
infection from pony 7378 were induced and cytolysis measured against EAV-
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infected and uninfected autologous targets. In this assay the effector: target ratios 
were increased with respect to the previous assay and N antigen expression of 
EAV infected EDC’s was checked by immunofluorescence at the time effectors 
were added to the targets. Again, there was no evidence for EAV-specific 
cytotoxicity (Table 4.5) even though immunofluorescence results (not shown) 
indicated that approximately 80% of the cells were expressing EAV N protein 
and the viability of the effectors was approximately 80% as determined by 
Trypan Blue exclusion staining. The assay was repeated again using 
cryopreserved PBMC’s but produced similar results (not shown).
Monocytes and macrophages are the main cell targets of arteriviruses. Damage of 
these cells during freezing and thawing processes of PBMC could have resulted 
in the depletion of EAV permissive cells in the induction cultures, thereby 
preventing virus antigen expression, protein processing and presentation of virus 
peptides by MHC-I on the surface of antigen presenting cells. Consequently, a 
new cytolysis assay was set up using fresh PBMC’s in the induction cultures. 
This time, effectors derived from pony 7378 PBMC’s collected 4 months post­
infection showed EAV specific cytolytic activity. The specific lysis induced by 
EAV-stimulated effectors on EAV-infected targets was more than double that for 
mock-infected targets or induced by mock-stimulated PBMC’s (Fig. 4.6).
Hematoxylin-eosin staining of 7 day-old PBMC cultures showed a marked 
reduction in the numbers of monocytes in the EAV induced effectors compared 
with the mock-induced effectors (Fig 4.7). Samples from the EAV induced 
PBMC’s taken 24 hours after virus inoculation revealed EAV N antigen 
expression on the PBMC’s (Figure 4.7c). The morphology of the infected cells
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suggested that they were monocytes. To check whether cryopreservation could 
have damaged EAV-permissive PBMC subpopulations in the induction cultures, 
cryopreserved PBMC’s isolated from pony 5062 before infection and collected 
fresh 6 weeks post-infection (viraemia was cleared by week 4 post-infection) 
were infected with EAV using the same conditions as those described above. 
Twenty-four hours after inoculation with the virus, the cells were resuspended, 
washed, fixed and checked for N antigen expression by immunofluorescence. 
Only freshly collected PBMC’s were positive (data not shown).
4.3.5. Effects o f equine serum origin on the induction o f cytotoxic cells. 
Pre-infection autologous serum was used to prepare the induction medium used 
in the above experiments and also in the first 2 assays performed to evaluate 
genetic restriction of EAV-specific cytotoxicity (section 4.3.6). Since the 
availability of this reagent posed a limitation to the number of assays that could 
be performed, an experiment was set up to test whether the use of heterologous 
equine serum affected the generation of cytotoxic cells. A pool of 4 EAV VN 
negative sera, obtained before infection from ponies 5062, 697b, 07d41 and 
7b69, was used as the heterologous serum. Two sets of induction medium whose 
composition differed only in the source of equine serum (autologous or 
heterologous) were used to prepare EAV stimulated and mock-induced effectors. 
Cytotoxic effector cells were prepared from PBMC collected from pony 027a 6 
months post-infection. The lytic activity of the effectors was tested against EAV 
infected or uninfected targets. The results (Figure 4.8) show no difference 
between the specific lysis obtained by either set of EAV-induced effectors
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demonstrating the adequacy of heterologous serum as a component of induction 
medium.
4.3.6. Genetic restriction o f EAV specific cytotoxicity.
The ponies used as sources of effector cells in these studies were from an outbred 
population and it was not possible to determine their MHC-I haplotype. To 
determine whether the virus-specific cytolytic activity exhibited by EAV 
stimulated effectors collected from convalescent ponies was genetically 
restricted, a series of cross-matching cytotoxicity assays were performed. In 
these experiments, EAV induced and mock-induced PBMC’s from one 
individual were incubated with autologous or allogeneic EAV or mock-infected 
targets. The first of the experiments (Fig 4.9.a) showed EAV induced 7378 
PBMC’s collected 6 months post-infection specifically lysed autologous and 
027A derived EAV-infected targets. All uninfected and 5D66 derived EAV 
infected cells showed low levels of lysis. Assuming that cytolysis was mediated 
by MHC-I restricted CTL, the data suggested that pony 7378 shared a MHC-I 
allele with pony 027A but not with 5D66. To test this hypothesis, a second cross 
matching cytolysis experiment was carried out (Figure 4.9.c) in which PBMC’s 
collected 6 V2 months post-challenge from pony 5D66, were incubated with EAV- 
infected or uninfected EDC’s from ponies 5D66, 7378 and 027A. Only killing of 
autologous EAV infected targets was observed, supporting the hypothesis that 
cytolysis was genetically restricted by MHC-I. In a further experiment, EAV- 
induced and mock-induced PBMC from pony 027A, collected 8 months post­
infection, were incubated with infected and uninfected targets from the three 
ponies. This time, 027A effectors recognised EAV-infected target cells from
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ponies 027A and 7378, but not uninfected cells or EAV-infected cells from pony 
5D66 (Fig 4.9.e). Mock-induced effectors did not show significant specific 
cytolytic activity in any of these experiments (Figs 4.9.b, 4.9.d and 4.9.f).
4.3.7. Attempts to block effector cytolysis with anti-MHC-I monoclonal antibody. 
The results of the CTL assays presented above suggest that EAV-specific 
cytolysis was mediated by MHC-I restricted CD8+ T lymphocytes. Blocking of 
MHC-I molecules on the targets with specific MAb’s was performed to obtain 
further evidence for the MHC-I restricted nature of cytotoxicity. In this 
experiment, effectors (EAV- and mock-induced) derived from the PBMC of 
pony 5d66 collected 7 months post-infection were split into 2 sets. Set A 
effectors were used used in a standard CTL assay. Set B cells were used in a 
CTL assay at an effector; target ratio of 50:1 in which the targets contained 3p.g, 
Ipg or 0.3 pg per well of anti-MHC-I MAb H58A. The results (Fig. 4.10) showed 
that the presence of the anti-MHC-I antibody did not prevent the EAV specific 
cytotoxicity.
4.3.8. Further analyses o f genetic restricted cytolysis
The genetic restriction of the EAV specific cytotoxicity was examined further 
using effectors and targets derived from another group of ponies that underwent 
an EAV experimental infection. A cytolysis assay using effectors derived from 
pony 7d41 obtained 5 months after challenge and targets originated from ponies 
697b, 5062, 7b69 and 7d41 showed again the genetic restricted nature of the 
EAV specific cytolysis exhibited by EAV induced effectors (Fig. 4.11). Effectors 
derived from pony 7d41 recognised only autologous targets.
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A second cytolysis assay was performed with this set of 4 targets using effector 
cells induced from PBMC’s collected 6 months post-infection from ponies 697b 
and 7b69. The results of this experiment (Fig. 4.12) showed an EAV-specific 
cytotoxic response of 697b effectors, which was restricted to autologous targets. 
In contrast, 7b69 effectors showed a more promiscuous killing causing specific 
lysis of EAV infected targets from ponies 7d41, 7b69, 697b and 5062 (Fig. 4.12). 
It should be noted that relatively high levels of lysis were obtained in all targets 
after incubation with mock-induced 7b69 effectors in contrast to those obtained 
with mock induced 697b effectors. The relatively high lysis levels produced by 
7b69 effectors in this assay (both on infected and uninfected targets) opens the 
possibility of the activation of phenotypically different subpopulations of 
cytotoxic effector cells, including non-MHC restricted killer cells. Lymphokine 
activated killer cell (LAK) mediated cytotoxicity has been demonstrated in the 
horse as well as in other species. These cells can lyse, following in vitro 
stimulation with IL-2, targets from an equine lymphoma cell line (T8888) but not 
xenogeneic targets such as Daudi and EL4 cells and suggested these cells are of 
the T-cell lineage (Hormanski et al., 1992). Viveiros et al. (1999) characterised 
further the cytolytic activity of equine NK and LAK cells showing that K-562 
cells (MHC-I negative) could be lysed by both LAK and NK cells whereas 
T8888 cells (MHC-I positive) could only be lysed by LAK cells. These effectors 
could have proliferated and been stimulated in this particular assay.
The promiscuous killing of effectors derived from pony 7b69 was not so evident 
in a further experiment designed to test the effects in the assay of AIM-V 
medium as a component of the Induction Medium. PBMC’s from pony 7b69
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collected 7 months post-infection were used to prepare 2 sets of induction 
cultures using either complete Induction Medium or Induction Medium deprived 
of AIM-V medium. Each set was split into 2 subsets, one inoculated with EAV 
and the other left uninfected. After a 7-day incubation period at 37°C in a 5% 
CO2 atmosphere, the PBMC’s were used in a cytolysis assay. The results (Fig. 
4.13) showed a higher cytolytic activity of the effectors derived from PBMC’s 
incubated in induction medium containing AIM-V. Both sets of effectors 
however produced similar results showing EAV-specific cytotoxicity against 
targets from 7b69 and 697b but not from 7d41. In this case however, mock 
stimulated effectors showed less cytolytic activity than in the previous 
experiment. The cytotoxicity observed in this assay was virus induced, exerted 
over infected cells only and appeared to be genetically restricted suggesting it 
was T-lymphocyte mediated. The lysis of only autologous infected targets by 
697b effectors and the lysis of autologous and 697b infected targets by 7b69 
effectors could be the result of pony 697b sharing an MHC-I allele with 7b69, 
being this MHC-I superseded by other alleles in the presentation of EAV 
antigens to CDS T-lymphocytes during the natural infection.
In summary, the results of the cross-matching assays suggest, but do not 
confirm, that the virus specific cytotoxicity observed in our cytolysis assays is 
mediated by CD8+ MHC-I restricted CTL. Testing the cytolytic activity of 
specific subpopulations of lymphocytes from the effectors’ pool was carried out 
to further characterise the EAV specific cytotoxic responses.
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4.3.9. Phenotype o f cytotoxic effector cells
In order to determine whether the cytotoxic effectors were CD8+ or CD4+ cells, 
biomagnetic selection and depletion of specific lymphocyte subpopulations of 
effectors and subsequent analysis of their cytolytic properties was conducted. 
EAV-induced and mock-induced effectors derived from pony 697b PBMC 
collected 7 months post-infection were split into 2 subsets. One of them was 
processed directly for measurement of EAV-specific cytolytic activity. The other 
subset was processed for selection and depletion of CD4+ or CD8+ T cell 
populations as indicated in materials and methods, and assayed for cytolytic 
activity. The concentrations of the selected and depleted effectors were intended 
to be adjusted to obtain effector: target ratios of 6:1. However, in this particular 
experiment it was not possible to obtain this ratio with the CD8+ selected 
effectors and these were used at a 1:1 ratio. The results displayed in Fig. 4.14 
show, as expected, very little cytolytic activity of all subpopulations derived 
from mock-induced effectors. Unselected and CD4-ve and CD8-ve effectors 
from EAV induction cultures lysed EAV-infected targets in contrast to CD4+ve 
selected T cells. It is difficult to compare the levels of killing of CD8+ve selected 
cells since they were used at an effector: target ratio of 1:1 only. These results 
indicated that not all effectors were CD8+ T cells or that the selection procedure 
of CD8+ T cells was sub-optimal.
A second experiment was conducted using EAV-induced effectors only. This 
time the MAb’s were used at a concentration of 2 pg / 10  ^ cells and a control of 
the selection procedure was included in that PBMC’s were subjected to
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biomagnetic selection in the absence of CD4 or CDS specific MAb’s. The 
unprocessed effectors were used at a 25:1 ratio with respect to the targets 
whereas the selected effectors were used at a 6:1 ratio. Immunoperoxidase 
staining of acetone-fixed PBMC collected from the depleted fractions with 
monoclonal antibodies to CD4 and CDS antigens showed a complete absence of 
CD8+ cells and almost complete absence of CD4+ cells in the CDS and CD4 
depleted populations respectively. In contrast, both CD4+ and CD8+ T- 
lymphocytes were present in the buffer control depleted sample. The results of 
the cytolytic assay (Fig. 4.15) show that only the CD8+ enriched fraction of the 
PBMC and the untreated effectors induced high percentages of cytolysis of EAV 
infected targets. In contrast, the CD8+ depleted and the CD4+ enriched cell 
subpopulations presented very low cytolytic activities. These results suggested 
that the in vitro EAV-specific cytotoxicity observed in all these experiments was 
mediated by CD8+ T-lymphocytes. The presence of these cytotoxic lymphocytes 
could explain the moderate levels of EAV-specific cytolysis induced by the 
CD4+ depleted effectors and the negative cell fraction of the buffer separation 
(Buffer control negative).
Further characterization of the effectors was performed by flow cytometry. 
Following 7 days culture, EAV-induced and mock-induced cultures from 5062 
PBMC collected one year after infection were analysed for CD4 and CD 8 
expression. Light scatter analysis of both sets of effectors show two cell sub­
populations in contrast to freshly isolated PBMC. In a previous experiment, 
propidium iodide staining of EAV- and mock-induced effectors showed that one 
of these subpopulations contained many dead cells (Fig. 4.16) and hence only
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live cells were gated (Rl) for phenotypic analysis of the effector cell population. 
Incubation of PBMC in the presence of EAV resulted in a lower percentage of 
live cells in comparison with the mock-induced cultures. However, EAV-induced 
effectors showed a higher proportion of cells with increased size and granularity 
(region R2), indicative of activated lymphoblasts. In addition, EAV-induced 
PBMC displayed an upregulation of either CD4 or CDS on a sub-population of 
cells, as evidenced by a second peak of higher fluorescence intensity for CD4+ 
and CD8+ cells. Overall, there was an increase in the CD8/CD4 ratio (from 0.43 
to 0.77) comparing the mock- with EAV-induced cultures, resulting from an 
increase in the proportion of CD8+ cells and decrease in the proportion of CD4+ 
cells in the Rl gate. Comparison of the number of cells within the R2 gate 
compared with the Rl gate demonstrated an increase in the proportion of both 
CD4+ and CD8+ cells within the activated lymphoblast population, comparing 
mock-induced versus EAV-induced cultures. Thus, the proportion of CD4+ cells 
in the R2 gate increased from 9% to 30% and of CD8+ cells from 18% to 42% 
(relative to the total number of viable CD4+ or CD8+ cells). Furthermore, the 
majority of CD4+ and CD8+ cells present within the R2 gate for the EAV- 
induced cultures displayed upregulated expression of CD4 or CD8 respectively. 
These data indicate activation of both CD8+ and CD4+ lymphocytes in response 
to EAV induction.
4.3.10. EAV specific cell-mediated cytotoxicity before and at early stages o f  
convalescence.
To obtain further evidence for the nature of the EAV-specific CTL responses, 
cytolysis assays were performed using effectors derived from PBMC collected
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from pony 5062 before infection, one month post-infection and 3 months post­
infection (Fig. 4.18). Mock-induced effectors showed low levels of specific lysis 
for all targets whether they were infected or not. As expected, EAV-induced 
effectors prepared from PBMC collected from the pony before EAV infection 
did not produce significant lysis of EAV-infected autologous targets or of targets 
derived from pony 7378. However, it was unexpected to observe relatively high 
specific lysis of EAV-infected targets derived from pony 697b. Unfortunately, 
allogeneic mock-infected targets were not included in this assay. One month 
post-infection, EAV-induced cytolysis was observed for EAV-infected 
autologous targets as well as both infected and mock-infected 027a derived EDC. 
Cytolysis of 697b targets was not observed in this assay. The results obtained 3 
months post-infection showed elevated levels of lysis only in autologous EAV 
infected targets, being consistent with previous results.
4.4. Discussion
Understanding virus-host interations during equine viral arteritis has been 
hampered by the lack of methods to measure cellular immune responses to this 
virus. The work presented describes for the first time methods to assess cytotoxic 
T-lymphocyte responses in ponies against EAV. The methods employed were 
essentially those described by Allen et a l (1995) and O’Neill et ah (1999) with 
some modifications. The first of these was the use of primary EDC’s as virus- 
infected target cells instead of in vitro stimulated lymphoblasts. A few attempts 
to detect EAV N antigen in lymphoblasts after virus inoculation proved 
unsuccessful. The use of dermal cells as targets for cytotoxic assays has been 
documented in immunological studies performed in species other than equine
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(Onishi et a l, 1999; Sharpe et a l, 2001; Korsoy et a l, 2001; Flomemberg et a l, 
1996). In other studies in horses, detection of cytotoxic cellular immunity has 
been achieved by using methods employing mitogen stimulated lymphoblasts 
(Hannant and Mumford 1988; Allen et a l, 1996; O’Neill et al, 1999), primary 
kidney fibroblasts (McGuire et a l, 1997) and primary equine dermal cells 
(Hannant, personal observations) as targets. The present study has found EDC 
easy and convenient to use. These cells are more easily accessible than equine 
kidney cells and do not require previous incubation under special conditions (in 
contrast to mitogen stimulated lymphoblasts). Moreover, they retain chromium 
efficiently and support EAV replication. However, they have the disadvantage of 
not constitutively expressing MHC-II which excludes the possibility of 
measuring CD4+ mediated cytotoxicity and so the significance of this 
mechanism in vivo remains unknown.
In the present study, generation of virus-specific CD8+ T lymphocytes was 
achieved by incubating the PBMC for a few days in the presence of live virus 
without adding exogenous cytokines such as IL-2. Previously, it has been shown 
that there is a positive correlation between the amount of exogenous EL-2 in 
induction cultures and the promiscuity of equine cytotoxic effector cells for 
influenza virus infected targets (Hannant and Mumford 1988). It is worth noting 
however, that unlike EHV-1 CTL induction, cytotoxic activity against EAV 
infected cells could not be induced using cryopreserved mononuclear cells. This 
is probably due to the damage of EAV permissive subpopulations of cells during 
the freezing and / or thawing processes. In this regard, it should be noted that T- 
lymphocytes, the major population of PBMCs sensitive to EHV-1 infection, are
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not affected by the freezing and thawing process. In EAV-specific cytolytic 
assays, the number of monocytes in EAV-induced cultures (7 days post­
induction) much reduced in comparison to the mock-induced PBMC. Moreover, 
EAV N antigen expression was clearly detected in 24 hours-old EAV-induced 
cultures prepared from fresh but not cryorecovered PBMC. Taken together, these 
observations suggest that EAV-infected monocytes (principal cell target of 
arteriviruses in vivo) act as the main antigen presenting cells to CD8+ T cells and 
CD4+ T cells through MHC-I and MHC-II molecules respectively. Activation of 
CD4+ T cells would result in production of IL-2, which in turn would help 
expansion and differentiation of CD8+ T cells into cytotoxic effectors. 
Monocytes are cleared from the cultures by day 7 post-induction as a result of 
virus infection or by cell-mediated cytolysis. Alternatively, antigen presentation 
to CD4+ T cells could have been provided by virus specific B cells.
EAV-specific cytotoxic cells have been induced from PBMC collected from 
EAV convalescent ponies over a period of 1 year post-infection. These cells, 
generated after in vitro stimulation with virus antigen, expressed CD8+ and 
showed a genetically restricted cytolytic activity, possibly associated with 
recognition of virus derived peptides presented by MHC-I molecules, although 
this could not be confirmed directly by blocking of MHC-I with MAb H58A. 
However, this reagent has not been used before to block CTL lysis and it is 
possible that binding of the MAb to its epitope does not interfere with peptide 
antigen recognition on the target cell. Determination of the equine leucocyte 
antigen of the ponies used in the study (which was not possible at the time these 
experiments were performed), would have helped to definitively corroborate the
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MHC-I restriction of the cytolytic activity. However, there is strong evidence for 
EAV-specific cytotoxic effector cells recognising EAV-infected target cells via 
MHC-I presentation because a) only MHC-I antigen expression (and not MHC- 
II) could be detected on EDC, b) the cytotoxic memory response was genetically 
restricted, c) the reduction of monocytes from the EAV induced effectors, 
making unlikely that the cytotoxicity was mediated by macrophages recognising 
infected cells via Fc receptor IgG interactions and d) cytotoxic cells were CD8+ 
T-lymphocytes.
Clinical recovery from EAV and the reduction in virus excretion from nasal 
secretions coincides with the development of VNAb in serum (usually after the 
first week of infection), as observed in the ponies used in this study and 
described in other reports (Fukunaga el ah, 1981; McCollum et a l, 1969; 
Castillo-Olivares et a l, 2001, Chapter 2). However, cell associated viraemia 
persists for longer periods ranging from 2 or 3 weeks after infection to around 3 
months post-infection (Neu et al, 1987; Castillo-Olivares, unpublished 
observations). Whether the resolution of viraemia is the result of a cell-mediated 
clearance mechanism or due to the eventual disappearance of leucocytes infected 
during the first few days is not clear but is consistent with cytotoxic lymphocytes 
eventually eliminating virus infected cells in blood and other tissues. In this 
study, the EAV infected ponies recovered well from the infection and were the 
source of PBMC’s used as effectors in the cytotoxicity assays.
The detection of CD8+ T lymphocyte precursors from EAV convalescent ponies 
indicates that cellular immunity might play an important role in the final
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clearance of the infection. The temporal development of CTL responses was 
studied in one pony but the results from sequential cytolysis assays performed 
with 5062 effectors showed that the capacity of the effectors to recognise and 
lyse infected targets increased during the first 3 months post-infection, point at 
which the immune system probably returns to a basal resting state characterised 
by the predominance of memory cells in the circulating PBMC. By 1-3 months, 
cell-associated viraemia in the majority of LP3 A+ infected ponies was cleared. In 
PRRSV infections in pigs it appears that a combination of cellular and humoral 
immune clearance mechanisms are necessary to clear infection. This infection 
induces an antibody response to viral antigens which is detectable by day 9 post­
infection (Labarque et al., 2000) but lymphoproliferative responses and 
neutralizing antibodies were not detectable until week 4 post-infection (Lopez 
Fuertes et a l, 1999) coinciding with clearance of viral infection from blood and 
lungs. Observations in mice infected with LDV indicate that cytotoxic 
lymphocytes are stimulated but disappear 30 days later leading to a life-lasting 
persistent infection (Even et a l, 1995). This study supports the hypothesis that 
CTL’s contribute to the resolution of EAV viraemia in ponies. However, the 
mechanism of viral persistence in LDV infections, which involves a process of 
clonal deletion of new LDV-specific CD8+ cells in the thymus leading to a state 
of tolerance to LDV-CTL epitopes, is probably different to that occurring in 
EAV persistently-infected stallions. Further analysis of additional immunological 
parameters is required to define precisely the mechanisms of viral clearance or 
persistence in EAV infections.
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The detection of CD8+ T cytotoxic precursors cells during equine viral arteritis 
and their probable contribution to EAV clearance, together with the high levels 
of immunity provided by live vaccines (Doll et al., 1968; McCollum, 1970; 
McCollum et al., 1986) and the deletion mutant EAV-GlA (Chapter 3), indicate 
that marker vaccination approaches would benefit from the induction of this type 
of immune response. Incorporation of virus proteins containing CTL epitopes 
common to most equine MHC-I haplotypes as well as choosing an appropriate 
antigen delivery system capable of inducing the processing of proteins by the 
endocytic pathway for antigen presentation by MHC-I would be necessary for 
the design of marker sub-unit vaccines stimulating CTL responses.
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yFigure 4.1 EAV nucleocapsid protein (N) expression in EDC 24 hours 
after infection with EAV at an m.o.i. of 0.3. Detection was performed by 
indirect immunofluorescence using SP07 rabbit antibody and FITC 
conjugated goat anti-rabbit IgG.
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Figure 4.2. Expression of MHC molecules on EDC.
Suspensions of EDC were incubated with MAb specific for either equine MHC-1 
(H58A), equine MHC-II (H42A) or equine CDS (HT14A - serving as an isotype 
control). MAb binding was detected using FITC-conjugated goat anti-mouse IgG. 
Panels a) and b) show cell-surface expression of MHC-I and MHC-II respectively 
(open histograms); in both panels the isotype control is shown as a closed 
histogram
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EAV infected EDO's Non-infected EDO's
Medium Mean cpm STDV %STDV Mean cpm STDV %STDV
S pontaneous release 
Total re lease
CTL medium 
2%TX100
3309.2
17930.3
104.1
508.0
3.1
2.8
2840.9
18543.0
145.8
225.7
5.1
1.2
% Spontaneous e lea se
18.5 15.3
Table 4.3. Capacity of EDC’s to retain and release ^^Cr under the physical conditions 
of the CTL assay. The mean and standard deviations of 6 replicate samples are shovm
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EAV Infec ted targets Mock Infected targets
Effectors E;T ratio mean cpm % specific lysis mean cpm % specific lysis
■D
8
10:1 2240.67 1.10 2302.67 2.58
3T3
CI 5:12.5:1 2036.502007.50 -1.87-2.29 1941.331960.83 -2.24-1.98
s
3
10:1 2033.67 -1.91 2071.83 -0.50
■oc 5:1 2040.33 -1.82 2004.33 -1.40
o
2.5:1 1986.17 -2.61 2002.17 -1.43
TritonXlOO tot.Cr release 9029.17 100.00 9604.83 100.01
10% RPMI sp. Cr release 2165.67 23.00 2109.33 22.00
Table 4.4. Cytotoxic activity exhibited against autologous targets by in vitro stimulated 
effectors derived from cryopreserved PBMC collected from pony 5d66 on day 21 post­
infection.
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EAV infecited targets Mock infected targets
Effectors E:T ratio cpm % specific lysis cpm % specific lysis
T3 50:1 2864.43 1.77 2450.52 0.56
Ü3
T3
_C 25:1 2791.64 1.00 2291.56 -0.77
(0
UJ 12.5:1 2735.63 0.41 2520.91 1.15
8 50:1 2763.38 0.70 2456.02 0.61
~o
Ç 25:1 2777.83 0.86 2545.77 1.36
o
12.5:1 2809.31 1.19 2512.80 1.08
2%TritonX100 tot Cr release 12213.71 100.00 14314.50 100.00
10%RPMI sp Cr release 2696.32 22.08 2383.66 16.65
Table 4.5. Cytotoxic activity exhibited against autologous targets by in vitro 
stimulated effectors derived from cryopreserved PBMC collected from pony 7378 on 
day 42 post-infection.
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Figure 4.6. Cytotoxic activity displayed against autologous 
targets by in vitro stimulated PBMC collected from pony 7378 
four months post-EAV infection. The PBMC were used fresh for 
in vitro induction. Results show the % specific lysis of targets at 
different effector: target cell ratios; 50:1, 25:1 and 12.5:1.
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Figure 4.7. Features of in vitro stimulated PBMC cultures. 
Hematoxylin and eosin staining of 7 day old PBMC induction 
cultures shows a significant proportion of monocytes in mock- 
induced cultures (a) (white arrows) which are absent in EAV- 
induced cultures (b). Detection by immunofluorescence of EAV 
nucleocapsid (N) antigen in a 24 hour-old EAV-induced PBMC 
culture (c).
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Figure 4.8. Effect of the source of serum (autologous vs 
heterologous) on the induction of EAV cytotoxic effectors. 
Effectors derived from PBMC of pony 027a were collected 6 
months post-infection and the lytic activity was tested against 
EAV infected and mock infected autologous targets. The 
effector: target ratios are indicated in the boxes.
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Figure 4.9. Genetic restriction of EAV specific 
cytotoxicity. Cytotoxic activity of EAV-induced and 
Mock-induced effectors derived from ponies 7378, 5d66 
and 027a was tested against EAV-infected and Mock- 
infected autologous and allogeneic EDC targets. PBMC 
were collected from pony 7378 at 6 months post­
infection (a and b), from pony 5d66 at 6.5 months post­
infection (c and d) and from pony 027a at 8 months 
post-infection (e and f). Effector: target (E:T) ratios 
used for each set of effectors are indicated in the figure.
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Figure 4.9. Genetic restriction of EAV specific 
cytotoxicity. Cytotoxic activity of EAV-induced and 
Mock-induced effectors derived from ponies 7378, 5d66 
and 027a was tested against EAV-infected and Mock- 
infected autologous and allogeneic EDC targets. PBMC 
were collected from pony 7378 at 6 months post-infection 
(a and b), from pony 5d66 at 6.5 months post-infection (c 
and d) and from pony 027a at 8 months post-infection (e 
and f). Effector: target (E:T) ratios used for each set of 
effectors are indicated in the figure.
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Figure 4.9. Genetic restriction of EAV specific 
cytotoxicity. Cytotoxic activity of EAV-induced and 
Mock-induced effectors derived from ponies 7378, 5d66 
and 027a was tested against EAV-infected and Mock- 
infected autologous and allogeneic EDC targets. PBMC 
were collected from pony 7378 at 6 months post-infection 
(a and b), from pony 5d66 at 6.5 months post-infection (c 
and d) and from pony 027a at 8 months post-infection (e 
and f). Effector; target (E:T) ratios used for each set of 
effectors are indicated in the figure.
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Figure 4.10 Anti-MHC-I MAb blocking experiment of 
EAV specific cytotoxicity. Effectors derived from pony 
5d66 PBMC were incubated with EAV infected and Mock 
infected autologous targets in the absence (a, b) or presence 
(c, d) of different concentrations of anti-MHC-1 MAb.
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EAV specific cytotoxicity. Effectors derived from pony 
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(c, d) of different concentrations of anti-MHC-I MAb. E: T 
ratio 50: 1
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Figure 4.11. Genetic restriction of EAV specific 
cytotoxicity. EAV induced and mock induced effectors 
derived from pony 07d41 were incubated with EAV 
infected and mock infected autologous and allogeneic EDC 
targets.
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Figure 4.12. Genetic restriction of EAV specific 
cytotoxicity. Effectors derived from ponies 697b (a 
and c) and 7b69 (b and d) were tested against 
autologous and allogeneic EAV infected and mock 
infected EDC targets.
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Figure 4.12. Genetic restriction of EAV specific 
cytotoxicity. Effectors derived from ponies 697b (a and 
c) and 7b69 (b and d) were tested against autologous 
and allogeneic EAV infected and mock infected EDC 
targets.
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the composition of the induction medium and 
assessment of genetic restriction of cytotoxicity. 
Cytotoxicity of EAV (a and b) and mock ( c ) induced 
effectors generated in induction medium with (b and c) 
or without AIM-V medium (a and c) is shown.
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Figure 4.14. Phenotype of EAV specific effectors. 
EAV induced and mock induced effectors derived 
from pony 697b were processed for enrichment or 
depletion of CD8+ or CD4+ cells and tested against 
EAV infeted or mock infected autologous EDC 
targets.
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Figure 4.15. Phenotype of EAV specific cytotoxic effectors. Effectors 
derived from pony 697b (6 months post-infection) were tested for 
cytolytic activity against either EAV-infected or mock-infected 
autologous EDC targets. Cytolytic activity of fractionated EAV 
induced effectors, used at an effector: target ratio of 6:1 is shown in 
figure a). Effectors were either enriched for or depleted of specific cell- 
types, using MAb against CDS or CD4. Buffer control samples were 
subject to the same separation procedures, but in the absence of Mab. 
Cytotoxic activity of non-fractionated effectors, used at an effector: 
target ratio of 25:1 is shown in figure b).
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Figure 4.18. EAV specific cytotoxic activity of effectors 
derived from PBMC collected before, 1 month and 3 months 
post-infection against EAV infected and mock infected 
autologous and allogeneic EDC targets.
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Figure 4.18. EAV specific cytotoxic activity of effectors 
derived from PBMC collected before, 1 month and 3 months 
post-infection against EAV infected and mock infected 
autologous and allogeneic EDC targets.
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Figure 4.18. EAV specific cytotoxic activity of effectors 
derived from PBMC collected before, 1 month and 3 months 
post-infection against EAV infected and mock infected 
autologous and allogeneic EDC targets.
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Chapter 5: Expression of single EAV genes in mammalian cells 
for identification of viral proteins containing CTL epitopes.
5.1. Introduction
The detection of cell mediated cytotoxic T-lymphocyte responses following EAV 
infection, and the solid immunity conferred by EAV-GlA in the absence of a 
strong VNAb response suggest cellular immunity may play an important role in 
clearing virus infection. Therefore, the induction of CTL responses could be 
desirable or even necessary for the development of efficient EAV vaccines, an 
important consideration for vaccines based on single virus genes or their 
products. Identification of viral proteins containing CTL epitopes would then be 
required. The EAV CTL assay developed in this project (Chapter 4) will be 
adapted for this purpose. Single EAV genes will be expressed in EDC and 
incubated with EAV-specific cytotoxic effector cells and the levels of target lysis 
determined.
A plethora of methods and vectors have been used over the last decade by 
researchers for expression of heterologous genes in mammalian cells, ranging 
from plasmid DNA transfection to live recombinant viral vectors (Makrides, 
1999). Viral vector expression systems such as vaccinia (Hammond et al., 1998; 
McMichael et a l, 1986) or retroviral vectors (Lonning et a l, 1999) have been 
used to generate CTL targets to identify proteins harbouring CTL epitopes. 
Alternatively, other investigators identified viral proteins important for the
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generation of CTL’s using plasmid transfection or vaccinia recombinants to 
generate antigen presenting cells in vitro (Rouse et a l, 1994; Hammond et al.,
1998).
The purpose of the work presented in this chapter was to investigate methods for 
the identification of target proteins for EAV specific CTL’s. Antigens derived 
from PRRSV ORF’s 2, 5 and 6 have been recognised by pig T-lymphocytes in 
lymphoproliferation and delayed-type hypersensitivity assays (Bautista et al.,
1999). However, the only information on the antigenic specificity of the CTL 
responses during arterivirus infections comes from the studies of Even et al. 
(1995) demonstrating that 3T3 cells expressing the nucleocapsid protein of LDV 
(N/VP-1) stimulated the proliferation in vitro of LDV-specific CTL’s. Thus, the 
N protein of EAV, encoded by 0RF7 was chosen as the primary target for 
investigation. To generate EAV CTL targets, EAV0RF7 was cloned into a 
mammalian expression plasmid vector and delivered into EDC by a non­
liposome lipid transfection technique. Alternatively, baculovirus transduction 
was used. The system based on the Autographa Californica nucleopolyhedrosis 
baculovirus has been extensively used for the expression of recombinant proteins 
in insect cells (Galleno and Sick, 1999). Baculoviruses also have the capacity to 
to transduce mammalian cells, i.e. delivering their genetic material into the cells 
without viral replication. Various reporter genes have been expressed in 
mammalian cells using this technique (Hofmann et ah, 1995; Boyce and Bucher, 
1996; Shoji et al., 1997; Aoki et al., 1999). Attempts will be made to generate 
recombinant baculoviruses encoding EAV 0RF7 downstream of a mammalian 
promotor for expression of the virus gene in mammalian cells.
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5. 2. Materials and methods
5.2.1. Polymerase chain reaction (PCR).
Amplification of DNA by PCR for analysis of constructs and for cloning was 
performed with AmpliTaq DNA polymerase (Perkin Elmer Applied Bio systems) 
and Pwo DNA polymerase (Boehringer Manheim, Germany) respectively. PCR’s 
with AmpliTaq were typically performed in reactions containing lOmM Tris- 
HCl, 1.5 mM MgCli, 50mM KCl, 0.2 mM desoxyribonucleotides (dNTP’s), 0.4 
|iM of each primer and 0.025 units of the enzyme. Reactions with Pwo DNA 
polymerase were performed in lOmM Tris-HCl, 25 mM KCl, 5 mM (NH4)2S0 4 , 
2.5 mM MgS0 4 , 0.5 \iM of each primer, O.OSmM of dNTP’s and 0.05 units of 
enzyme.
The reactions were amplified in a DNA engine Tetrad Thermal cycler (M.J. 
Research Inc.). Cycles typically comprised the following steps;
1) DNA dénaturation phase at 94°C for 4 min.
2) 30-40 cycles of:
a. dénaturation step at 94°C for 45-60 seconds
b. primer annealing step at 45 -  60 °C for 60 seconds
c. extension step at 70 -72 °C for 90 to 120 seconds
3) a final extension step at 70 -  72 °C for 5 minutes.
The number of cycles and the length and temperature of each step varied 
depending on the melting temperature (Tm) of the primers (annealing 
temperature usually 5 °C below primer Tm) and length of the DNA target.
The primers were obtained from Genset (France) and working stocks were 
prepared in sterile MQ water to 4 pmol / p.1.
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5.2.2. Electrophoresis o f DNA on agarose gels
Agarose gels (0.7 % - 1.2 %) were prepared in TAB buffer (40mM Tris, 20mM 
acetate, 2mM EDTA) containing 5 |Lig / ml of Ethidium Bromide. DNA samples 
were diluted in loading buffer, 10-15 ul added to each well and the gel run at 70- 
120 volts for 30 to 60 min. A DNA molecular weight marker (Ikb DNA ladder, 
Gibco Life Technologies) was included in each assay.
TAE buffer was prepared as 5Ox concentrated solution: 2M Tris base, 57.1 ml 
glacial acetic acid, 100 ml 0.5 M EDTA pH 8.0.
Loading buffer was prepared as a 6x concentration solution: 0.25% Bromophenol 
Blue, 40% sucrose, 20mM EDTA.
5.2.3. Purification o f DNA from solutions andfrom gels.
PCR products and plasmids were purified taking advantage of the selective 
binding properties of DNA to silica-gel in the presence of chaotropic salts at low 
pH. For these procedures the commercially available QIAquick Nucleotide 
Removal and QIAquick Gel Extraction kits from QIAGEN (Germany) were 
used.
After DNA separation by electrophoresis, the desired DNA fragment was sliced 
from the gel. Typically 400 mg were solubilised in buffer QG at 50°C. To ensure 
the pH is adequate for binding of the DNA to the silica membrane colums, 10 |_il 
of 3M sodium acetate was added. The DNA sample was added to silica gel 
membrane spin mini-columns and these were centrifuged at 13000 rpm in an 
eppendorf microfuge for 1 min. The columns were washed twice in the ethanol 
containing buffer PE. The DNA was eluted by adding 50 [i\ of sterile MQ water 
to the column and centrifuging 1 minute later for 1 min at 13000 rpm.
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DNA fragments and plasmids in solution were purified in the same way with the 
exception that 10 volumes of buffer PN were added to the DNA sample and 
centrifuged at 6000 rpm in the initial steps. Washing and elution steps were 
performed as above.
5.2.4. Adding adenosine and thymidine residues to the 3 ’ ends o f DNA ( ‘tailing’). 
Purified DNA fragments were modified in their 3’ ends by the action of 
AmpliTaq DNA polymerase in PCR reactions under normal buffering conditions 
but in the presence of only one of the dNTP’s: 10 mM Tris-HCl, 1.5 mM MgCl%, 
50 mM KCl and, 200 p,M dATP or 2 mM dTTP and 5 units of AmpliTaq. The 
reaction was incubated at 70°C for 35 min.
5.2.5. Dephosphorylation o f 5 ’-ends o f DNA fragments
The Shrimp Alkaline Phosphatase (SAP) (Roche) was used in a reaction 
containing: 50mM Tris-HCl, 5 mM MgCli, and 0.01 enzyme / pmol of 5’- 
phosphorylated DNA ends. These were calculated according to the formula: (p.g 
DNA / kb size of DNA) x 3.04. The reaction was incubated at 37°C for 1 hour 
and subsequent inactivation at 65°C for 15 minutes.
5.2.6. Restriction digestions
Enzymes and buffers for restriction digestions were obtained from Promega 
(Madison, USA). Enzymes were used typically at 5 units / \xg of DNA at the 
recommended temperature for each specific enzyme. Single digests were 
performed in the buffer recommended by the manufacturer for that enzyme.
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Double digestions were performed sequentially including a purification step of 
the digested DNA, using the nucleotide removal procedure detailed above, in 
between the two enzymatic reactions. Enzymes were inactivated at 70°C for 5 
min. after digestion.
5.2.7. Ligation o f plasmid vectors and inserts
Enzyme and buffer were obtained from Promega (Madison, USA). Ligation 
reactions were performed at 4°C overnight in 30 mM Tris-HCl, pH 7.8, 10 mM 
MgCl], 10 mM DTT and 1 mM ATP, using an insert; vector molar ratio of 3:1 
using 1 Weiss unit of T4 dNA ligase for 100 ng of vector.
5.2.8. Production o f competent E. coHDHlOB cells
This was done following the method of Hanahan (1985). A bacterial colony was 
picked and inoculated into 10 mis of LB broth and grown overnight at 37°C. The 
following day 50 ml of LB broth were inoculated with 1 ml of the overnight 
culture and grown at 37°C until the optical density (O.D.) reached 0.3-0.5. The 
bacteria were incubated in ice for 10 min, spun at 2000 rpm for 5 min, the pellet 
resuspended in 25 ml of cold buffer STB (100 mM KCl, 50mM CaCl:, 10 mM 
CH3-C00K) and incubated at 4°C for 30 min. After pelleting the cells by 5 min 
centrifugation at 2000 rpm the bacteria were resuspended in 2 ml of cold buffer 
FTB (100 mM KCl, 50mM CaCli, 10 mM CH3-C00K, 15% glycerol) aliquoted 
and stored at -70°C.
LB broth: 10 g Triptone (Oxoid), 5 g Yeast Extract (Oxoid), 5 g NaCl (BDH), 1 
litre MQ water. The medium was autoclaved at 15 p.s.i. for 15 min, cooled down
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to room temperature and stored in the dark until used. LB A broth contains 100 
p-g / ml of ampicillin.
LB agar plates were prepared by dissolving 10 g Triptone (Oxoid), 5 g Yeast 
Extract (Oxoid), 5 g NaCl (BDH) and 13.6 g Agar (Oxoid) in 1 litre MQ water. 
The medium was autoclaved at 15 p.s.i. for 15 min, cooled down and poured 
slowly onto petri dishes (15 mis / plate). LB A agar plates were prepared by 
pouring the LB agar onto petri dishes containing 15 pi of ampicillin (100 pg / 
pi).
Ampicillin stock stolution: 100 pg dissolved in sterile MQ water and stored at -  
20°C.
5.2.9. Transformation o f competent cells
One vial of competent E coli was thawed slowly by incubation in ice for 30 
minutes. Approximately 10 ng of DNA were inoculated into 100 pi of bacteria 
and incubated in ice for 30 min. The bacteria were heated at 42°C in a water bath 
for 90 seconds and then added to 1 ml of LB broth without ampicillin pre­
warmed at 37°C and incubated at this temperature for 1 hour. Fifty pi of the 
bacterial suspension was streaked onto an LBA agar plate and incubated 
overnight at 37°C. If the cells were transformed with vectors containing the a- 
peptide of the P-galatosidase gene (such as pGEM-T’, Promega), the bacteria 
were streaked onto LBAG agar plates to allow ‘blue-white’ screening of 
transformants. LBAG agar plates were prepared by adding and spreading 40 pi 
of X-gal (50 mg/pl) and 100 pi of 0.1 M IPTG onto the surface of LBA agar 
plates 10 min before streaking the bacteria.
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IPTG solution (0.1 M); 1.2 IPTG (Promega) dissolved in 50 ml sterile MQ water 
and stored at 4°C.
X-gal solution (50 mg / ml): 100 mg of X-gal (Promega) dissolved in 2 ml N,N’- 
dimethylformamide (Sigma). Stored at -20°C.
5.2.10. Plasmid preparations
Plasmid DNA was isolated and purified from E coli cultures by alkaline lysis and 
binding of DNA to silica at high salt concentrations. The commercially available 
QIAprep (QIAGEN, Germany) was used for this purpose. Five ml of an E  coli 
overnight culture in LBA broth were pelleted by centrifugation and resuspended 
in 250 pi of the RNAse containing buffer PI. Addition of 250 pi of buffer P2 
containing the detergent SDS and NaOH produced lysis of the bacteria and 
denaturing of the chromosomal DNA at the same time of releasing the plasmid 
DNA. Neutralisation of the reaction and adjusting the salt concentration with 350 
pi of buffer N3 causes the plasmid DNA to bind to the silica membrane filters of 
the spin columns to which the samples were added after removing the précipité 
by centrifugation for 10 min at 13000 rpm. The minicolumns were centrifuged, 
the flow-through removed and the columns washed twice with 0.5 ml of buffer 
PB by centrifugation at 13000rpm for 1 min. After removing the residual PE 
buffer by centrifuging for an extra minute the DNA was eluted by incubating the 
membranes with 50 pi of sterile MQ water for 1 minute and centriftigation for 1 
minute at 13000 rpm.
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5.2.11. Sequencing
Sequencing was performed using the dRhodamine Terminator Cycle Sequencing 
kit (Perkin Elmer Applied Bio systems). The dichlororhodamine dye 
dideoxynucleotide terminators, dNTP’s, MgCh, AmpliTaq FS polymerase and 
buffer were provided in a single solution which was then used (4pl) with 3 pi of 
DNA (0.03 -  0.2 pg / pi), 0. 4 pi of primer (4 pmol/pl) and 2.6 pi of sterile MQ 
water. The reaction was subjected to 25 cycles of;
1) 96°C, 30 seconds
2) 50°C, 15 seconds
3) 60°C, 4 min
followed by a final incubation step at 4°C.
The DNA (10 pi) was finally precipitated by adding a 95% ethanol solution (25 
pi) and 3M sodium acetate (1 pi) and incubating the mixture for 7 min on ice. 
After centrifuging at 13000 rpm for 15 min, the pelleted DNA was resuspended 
in 70% ethanol (125 pi) and centrifuged again at 13000 rpm for 10 min. The 
DNA pellet was then dried out and resuspended in 10 pi of Hi-Di Formamide 
before loading the samples into the ABI Prism 3700 DNA Analyser.
5.2.12. Tissue culture techniques
Mammalian primary (EDC) and continuous cell lines (RK-13, COS-7 cells) and 
the insect cell line Sf9 were used through the study.
RK-13 cells and EDC’s were obtained and cultured as described previously 
(Chapters 2 and 4 respectively). COS-7 cells were obtained from the European 
Collection of Cell Cultures (ECACC). This cell line was grown in 10% MEM in
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75 cm  ^tissue culture flasks and passaged routinely once a week using a splitting 
ratio of 1:3.
The insect cell line Sf9 was obtained from Gibco-Life Technologies and grown 
in insect cell growth medium [TNM-FH medium (Sigma) supplemented with 
10% heat inactivated bovine serum (Gibco Life Technologies) and 50 lU/ml 
penicillin and 50pg/ml streptomycin (Gibco Life Technologies)]. Cells were 
cultured in 75 cm^ tissue culture flasks as monolayers which were split 1:3 
weekly by replacing the medium and resuspending the cells in fresh insect cell 
growth medium.
5.2.13. Transfection o f plasmid DNA
Transfections of plasmids into EDC’s, COS-7 and RK-13 cells were performed 
using the non-liposomal lipid reagent FuGENE (Boehringer Manheim). The 
reagent was added to a small volume of SFMEM [minimum essential medium 
Eagle with Earle’s salts (Sigma, M2279) supplemented with 100 lU of penicillin 
per ml, 10 pg of streptomycin per ml, non-essential amino acids, L-glutamine to 
a final concentration of 2 ml] and incubated for 5 min at room temperature before 
adding it to the plasmid preparations. The mixture was incubated for 15 min at 
room temperature and added slowly and evenly to 80 % confluent cell sheets, 
previously washed in SFMEM. After addition of 10% MEM the cells were 
incubated at 37°C without removing the reagent.
Insect cells were transfected using the cationic liposome reagent Lipofectin 
(Invitrogen) . Cells were seeded onto 6 well flat bottomed plates at a density of 
10  ^cells / well and incubated at 28°C for 24 hours in insect cell growth medium. 
Then the cell sheets were carefully washed with serum free insect cell growth
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medium and 1.5 ml of this medium was added to each well. A volume of 50 pi 
containing linearised baculoviral DNA and the plasmid was mixed with 50 pi of 
a solution containing 100 pg / ml of lipofectin transfection reagent. This mixture 
was incubated for 20 min at room temperature and then added to the cells. The 
cells were incubated fiirther for 5 hours at 28°C after which 1.5 mis of insect cell 
growth medium were added and the incubation continued for 4 days.
5.2.14. Detection o f expression o f recombinant genes in mammalian cells 
The reporter gene lacZ was detected in EDC’s, RK-13 cells or COS-7 cells by 
staining the cells with a 0.2 % X-Gal solution prepared by diluting an X-Gal 
stock solution (2% X-Gal, dymethy 1-fbrmamide) in 2mM MgCb, 5mM 
K4Fe(CN)6  • 3H20, 5mM K3Fe(CN)g. Cells were washed with PBS after 
removing the medium, fixed with 0.25% glutaraldehyde in PBS, washed again 
with PBS and incubated with the X-Gal solution overnight. After removing the 
X-Gal solution the cells were covered with PBS and observed for the 
development of blue colour.
EAV protein expression was detected by indirect immunofluorescence. Cells 
were washed with PBS before being fixed with 0.4% Triton-X-100 -  4% 
formaldehyde in PBS or 4% formaldehyde in PBS. After removing the fixing 
solution and washing with PBS, a 1/100 dilution of anti-N specific rabbit 
polyclonal antibody a-SP07 (de Vries et al., 1992) in PB A (0.2% bovine serum 
albumin (Sigma) in PBS) was applied for 1 hour at 37°C. Finally, after washing 
the cells in PBS, FITC conjugated goat anti-rabbit IgG (Dako, Denmark) was 
added to the cells at a 1/40 dilution in PB A for 1 hour at 37°C before a final
178
washing step was performed and cells observed on a Leica microscope under UV 
light.
5.2.15. Baculovirus plaque assay
Dilutions of recombinant baculovirus and a control BacPakô baculovirus were 
absorbed (100 pi) to Sf9 insect cell confluent monolayers prepared on 6 well flat 
bottomed plates and incubated for 1 hour at 20°C. Then they were replaced by 2 
mis of a 1 % agarose overlay [1:1 insect cell growth medium, 2 % low-melting 
point agarose (Sigma) in water]. Once the agarose set, 2 mis of fresh insect cell 
growth medium was added and the plates incubated at 28 °C for 3 days. The 
medium was removed and 1.5 mis of a neutral red solution [0.025 % neutral red 
(Sigma), PBS] was added to each well and incubated for 3 hours. Then the stain 
was aspirated and plates were inverted and incubated overnight at room 
temperature. Pale pink plaques were observed in a red backround and were 
examined under the microscope to check that they consisted of insect cells which 
did not uptake the stain. Several plaques were picked by aspirating the agarose 
with a sterile pasteur pippette and transferred to 0.5 mis of serum free insect cell 
medium and stored at 4°C until used. Each plaque pick was used to infect a fresh 
cell monolayer. After a 3 day incubation period the tissue culture fluid was 
harvested and stored at 4°C while the cell sheets were washed with PBS. After 
fixing the cells with 0.25% glutaraldehyde and washing twice in PBS the cells 
were incubated with 1 ml of medium containg 0.002 % X-Gal for 2 hours to 
check that the recombinant viral plaques did not contain BacPakô. BacPakô 
infected cells, included as a control in the assay, developed a blue colour in 
contrast to the recombinant baculovirus infected cells.
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5. 3. Results
5.3.1. Expression ofEAV0RF7 hyplasmid transfection.
The multipurpose mammalian cell expression vector pcDNA3 (Invitrogen) was 
chosen for expression of EAV 0RF7 in EDC. Apart from the conventional 
prokaryotic origin of replication and selection markers (colEl and ampicillin 
resistance gene respectively) which allow plasmid propagation in bacteria, this 
vector has a multiple cloning site flanked upstream by a human cytomegalovirus 
immediate-early promoter (CMV) and phage T7 promoter and downstream by a 
bovine growth hormone polyadenylation site for protein expression in 
mammalian cells. In addition, it contains the simian virus 40 (SV40) origin of 
replication which allows the replication of the plasmid in COS-7 cells. At the 
time this work was performed, co-workers had experienced some difficulties in 
cloning different genes into this vector directly from PGR products but not by 
sub-cloning from other vectors. The strategy used, outlined in Fig. 5.1, involved 
cloning of 0RF7 into an intermediate plasmid vector (pGEM-T’, Promega) from 
an adenosine (A’) ‘tailed’ PGR product, followed by sub-cloning into pcDNA3.
5.3.1.1. Cloning o f EAV 0RF7 into plasmid pGEM- T \
Amplification of the EAV nucleocapsid gene was performed by PGR from 
cDNAlOô (de Vries et al., 1992) using primer 2510001 (5’-
TAGGATGG AGG ATGGGGTG AAGAGG-3 ’) and primer 2510002 (5’-
TAGGATGGTTAGGGGGGTGGTG-3 ’). These primers contain BamHl 
restriction sites for eventual insertion of the gene into the multiple cloning site of 
pcDNA3 (Fig. 5.2). A Kozak sequence (Kozak, 1989) was included in the 
forward primer 2510001 for efficient translation of m-RNA in mammalian cells.
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To minimise the introduction of mutations during PCR, a proof reading (3’-5’ 
exonuclease activity) thermostable DNA polymerase {Pwo, Boehringer 
Manheim, Germany) was used in the PCR reaction. A band of approximately 330 
nucleotides was visualised after running the PCR product in an ethidium bromide 
0.9% agarose gel and was then purified. The Pwo enzyme, due to its 3’-5’ 
exonuclease activity, generates blunt-ended PCR fragments and therefore the 
addition of adenosine to the 3’-ends is required for efficient ligation into the 
cloning plasmid vector pGEM-T’. This was achieved by incubating the purified 
0RF7 PCR product with AmpliTaq DNA polymerase in the presence of dATP. 
In these conditions, the AmpliTaq DNA polymerase incorporates single A’ 
residues to the 3’ terminal ends of double stranded DNA. Once the reaction was 
completed, the modified 0RF7 PCR product was purified from enzyme, buffer 
and salts and resuspended in water. Then it was inserted into the T’-tailed 
pGEM-T vector and transformed into DHIOB E  coli and incubated on LB AG 
plates overnight The 3’ T overhangs in the pGEM-T’ vector are positioned 
within the a-peptide sequence of the P-galactosidase gene. Insertional 
inactivation of the enzymatic activity allows visual screening of recombinant 
clones which appear white in LB AG agar plates. Four white bacterial colonies 
and one blue colony were selected, resuspended in sterile water and heated at 
95°C for 4 minutes to lyse the cells. The presence in the lysates of the 
recombinant plasmid was checked by PCR with the EAV0RF7 specific primers 
250001 and 250002. A band of the expected size was obtained from samples of 
the four white clones and small plasmid preparations were made of each of these 
clones. Restriction digestions of the plasmid preparations with BaniBl showed 
fragments of approximately 3000 base pairs and 330 base pairs confirming the
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presence of EAV 0RF7 in the pGEM-T plasmid. Sequencing of the insert using 
primers M13+ ( 5 -GTTTTCCCAGTCACGAC-3 ) and M13- (5’-
CAGGAAACAGCTATGAC-3 ’), which flank the multiple cloning site of 
pGEM-T vector, confirmed the presence of the EAV 0RF7 gene insert in the 
plasmid preserving the BamWL restriction sites. One of these recombinant 
plasmids was selected and denoted pGEM-T / 0RF7.
5.3.1.2. Subcloning o f EAV 0RF7 into pcDNA3
For subcloning into pcDNA 3, plasmid pGEM-T / 0RF7 was digested overnight 
at 37°C with BamHl and the enzyme was subsequently inactivated by heat and 
the reaction run on a 0.9 % agarose gel. The 330 base pairs fragment was 
purified from the gel and ligated into pcDNA3 digested with BamHi and 
dephosphorylated at its 3’ends. The ligation reaction was transformed into 
competent DHIOB cells and these were plated out onto LB A plates. Seven 
bacterial clones were checked for the presence of the recombinant plasmid by 
PCR using 0RF7 specific primers 2510001 and 2510002. Amplicons from five 
of the clones produced a positive result (Fig. 5.2). To check the orientation of the 
insert in the plasmid , a new PCR reaction was prepared using primer 2510001 
and primer CMV seq (r) (5’-GAAGGCACAGTCGAGGCT-3’), specific for 
pcDNA3 and positioned downstream of the multiple cloning site in reverse 
orientation. Three clones contained the insert in the correct orientation in the 
recombinant plasmid, with the translation initiation codon downstream of the 
CMV / T7 promoter elements. Large scale plasmid preparations were made for 
each plasmid. Sequencing PCR reactions using primers CMVseq (5’- 
ATAAGCAGAGCTCTCTGGC-3 ’) and CMVseq(r) confirmed that the 0RF7
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sequence, the insert-vector junctions and orientation were correct for one clone 
3 c. This recombinant plasmid was denoted pcDNA3 / 0RF7.
5.3.1.3. Expression o f EAV N  in EDC by pcDNA3 /  0RF7 plasmid transfection. 
Preliminary experiments to test the efficiency of expression of recombinant 
proteins via a cationic lipid (FUGENE) mediated delivery of recombinant 
plasmids into EDC were conducted using the pcDNA3 / lacZ plasmid, made and 
supplied by Dr McAleer. This plasmid has the backbone of pcDNA3 into which 
the P-galactosidase gene was inserted dowstream of the T7 / CMV promoter 
region for expression in mammalian cells.
An experiment was set up to compare the levels of protein expression between 
EDC and C0S7 cells after plasmid transfection of pcDNA3 / lacZ. Subconfluent 
monolayers of C0S7 cells and EDC prepared on 6 well plates (approximately 
2x10^ cells / well) were incubated for 15 minutes with 1 pg of the plasmid 
prepared in a 100 pi suspension of SFMEM containing 1.5 pi of FUGENE. After 
15 min incubation at room temperature, 1 ml of 10% MEM was added to each 
well and the plates were incubated for 24 hours before checking expression of 
the lacZ gene. The medium was discarded and cells washed twice with PBS 
before being fixed with glutaraldehyde for 15 minutes. Three washes with PBS 
preceeded the addition of X-Gal solution which was incubated with the cells for 
three hours at 37°C. After this incubation period, 5 % of the EDC turned blue 
indicating poor efficiency of transfection in these cells, as opposed to C0S7 cells 
which showed 50 % lacZ expression efficiency (data not shown).
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A second experiment was performed to optimise the FUGENE mediated 
transfection of pcDNAS plasmids in EDC. For this, two 24 well plates were 
prepared with 4 sets of EDC monolayers containing 2.5 x 10"^ , 5 x 10"^ , 10x10"^ 
or 20 X 10"* cells per well. After 24 hours incubation at 37°C, each set of cells of 
each plate was incubated with 0.125, 0.250, 0.500 or 1 pg of pcDNA3 / lacZ 
prepared in 50 pi of SFMEM containing 1.5 pi of FUGENE. Then 1 ml / well of 
either 10% MEM or 20% MEM was added to the plates and these were incubated 
for a further 24 hours at 37°C. Expression levels of the reporter gene after X-gal 
staining was highest when the cells were seeded at 20x10"  ^ cells / well, 
transfected with 1 pg of plasmid and incubated in 20% MEM after transfection. 
However these levels were never higher than 10% (data not shown).
Expression from the pcDNA3 / 0RF7 construct was tested on C0S7 cells to 
verify the quality of the construct and determine the time of maximum 
expression after transfection. In this experiment. Vaccinia MVA / T7 co- 
infection was used to facilitate the expression of the EAV N gene. This 
recombinant virus encodes the RNA polymerase of phage T7, which once 
synthesized, provides cytoplasmic transcription of expression cassettes 
containing the CMV/T7 promoter elements such as the one contained in the 
pcDNA3 / 0RF7 plasmid. Four 24-well plates were inoculated with 3x10"^  cells / 
well and incubated in 10% MEM for 24 hours before being tested. For each 
plate, the cells were either a) mock infected; b) infected with EAV at an m.o.i. of 
0.8 TCID5 0 / cell; c) infected with Vaccinia MVA / T7 at an moi of 10 pfu / cell; 
d) transfected with 240 ng of pcDNA3 / 0RF7 per well or e) infected with 
Vaccinia MVA / T7 at an m.o.i. of 10 pfu / cell and transfected with 240 ng of
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pcDNA3 / 0RF7 per well. Cell monolayers were first inoculated with 250 pi of 
either SFMEM (a and d), EAV (b) or MVAT7 (c and e). Transfections were 
conducted using FUGENE; plasmid pg ratio of 12:1 (d and e). After 1 hour 
incubation all the wells were incubated in 10% MEM for various periods of time. 
The cells were fixed at 1 hour, 2.5 hours, 5 hours or 24 hours post-transfection. 
For each plate, one replicate was fixed with 4% formaldehyde whereas the other 
was fixed with 4% formaldehyde, 0.4% Triton-X-100. Detection of the EAV N 
antigen by immunofluorescence revealed 0RF7 expression from EAV infected 
cells only at 24 hours-post inoculation and from cells simultaneously infected 
with vaccinia MVAT7 and transfected with pcDNA3 / 0RF7 at 5 and 24 hours 
post-inoculation. An example of the immunostaining pattern obtained in 
pcDNA3 / 0RF7 transfected and MVAT7 co-infected COS-7 cells fixed at 24 
hours is shown in Figure 5.3. The use of 0.4 % Triton-X-100 to permeabilise the 
cells was necessary to detect an immunofluorescence signal. These experiments 
corroborated that the cloning of EAV 0RF7 into the pcDNA3 expression vector 
was satisfactory and gave an indication about the time of maximum expression. 
However, RNA transcription from the cytoplasm, provided by the T7 RNA 
polymerase expressed from the recombinant vaccinia MVA /T7, was required for 
detectable expression of the N protein. This may indicate either that the plasmid 
was inefficient at entering the nucleus or that 0RF7 mRNA transcripts in the 
nucleus were inefficiently translated (eg. RNA instability, low efficient export to 
the cytoplasm).
In order to test expression of 0RF7 in EDC and RK-13 cells following 
transfection of pcDNA 3 / 0RF7, EDC and RK-13 cells were seeded at lO'^  cells
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/ well and incubated for 24 hours in 20% MEM and 10%MEM respectively 
before being transfected with 240 ng of either pcDNAS / 0RF7 or pcDNA3 / 
lacZ using FUGENE: pg plasmid ratios of 3:1, 6:1 and 12:1. Half of the wells 
receiving pcDNA 3 / 0RF7 were co-infected with Vaccinia MVA T7. Positive 
controls were provided by EAV infected cells and negative controls provided by 
MVA / T7 infected and mock-infected cells. After an incubation period of 24 
hours at 37°C, the cells were fixed with 4% formaldehyde, 0.4% Triton-X-100 
solution and expression of the recombinant genes tested by immunofluorescence 
or X-gal staining. Results indicated that RK-13 cells expressed both recombinant 
genes and that the efficiency correlated with the FUGENE: plasmid ratio in the 
following order: 3:1 > 6:1 > 12:1. However, EDC’s failed to express either 
recombinant gene efficiently (less than 5% cells expressing the recombinant 
gene). Intriguingly, expression of EAV N in RK-13 cells was observed in the 
presence and absence of MVA/T7 (data not shown).
5.3.2. Expression o f heterologous genes in EDC hy baculovirus transduction
5.3.2.1. Expression oflacZ in EDC by baculovirus transduction 
At the time these experiments were being conducted. Dr McAleer at the AHT 
expressed successfully the P-galactosidase enzyme in C0S7 cells and equine 
embryonic lung cells (EEL) by the use of a recombinant baculovirus (Bac-CMV / 
lac Z) which encodes the lacZ gene under the control of the CMV / T7 promoter. 
These results demonstrated the potential of baculovirus transduction for high 
efficiency expression of EAV genes in EDC. A preliminary experiment was set 
up to test the validity of this approach for expression of lacZ in these cells. 
Doubling dilutions of the Bac-CMV / lacZ baculovirus stock, used by Dr
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McAleer, were made in SFMEM or in 20% MEM and 100 pi of each dilution 
inoculated into each of four replicate wells of EDC monolayers seeded 24 hours 
earlier at 10"^  cells / well. Wells inoculated with baculovirus suspensions in 
SFMEM were replaced by fresh 20 % MEM after 4 hours incubation at 37°C and 
then incubated for a further 20 hours. The monolayers inoculated with the 20% 
MEM baculovirus suspension were incubated for 24 hours without medium 
change. After the incubation period, the cell sheets were stained with X-Gal. The 
results of this experiment showed: a) that heterologous expression of lacZ could 
be achieved by baculovirus transduction and that the expression levels were 
higher when the inoculum was replaced after 4 hours with fresh 20% MEM; b) 
that the efficiency of expression of the reporter gene was dose-related, ranging 
from 100% at % and dilutions to < 1% at dilution 1/128; and c) that the 
baculovirus might have a toxic effect on the cells since the cell density in each 
well increased with the baculovirus dilution. An example of lacZ expression on 
EDC transduced with Bac-CMV / lacZ at a dilution of Va is illustrated in Figure
5.4.
Since the lac Z gene was cloned at the polyhedrin locus it is possible that during 
propagation of the virus in insect cells the recombinant gene had been expressed 
and the enzyme incoorporated into virions. To determine whether the lac Z 
activity observed in the EDC transduced with Bac-CMV /lac Z was due to de 
novo synthesis of the enzyme and not as a result of the delivery of preformed 
enzyme into the cells, expression of the reporter enzyme was tested in the 
presence or absence of cycloheximide, a strong protein synthesis inhibitor. EDC 
monolayers were prepared in 96 well plates and grown overnight at 37°C and
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inoculated with Bac-CMV / lacZ suspensions with or without cycloheximide at a 
concentration of 50 pg / ml. After a 4 hour incubation period at 37°C all the cells 
were washed with PBS and half of the wells were fixed with glutaraldehyde and 
stained with X-gal. The other half were incubated for a further 24 hours in the 
same medium. Then the cells were washed in PBS, fixed in glutaraldehyde and 
incubated with X-gal. Enzymatic activity was only detected in the 24 hour 
cultures that were incubated in the absence of cycloheximide (data not shown). 
These results indicated that the enzyme activity following baculovirus 
transduction was a result of de novo synthesis of P-galactosidase.
5.3.2.2. Sub-cloning o f the EAV0RF7 mammalian expression cassette from  
pcDNA3 /  0RF7 into the baculovirus transfer vectorpVL1393.
For expression of EAV 0RF7 in EDC by baculovirus transduction it was 
necessary first to insert this gene into an appropriate baculovirus transfer vector 
for eventual recombination with linearised baculovirus DNA after cotransfection 
in Sf 9 insect cells. Regulatory elements necessary for expression of heterologous 
genes in mammalian cells need to be present in the final recombinant 
baculovirus. Since these are not provided by the shuttle vector pVL1393, the 
cloning strategy, outlined in Fig. 5.5., was based on the insertion of the Nrid -  
Smal fragment of pcDNA3 / 0RF7 into the multiple cloning site of pVL1393. 
This DNA fragment contains the EAV 0RF7 gene downstream of CMV / T7 
promoter sequences and upstream of the BGH polyadenylation site (poly A’).
The restriction enzymes Nrul and Smal were selected for digestion of pcDNA3 
since they are unique in the vector and are not present in EAV0RF7. In addition, 
they generate blunt-end DNA fragments to which single adenosine residues
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could be added at the 3’- ends of the molecule facilitating the rapid insertion into 
thymidine tailed vectors. Approximately 10 pg of plasmid pcDNA3 / 0RF7 were 
digested with Nrul for 4 hours at 37°C. Once the enzyme was inactivated for 15 
min at 65 °C, the digest was purified and a second restriction digestion was 
performed with Smal at 25 °C overnight. After inactivating the enzyme for 15 
min at 65°C, approximately 6 pg of the digest was run on a 0.7 % agarose gel. 
This procedure separated two DNA fragments of approximately 2217 and 3562 
base pairs corresponding to the expected sizes of the Nrul -  Smal digested 
pcDNA 3 /0RF7 plasmid. The smaller DNA fragment was purified from the gel 
and A’ residues were added to 3’ ends before storing at -  70C.
The plasmid pVL1393 was digested with Smal at 25°C overnight to generate a 
linearised DNA fragment which was subsequently T’ tailed. Initially, the PCR 
reaction conditions used to generate the T’tailed pVL1393 were the same as 
those used for adding A’ residues to DNA fragments. However, subsequent 
ligation reactions of insert and vector and subsequent transformation of 
competent E coli DHIOB cells produced very few bacterial clones, all of which 
contain the pVL1393 without the Nrul -  Smal fragment insert. The failure was 
attributed to inefficient T’tailing of the vector. When the concentration of dTTP 
was increased 10 times to achieve a final concentration of 20 mM, ligation was 
successful and transformation of the ligation reaction produced recombinants 
containing the insert and the T’ tailed vector. Indeed, PCR- screening of bacterial 
clones using EAV0RF7 specific primers identified five EAV0RF7 positive 
clones, 3a, 2d, 2c, 2a and la  (Fig 5.6.). Double and single restriction digests of 
plasmid preparations from three of these positive clones (3a, 2a and la) with
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BamVÜ, SndBl and BamVïL and SnaSi (Fig. 5.7.a) failed to indicate presence of 
the 0RF7 cassette for clones la  and 2a but produced for clone 3a DNA bands 
which correspond to a recombinant plasmid in which the EAV0RF7 expression 
cassette is in reverse orientation respect to the polyhedrin promoter of pVL1393 
(314, 333, 1065, 1099 and 8921 for the double digests, 1065 and 10660 for 
SnaBl and 333, 1099 and 10303 for Bam}A£). PCR reactions using EAV 0RF7 
specific primers and EAV0RF7 2510001 primer and the polyhedrin specific 
primer pVL1393(f) (5 -AAATGATAACCATCTCGC-3’) of plasmid
preparations from clone 3 a, 2a, 2d and two previously untested clones 3b and 4b 
indicated that while EAV0RF7 PCR products were obtained for all the clones, 
only 3 a and 2d produced PCR products using the second pair of primers 
(Fig.5.7.b). These results confirmed that the EAV0RF7 expression cassette was 
inserted in reverse orientation to the PH promoter in these plasmids. Another 
restriction digestion of clone 3 a plasmid was performed using Hindlll and Xhol 
enzymes (Fig. 5.1.6) corroborated the orientation of the insert. Sequencing of the 
recombinant plasmids 3a, 2d and 3b using polyhedrin specific primers pVL1393 
(f) seq and pVL1393(r) confirmed the orientation of the inserts in 3 a and 2b 
pVL1393 vectors were in reverse relative to the polyhedrin promoter whereas the 
one of 3b was in the same orientation and that the sequence across the junctions 
was correct for all three plasmids. Sequencing also revealed that all three 
plasmids presented a substitution of two guanines for two cytosines at positions 
1686 and 1687 and a deletion of a cytosine residue in the position 1797 of the 
pcDNA3. These positions are located downstrean of the EAV0RF7 and 
polyadenylation site on the SV40 promoter and are therefore unlikely to affect 
expression. A large scale plasmid preparation from clone 3a was made and this
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plasmid was denoted as pVL / pcD / 0RF7. Expression of the nucleocapsid 
protein was achieved in RK-13 cells after cationic lipid plasmid transfection of 
this plasmid and co-infection with Vaccinia MVA / T7 (not shown).
The same cloning strategy was used to try to make recombinant baculovirus 
pVL1393 based shuttle vectors containing pcDNA3 expression cassettes 
encoding either 0RF5 or 0RF6 of EAV. The latter derived from Nrul and Smal 
digested pcDNA3 / 0RF5 and pcDNA3 / 0RF6 plasmids which were made and 
supplied by Dr McAleer at the AHT. Only one recombinant plasmid was 
obtained for 0RF5 which was denoted as pVL /pcD /0RF5.
5.3.3. Generation o f recombinant baculovirus
To obtain recombinant baculoviruses, Sf 9 insect cells were co-transfected with 
pVL / pCD / 0RF7 and Bsu36I digested BacPakô AcNPV virus (Clontech). This 
baculovirus contains two Bsu36\ restriction sites positioned within ORF603 and 
within the essential ORE 1629 gene. These sites flank the lacZ gene at the 
polyhedrin locus. Digestion of the viral DNA with Bsu36I linearises the genome 
and deletes parts of the above mentioned genes as well as the polyhedrin locus. 
This viral DNA is unable to replicate or produce virus particles unless it 
recombines with a transfer plasmid vector containing baculovirus ORF’s 623 and 
1629. The plasmid pVL / pCD / 0RF7 provides these baculovirus sequences 
necessary for recombination as well as the EAV0RF7 mammalian expression 
cassette.
SF9 insect cells were transfected with 100 ng of Bsu36I digested BacPakô and 
500 ng of pVL / pCD / 0RF7 or pVL / pCD / 0RF5 and incubated at 28°C for 4
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days. After this period the tissue culture fluid from the co-transfections was 
harvested and used in a plaque assay to isolate recombinant baculovirus clones. 
Decimal dilutions of the co-transfection harvest and of a BacPakô virus stock 
were used to inoculate each of a series of Sf9 cell monolayers prepared in 6 well 
flat bottomed plates and a plaque assay performed as indicated in materials and 
methods. Several plaques were picked and all corresponded to recombinant 
baculoviruses.
Identification of recombinant baculoviruses was done by PCR with EAV0RF7 
primers 251001 and 251002 using DNA extracted from baculovirus infected cells 
or from virus particles contained in tissue culture fluid. Fresh cell monolayers 
were infected with each plaque pick and incubated for 3 days. When the cpe 
developed the cells were harvested and pelleted and washed in PBS. After 
resuspending the cells in TE buffer (10 mM Tris-HCl, pH 8.0, ImM EDTA) the 
cells were lysed by adding an equal volume of lysis buffer (50mM Tris-HCl, pH
8.0, 5% 2-mercaptoethanol, 0.4% w/v SDS, lOmM EDTA). Proteinase K to a 
final concentration of 25 p.g / ml and RNAse A to a final concentration of 2.5 pg 
/ ml were added and incubated for 30 min at 37°C. Then total DNA was 
extracted twice with an equal volume of phenol: chloroform for 5 min. and 
finally precipitated by the addition of 3M CH-COONa and ethanol. After a final 
wash in 75% ethanol the precipitate was dried and resuspended in TE buffer. 
Results from PCR indicated that EAV0RF7 could be amplified from most of the 
samples derived from infected baculoviruses. Four clones were selected for 
baculovirus transduction. Confluent monolayers of EDC’s prepared in a 96 well 
plate were used to inoculate Bac / CMVT7 / 0RF7 baculovirus clones 1, 2, 3, 4. 
BacPakô, EAV and mock infected wells were used as controls. For each clone 4
192
vims dilutions in SFMEM were used: undiluted, 2/3, 1/3 and 1/6. The cells were 
washed in SFMEM medium and then were inoculated with 100 pi of either 
EAVLP3A+ at an moi of 3, MVAT7 at an m.o.i. of 1 or SFMEM and incubated 
for 1 hour at 37°C. The vaccinia MVA/T7 and mock infected cells were washed 
again with SFMEM and were inoculated with 100 pi of the baculo vims 
suspensions and incubated for 4 hours at 37°C. All the wells were washed in 
SFMEM incubated in 10%MEM for 20 hours. The cells were then washed in 
PBS and fixed in 4% formaldehyde, 0.4% Triton-X-100 and subjected to 
immunofluorescence with the anti-N specific antibody SP07 and FITC 
conjugated anti-rabbit IgG. Results showed expression of the nucleocapsid 
antigen in EAVLP3A+ infected cells as well as in cells infected with MVAT7 
and transduced with the recombinant baculovimses (Fig. 5.8). Expression was 
not detected either in mock or BacPakb infected cells or in cells inoculated with 
the baculovimses alone. The results showed that all clones tested contained the 
CMVT7 / 0RF7 expression cassette in their genome and that this cassette is 
functional in EDC’s upon baculovims transduction although MVAT7 co- 
infection was necessary for detectable expression. The N antigen localised 
mainly in the perinuclear region and in the nucleus of baculovims transduced 
cells contrasting with EAVLP3A+ infected cells which show a widespread 
staining pattern of the cytoplasm with less proportion of cells stained in the 
nucleus (Fig. 4.1, Chapter 4). The efficiency of expression in baculovims 
transduced EDC’s was higher than 50% and indicated that baculovims 
transduction could be applied in the CTL assay to attempt to determine proteins 
that hold CTL epitopes.
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5.3.4. Attempts to measure EAV specific CTL activity using N  expressing EDC 
targets.
An EAV CTL assay experiment was designed to test whether the EAV N 
expressing EDC’s could function as targets for EAV cytotoxic effector cells. 
Transduction of EDC with the recombinant baculovirus Bac / CMVT7 / 0RF7 
was used to generate CTL targets expressing the N protein of EAV. Effectors, 
prepared as described previously, were obtained from pony 027a 10 months after 
infection with EAV. EDC from pony 027a were resuspended in 20% MEM 
medium at 4x10^ cells / ml and 4 mis aliquots prepared. Each aliquot was 
inoculated with either EAV at an moi of 0.3, MVAT7 at an moi of 1, a 
combination of MVAT7 at an moi of 1 and 0.5 mis of Bac / CMVT7 /0RF7 or 
0.5 mis of Bac / CMVT7 / 0RF7 only. One aliquot remained uninfected. These 
cell suspensions were radiolabelled with 15 pCi / ml of ^ ^Cr and seeded onto two 
96 well plates and incubated at 37°C for 24 hours. Effectors, a lysis solution or 
CTL medium were incubated for 4 hours with the targets of both plates and 
radioactivity of the medium measured as an indication of cell lysis. Specific lysis 
percentages were calculated as indicated in Chapter 4.
The results of this assay (Table 5.9) showed very little lytic activity of mock 
induced effectors against all the targets. In contrast, EAV induced effectors 
displayed different degrees of cytolysis on different targets. Thus, baculovirus 
transduced EDC co-infected with MVAT7 and EAV infected EDC were 
effectively lysed by the CTL effectors in contrast to mock infected EDC’s which 
showed low percentage lysis values. The values obtained for EDC infected with 
MVAT7 indicated that EAV induced effectors exhert some cytolytic activity on
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these cells, however the results are not conclusive since there is a small variation 
in the percentage lysis figures between the two plates. The percentage lysis 
values for baculovirus transduced EDC targets varied substantially between both 
plates making the interpretation of the results difficult. This variation is caused 
by the difference in the spontaneous target lysis between the two assays. In 
summary, in this experiment it has not been possible to determine whether the 
nucleocapsid protein of EAV is an important antigen for EAV specific cytotoxic 
lymphocytes. Interpretation of the results has been complicated by the variability 
between replicates and by the low total ^^Cr release of targets inoculated with 
baculovirus (approximately half of the total release from EAV, MVAT7 or mock 
infected targets) which indicate that EDC either did not uptake or did not retain 
the radiolabel.
5.4. Discussion
The purpose of this work was to establish a method to identify EAV proteins that 
serve as CTL targets. The strategy employed used non-replicative vectors for the 
delivery of EAV genes into equine dermal cells for the expression and 
presentation of derived peptides by MHC-I which could be then recognised by 
CTL effector cells using the newly established methods to measure CTL 
responses against EAV.
We chose the nucleocapsid N protein as a potential CTL target since this protein 
is expressed abundantly in EAV infected cells and internal antigens in other virus 
systems have been shown to be frequently recognised by cytotoxic lymphocytes. 
Such antigens have been shown to contribute to the development of CTL
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protective immune responses (Bangham et a l, 1986; McMichael et a l, 1986; 
Townsend et a l, 1984). Furthermore, the nucleocapsid protein N of LDV has 
been identified as a CTL target (Even et a l, 1995). We cloned successfully the 
nucleocapsid gene of EAV into pcDNAS and showed that the recombinant gene 
was fimctional since the protein was detected by immunofluorescence in 
pcDNAS / 0RF7 transfected C0S7 cells and RK-13 cells. However, expression 
was only detected when the cells were co-infected with recombinant vaccinia 
MVA / T7. This virus encodes the RNA polymerase of the phage T7 and hence 
enables transcription of the 0RF7 gene of EAV from the cytoplasm. The lack of 
detectable expression in the absence of cytoplasmic transcription may result from 
the plasmid failing to reach the nucleus where the mammalian RNA polymerase 
11 would have generated the 0RF7 m-RNA. However, we have shown that 
transfection alone was sufficient to drive the expression of the lac Z gene in 
COS-7 cells from pcDNA3 / lacZ indicating that delivery of the gene to the 
nucleus occurred efficiently. This suggests that blocking of the expression of 
EAVORF 7 in the absence of MVA/T7 was gene specific rather than related to 
the plasmid. For example, the EAV0RF7 may contain an early transcription 
termination signal or m-RNA splicing signals disrupting expression of full length 
m-RNA in the nucleus. Alternatively, the resulting m-RNA may be relatively 
unstable or poorly exported from the nucleus.
Although the EAV0RF7 gene was expressed abundantly in COS-7 and RK-13 
cells following transfection of pcDNA3 / 0RF7, the efficiency of expression in 
EDC’s was very poor making this approach not suitable for identifying CTL 
targets. All the plasmid transfection experiments were conducted using the non-
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liposome lipid reagent FuGENE and it is uncertain whether other transfection 
techniques (use of cationic liposomes, electroporation, dextran, calcium 
phosphate) would have been successful for the efficient expression of 
EAV0RF7. However, at the time these experiments were conducted, the 
potential of baculovirus transduction as a gene delivery system in equine cells 
was investigated in our laboratory. Heterologous genes have been expressed 
successfully using this technique (Condreay et al., 1999). Similarly, lacZ gene 
expression was detected in equine embryonic lung cells transduced with a 
recombinant baculovirus encoding this gene under the CMV / IE promoter. This 
recombinant baculovirus also transduced and induced lacZ gene expression in 
EDO’s., the cells used as targets in the EAV CTL assay. Therefore, the 
generation of a recombinant baculovirus containing the EAV0RF7 under the 
control of the CMV promoter was pursued. The baculovirus bac / 0RF7 was 
made by subcloning a Nrul-Smal fragment from the pcDNAS / 0RF7 into the 
BamHl multiple cloning site of pVL1393. This strategy was similar to that one 
used by Condreay et al., (1999). However in the latter case the fragment 
subcloned was slightly longer to include the SV40 promoter-neomycin- 
phosphotransferase expression cassette neccesary for generation of stably 
transfected cell lines. Baculovirus transduction of EDC’s resulted in the 
expression of the recombinant gene in approximately 50% of the cell sheet, 
although again co-infection of MVA/T7 vaccinia virus was required, which 
reinforces the hypothesis that the blocking of the expression in its absence was 
gene related. The N protein localised mainly to the nuclei and to discrete 
perinuclear foci in transduced cells as opposed to EAV infected fibroblasts in 
which N antigen shows a more widespread distribution. Importantly, the cells
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retained their original morphology indicating that the procedure was not highly 
toxic to the cells which is consistent with previous observations that indicate the 
low levels of toxicity of baculovirus transduction (Shoji et ah, 1997).
Baculovirus transduction was employed to assess the cytotoxic effect of EAV 
and Mock induced effector lymphocytes on Bac/ pcD / 0RF7 transduced EDC’s. 
The results of this experiment were not conclusive and further optimisation of the 
use of baculovirus transduction is required to obtain an answer to the question of 
whether this technique can be used to identify EAV CTL targets. Although as we 
discussed earlier, the EDC’s did not lose their normal cell architecture, the total 
^*Cr release of baculovirus tranduced targets was lower than that of EAV or 
mock infected EDC’s suggesting an alteration in the uptake or retention of the 
radiolabel ocurred during the overnight incubation period. This, in combination 
with the variability in the specific lysis between replicates, makes the assay 
difficult to interpret. It is important to note that baculovirus suspension was not 
removed after inoculation and this might have contributed to the observed 
decrease in the total release values of the baculovirus targets in comparison to the 
EAV, MVA/T7 or Mock targets. Further improvements of the current protocol 
should take this fact into account and test the effect of removing the baculovirus 
inoculum after a relatively short adsorption period.
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Figure 5.1. Cloning strategy to obtain an EAV0RF7 mammalian expression plasmid 
vector. The cDNA clone 106 was used as a template to generate a PCR product using 
primers 2510001 and 2510002 as indicated in the text. BamHl restriction sites are 
indicated in bold and the additional nucleotides included in the forward primer to obtain 
a Kozak sequence are indicated in red. The PCR product was A’ tailed and ligated into 
pGEM-T’ as an intermediate step before digestion of pGEM-T/0RF7 with BamHl and 
ligation of the digested 0RF7 PCR product into the multiple cloning site of the 
mammalian expression plasmid pcDNAS.
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Figure 5.2. Sizes of DNA fragments from PCR reactions using 
primers EAV0RF7 specific primers 250001 and 250002 on lysates 
of bacteria transformed with pcDNAS and EVA0RF7 ligation 
reactions. Lane 1 corresponds to the molecular weight marker 1 kb 
ladder, lane 2 corresponds to products from a positive control 
(pGEM-T/0RF7), lane S corresponds to a negative control 
(plasmid pcDNAS) and lanes 4-10 correspond to bacterial clones 
Sc, lb, la. Id, Ic, Sb and 4c.
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Figure 5.3. Expression of N antigen of EAV in C0S7 cells transfected with 
pcDNAS / 0RF7 and co-infected with recombinant vaccinia virus MVA / T7. 
Detection of N was done by immunofluorescence using anti-SP07 rabbit polyclonal 
antibody of cells fixed at 24 hours post-infection.
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Figure 5.4. Expression of the lacZ gene in EDC transduced with recombinant 
baculovirus Bac-CMV/lacZ. EDC’s were inoculated with the baculovirus preparation 
diluted 1:4 in 20%MEM, incubated for 24 hours at 37°C and stained with X-gal 
solution after fixation with glutaraldehyde.
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Figure 5.5. Outline of the cloning strategy used to generate a 
baculovirus ‘shuttle’ vector for expression of EAV0RF7 in EDC’s. 
The plasmid pcDNAS / 0RF7 was digested with Nrul and Smal 
restriction enzymes generating a DNA fragment with blunt ends 
containing the EAV0RF7 expression cassette with the CMV/T7 
promoter and polyadenylation signal (pA). This DNA was A’ tailed 
and inserted into a pVL1393 baculovirus shuttle vector previously 
digested with Smal at the multiple cloning site, positioned 
immediately downstream of the polyhedrin promoter (PH), and 
treated to add thymidine (T’) to its 3’ ends. The new ‘shuttle’vector 
pVL / pcD / EAV0RF7 used to generate the recombinant 
baculovirus, which contains the EAV0RF7 expression cassette in 
reverse orientation respect to the polyhedrin promoter, is 
represented in the figure. The relative positions of the restriction 
enzymes used in the characterisation of the recombinant plasmid 
and the theoretical sizes of the fragments they generate are shown. 
The black or blue colours indicate which enzymes have been used 
in the same restriction digestion experiment to characterise the 
recombinant plasmid. Green arrows represent primers 2510001 and 
pVL(f).
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Figure 5.5.
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Figure 5.6. Sizes of DNA fragments from PCR reactions using 
primers EAV0RF7 specific primers 250001 and 250002 on lysates of 
bacteria transformed with pVL1393 and pcDNA3 / 0RF7 ligation 
reactions. Lane 1 corresponds to products from a negative control 
(plasmid pcDNA3), lane 2 corresponds to a positive control, (pGEM- 
T/0RF7), lanes 3-10 correspond to bacterial clones 3a, 2d, 2c, 2b, 2a, 
Id, Ic and la and lane 11 corresponds to the molecular weight 
marker 1 kb ladder
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Figure 5.7. Selection of pVL1393 / pcD / 0RF7 positive bacterial clones.
A) Sizes of DNA fragments from BanûB / SnaBl double restriction digests 
(lanes 2-4), SnaBl restriction digests (lanes 5-7) and BamBl digests (lanes 
8-10) of plasmid preparations from clones 3a (lanes 2, 5 and 8), 2a (lanes 
3, 6 and 9) and la (lanes 4, 7 and 10). Lanes 1 and 11 contain Ikb DNA 
ladder. Faint 0RF7 DNA bands fragments are indicated by yellow arrows.
B) PCR reactions using primers LAV0RF7 specific primers 250001 and 
250002 (lanes 8-12) or primer 250001 and pVL (f) (lanes 2-6) on plasmid 
preparations from clones 3a (6, 12), 2a(5, 11), 2d (4, 10), 3b (3, 9) and 4b 
(2, 8). Lane 1 contains the Ikb molecular weight marker. Lane 7 is empty.
C) Sizes of DNA fragments from Xhol and Hindlll double restriction 
digests (lane 3) of plasmid 3 a. Lane 1 contains the 1 kb molecular weight 
marker. Lane 2 is empty.
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Figure 5.8. Expression of EAV N protein in EDC’s transduced with the recombinant 
baculovirus pVL / pcD / 0RF7 and co-infected with recombinant vaccinia MVA / T7. 
Expression was detected by IFI using a-SP07 rabbit polyclonal antibody 24 hours 
after transduction. Pictures were taken at lOOx (a), 200x (b) and 400x (c and d).
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Chapter 6: General discussion
In this project, two novel strategies for the generation of marker vaccines against 
EAV have been investigated and new methods have been developed to analyse 
the immune response of the horse to vaccination and infection with this virus. 
New knowledge has been gained on the understanding of adaptive immune 
responses that operate in clearance of EAV infection.
Marker vaccination is a concept applied in medical and veterinary sciences in 
which the induction of immune responses in the individual are both protective 
against the particular disease/infection under investigation and also, can be 
differentiated from those elicited by natural exposure to the pathogen. This 
vaccination strategy allows prevention of diseases and / or infections in 
immunologically naïve and susceptible animals and differentiation of these from 
naturally infected (and potentially infectious) animals. This in turn permits the 
simultaneous application of disease eradication and vaccination policies, which 
may otherwise be incompatible, as is the case for foot-and-mouth disease and 
classical swine fever in the European Union. The advent of marker vaccination is 
particularly advantageous for the control of virus diseases in which a persistent 
infectious carrier state exists, such as foot-and-mouth disease, or in those which 
induce latency (BHV-1 in cattle, Aujeszky’s disease of pigs or EHV-1 in horses) 
and have the potential to initiate an outbreak upon reactivation. In the case o f 
BHV-1 and Aujeszky’s disease, eradication policies have been applied in several 
European countries and marker vaccine immunisation forms an important part of 
those programmes (van Oirschot, 2001). If the vaccine is a key player in these
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control programmes, of no less importance is the application of sérodiagnostic 
tests capable of detecting the differential antibody responses in vaccinated and 
naturally infected animals. The huge development of recombinant DNA 
technology in the past two decades has made possible the development of marker 
vaccination strategies against many viral infections of domestic animals (van 
Gennip et ah, 2002 ; Pensaert et al., 1990; Bouma et al, 2000; van Oirschot, 
2001, Babiuk, 1999).
EAV causes a systemic infection in horses, which may result in abortion or 
neonatal foal death and the establishment of persistent infections in stallions. The 
latter has the potential to facilitate transmission of infection via the venereal 
route. Although the infection frequently passes clinically unnoticed, its 
abortigenic potential, the capacity to persist in stallions and the resultant 
restrictions imposed on trade, make this disease economically important. EAV is 
has a worldwide distribution but its prevalence varies significantly between 
geographical regions. This is the case in central European countries (areas of 
suspected high prevalence) and the UK (very low prevalence). The constant 
movement of horses between these two regions of different prevalence poses a 
risk of introduction of the disease to naïve populations via persistently infected 
stallions or their semen. The control of EAV in the regions of low prevalence 
such as the UK, relies heavily on prophylactic sanitary measures based on 
accurate and thorough serological surveillance of the breeding stock. The use of 
a whole virus inactivated vaccine in stallions in some countries complicates 
sérodiagnostic interpretation. Hence, knowledge of vaccination history is critical 
to accurate diagnosis and relies on co-operation between diagnostic laboratories.
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veterinary surgeons and horse owners/trainers. In this situation, the use of an 
effective marker vaccine should not only provide protection against the disease 
should this be introduced and reduce aerosol virus transmission, but it should not 
compromise sero-surveillance.
The studies presented in this thesis evaluated the potential of two different 
marker vaccination approaches for EAV focusing in the analysis of the immune 
responses elicited and their protective efficacy against virulent challenge. The 
strategies employed were quite different, one based on a single purified EAV 
antigen (the 6hisGLCCto) administered intramuscularly with adjuvant and the 
other based on a recombinant live virus lacking an immunodominant region of 
Gl and administered intranasally. It was therefore not surprising that 
fundamental differences were observed with regards to the type of immune 
responses that developed and protective efficacy. These vaccination studies not 
only have value for their application in prevention of EAV infection, but serve 
as tools to dissect and study the development of adaptive immune responses 
against virus infections in the horse. Furthermore, these studies serve as a 
vaccinology model which can be applied to the study of other related viruses that 
infect horses or other domestic animals, such as PRRSV of pigs.
6.1. EAVGl as a sub-unit vaccine.
The potential for EAVGl as a sub-unit vaccine for EAV was based on the 
findings of Chirnside et a l (1995a) who demonstrated that immunisation of 
ponies with an immunodominant region of Gl resulted in the induction of VNAb 
responses. By using the recombinant protein 6hisGLCCto (comprising all domains 
contributing to the formation of VNAb epitopes) as the sole immunogen in
211
combination with the Carbopol adjuvant, the VNAb response in ponies was 
improved over that reported by Chirnside et al (1995a). This response was 
protective against challenge with the LP3A virus strain and the degree of 
protection correlated with serum VNAb titres at the time of challenge. As 
expected for an inactivated vaccine, protection from infection was dependent 
upon the amount of serum antibody and was not complete when VNAb titres 
declined to low levels. In particular, the amount and duration of viraemia was not 
reduced in animals with low VNAb titres compared with unvaccinated controls. 
However, even in animals with low VNAb, reduction of virus respiratory 
excretion was still evident which would reduce the spread of infection in an 
outbreak situation.
The findings presented in Chapter 2 were corroborated in follow up experiments 
performed with commercial support (Boehringer Ingelheim VetMedica). In one 
study, 4 groups of 8 ponies were vaccinated with Carbopol adjuvanted vaccines 
containing either no antigen (placebo control), 4 pg, 8 pg or 32 pg of the 
6hisGLCCto protein. The vaccines were administered by the intramuscular route 
in two doses, 4 weeks apart.VNAb responses were measured and protective 
efficacy against challenge with EAVLP3A+ in the same way as described in 
Chapters 2 and 3. All vaccinated ponies responded with a VNAb response 
peaking 2 weeks after the second dose was administered (mean VNAb titres 2.5) 
with very little differences between vaccinated groups (Fig. 6.1.). By day 112, 
VNAb were no longer detectable and remained at this level until the ponies were 
challenged on day 211 (approximately 7 months). Vaccinated ponies mounted a 
strong anamnestic response to virus infection and VNAb titres peaked sooner in
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these animals than in those that received the placebo. Consistent with the faster 
response to virus infection and with the findings reported in this thesis, 
vaccinated ponies showed partial protection against EAVLP3A+ infection 
despite having undetectable pre-challenge VNAb titres. Whereas the virus 
excretion from the upper respiratory tract was reduced, both in amount of virus 
excreted and in duration of virus shedding (Fig.6.2.b), reduction of duration of 
pyrexia (Fig.6.2.a) and viraemia (Fig. 6.2.c) were more subtle. The levels of 
protection achieved appeared to be sub-optimal. Unfortunately, comparison with 
whole virus vaccines could not be made because this parameter was not included 
in the study design. Furthermore, comparison with published work was not 
possible because in most of these studies, group sizes were very small or 
animals were challenged with virus shortly after vaccination. In the absence of 
comparative vaccination / challenge studies the relative protective efficacy and 
duration of immunity afforded by the inactivated vaccines versus 6hisGL sub-unit 
vaccine is uncertain. The reduction of virus excretion with the potential 
prevention of respiratory spread provided by 6hisGLCCto vaccination, which 
offers the additional advantage of differential diagnosis against natural infection, 
makes the sub-unit vaccination approach an interesting prophylaxis strategy for 
equine viral arteritis. In-contact transmission studies are necessary to determine 
the minimum nasal virus excretion levels required for aerosol spread of infection.
The kinetics of the serum VNAb responses following 6hisGLCCto vaccination of 
ponies was not unexpected for a non-replicating anti-viral vaccine and similar 
results have been observed with other Carbopol-based vaccines in horses 
(Mumford et a l, 1988). It is possible however, that alternative vaccination
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regimes and the use of other adjuvants may extend the duration of serum 
VNAb’s. Re-vaccination 6 months after a primary 2-dose course of whole 
inactivated EAV virus vaccine prolonged the duration of VNAb for at least 6 
months (Fukunaga et al., 1990). The same effect was observed with a 
commercial whole virus inactivated vaccine in a field study which showed a 
correlation between the VNAb titres and vaccination history in stallions 
(Cardwell et al., 2002). Prolonged antibody responses after inactivated vaccine 
administration have been observed also in ponies immunised with equine 
influenza ISCOM vaccines (Mumford et al, 1994a).
6.2. EAV-GLA immunisation provides complete protection in the light of 
low titre VNAh response against wild type EAV.
A live marker vaccination strategy was also explored. Deletion of an 
immunodominant region of the envelope Gl protein had no apparent effect upon 
the ability of the vaccine virus to replicate in vivo. The vaccine induced an 
asymptomatic infection in ponies but provided full protection against a virulent 
challenge despite induction of a very weak VNAb response. This vaccination 
strategy offers a number of advantages compared with inactivated whole virus 
vaccines as summarised in Table 6.4. The main disadvantage is the requirement 
to demonstrate safety. Although ponies infected with EAVGL A did not show 
clinical signs, our studies did not demonstrate this feature was dependent on the 
deletion since we did not include a group vaccinated with the parental virus, i.e. a 
virus derived from cells tranfected with the original cDNA clone. At the time of 
writing, a study comparing replication and immunogenicity of EAVGLA and the 
parental virus (designated EAV515) in ponies showed that there were no
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differences in clinical signs, virus excretion or viraemia between ponies infected 
with either virus (Castillo-Olivares, unpublished observations). These results 
indicated that it is not possible to attribute the low virulence of EAVGlA to the 
deletion of 66-112 G l peptide and therefore further studies are necessary to 
demonstrate that the deletion mutant virus does not revert to virulence after 
passage in vivo. However, studies in stallions demonstrated that unlike wild-type 
EAV viruses, the cDNA clone derived virus EAV030H was genetically stable 
and not prone to the generation of novel genetic variants of increased virulence 
(Balasuriya et al., 1999b). It can be inferred therefore, that cDNA 03OH derived 
viruses and those derived from its derivative plasmid pEAN515 share the same 
biological properties. Equally important from the safety point of view is to know 
whether the post-infection viraemia could result in abortion in the pregnant 
mares.
These concerns need to be addressed before using the EAVGLA as a marker 
vaccine but there are some methods that could be applied to improve safety. First 
of all, it would be possible to adapt the virus to grow in non-equine cell lines in 
the same way as the current modified live virus vaccine was generated and 
reduce its capacity to replicate in vivo. Alternatively, a ‘knock out’ deletion could 
be introduced in the virus genome which could be rescued by a complementing 
cell line supplying in trans the deleted gene. This virus carrying the knock-out 
gene would be able to infect cells in vivo but would be replication deficient. 
Interestingly, recombinant sub-unit (Hulst et al., 1994; van Rijn et ah, 1996; 
Bouma et al., 2000) and live virus marker vaccines (van Gennip et al., 2000; 
2002) have been developed for classical swine fever (CSFV) using similar
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approaches to those described in this thesis for the prevention of EAV. The 
CSFV genetically modified live virus vaccines make use of a cDNA full-length 
clone of CSFV to replace the region encoding the E2 protein (the 
immunodominant antigen) with the E2 coding sequences of the related bovine 
viral diarrhoea virus (BVDV). Alternatively, an CSFV E2 expressing cell line 
was used to complement a CSFV E2 deficient genome to generate in vivo 
replication deficient virus. Both approaches provided protective immunity 
against CSFV infection. The replacement of E2 gene of CSFV by that of BVDV 
provided a positive serological marker. This is a strategy that has potential for 
EAV since replacement of the ectodomain of G l by the equivalent region of 
PRRSV or LDV was shown to result in the generation of viable viruses capable 
of replicating in RK-13 and BHK-21 cell lines (Dobbe et al., 2001). These 
studies suggested that EAVGl ectodomain does not determine cell tropism and it 
is not essential for virus infectivity. The latter assumption is supported by our 
studies and extends this observation to in vivo infections. However, it must be 
recalled that the Gl ectodomain was only partially deleted in the present studies.
6.3. Structure of EAV VNAb epitopes - additional VNAb epitopes in other 
parts of the virion.
All known VNAb epitopes of EAV have been mapped to the ectodomain of Gl 
and most of the genetic variation results from changes in the immunodominant 
region of Gl which is most frequently recognised by field EAV VN positive sera. 
However the VNAb depletion experiments (Chapter 2) suggest that other VNAb 
epitopes may exist in addition to those represented by Peptide 2 ( 81-96) and 
6hisGLCCto (18-122) antigens. These could be conformational epitopes located in
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Gl as has been demonstrated in various studies (Balasuriya et ah, 1995a, 1997; 
Deregt et a l, 1994) or linear and conformational epitopes present elsewhere in 
the virus envelope. The neutralisation activity of equine antiserum raised against 
wild type EAV and EAVGlA (Chapter 3) for wild-type EAV and EAVGlA does 
not support the hypothesis that important VNAb epitopes are present in other 
proteins apart from Gl. Otherwise, wild type EAV viruses would have been 
efficiently neutralised by AGl- specific equine antiserum. However, new 
information on virus structure coming from very recent studies (Wieringa et al., 
2002; 2003) demonstrates that GP4 and GP3 are structural proteins and form 
heterotrimer complexes with GP2b (Gs), and that antibodies in EAV equine 
antiserum are directed to GP3 (Hedges et al., 1999). Morevoer, GP4 of PRRSV 
is known to contain VNAb epitopes (Meulenberg et a l, 1997) which indicates 
that additional neutralising epitopes of EAV might be formed by these three 
proteins.
Analysis of the antigenic specificity of EAVGlA antiserum obtained during this 
project by westem-blot or immunoprécipitation would provide useful 
information about the antigenic structure of EAV neutralising epitopes.
6.4. Detection of CD8+ T-lymphocyte cytotoxic precursors and their 
potential role in clearance of viral infection.
Many studies have associated virus neutralising antibodies with protection 
against EAV infection. This is supported by challenge studies in ponies 
vaccinated with inactivated whole virus or Gl sub-unit vaccines. However, 
evaluation of the protective effect of other important immunological effector 
systems was not possible previously because of the lack of methods to evaluate
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them. The hypothesis that some of these adaptive responses may play an 
important role in EAV immunity is supported by the studies reported herein.
Table 6.3. Comparison of two different marker vaccination strategies for 
EAV.
EAVGLA 6HISGLECT0 / CARBOPOL
Protective efficacy very high. Good 
prevention of viraemia -  Potentially 
protective against abortion.
Protective efficacy high when VNAb titres 
are high. Less so when VNAb’s are low.
Duration of immunity, at least 6 weeks. 
Potentially long lasting
Duration of immunity is short. Could be 
improved -  adjuvants, dose regime.
Complete immune response: humoral, 
CTL’s, mucosal immunity.
Humoral immunity. CTL immunity less 
likely. No mucosal immunity although 
could be induced if used mucosal route.
Heterologous protection. Higher potential 
to protect against different strains.
Heterologous protection. Lower potential 
to protect against different strains.
Differential diagnostic test available 
(Peptide-1 ELISA), developed and 
thoroughly tested.
Differential diagnostic test available (N- 
ELISA). Further development and 
validation required.
Safety. Unknown. Demonstration of safety 
requires extensive and expensive studies.
Safety. Potentially very safe. Safety 
studies easier to perform.
Stability and ‘shelf life’. Dependence on 
cold chain. Lyophilisation could be a 
solution.
Chemically defined immunogen. 
Potentially very stable. Less dependent on 
cold chain.
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Indeed, the fact that EAVGlA infected animals were highly protected against 
infection in the absence of a strong VNAb response and the finding that EAV 
specific CTL responses could be detected in EAV-infected ponies suggested that 
cellular immunity could play an important role in protection against infection.
The contribution of CTL responses to clearance of EAV infection deserves 
further investigation and the deletion mutant virus would be a valuable tool for 
this. Comparing immune responses and immunity against virulent challenge of 
two groups of ponies vaccinated with live and inactivated EAVGlA would 
provide further evidence of the contribution of CTLs to protection against 
infection. Furthermore, analysis of EAV-specific antibody responses in the 
respiratory mucosa, specifically measuring IgG, IgA and VNAb in 
nasopharyngeal washes would indicate whether mucosal immunity was likely to 
have contributed to the efficient immunity observed in EAVGlA infected ponies. 
Indeed, it is becoming increasingly clear from other reports that the nature of 
induction site determines the type of immune response that is generated (Esser et 
ah, 2003). Thus, nasopharyngeal administration of EAVGlA possibly induced 
strong secretory IgA and CTL responses at the site of virus entry and local 
generation of memory T cells (both effector memory and central memory T cells) 
and provided immediate protection with a rapid recall response. Continuation of 
the work described in this project would help to characterise the mechanisms of 
induction of efficient antiviral immunity in the horse and the factors influencing 
these responses.
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6.5. Cellular immunity and persistence
During the course of EAV experimental infections conducted in the evaluation of 
6hisGLCCto vaccine, virus was isolated intermittently from the blood leucocytes 
of some control ponies between days 21 and 72 post-infection. Such long 
duration viraemias have been reported previously from EAV experimentally 
infected animals. For example Neu et al., (1988) isolated EAV from blood cells 
of EAV infected stallions and showed that in 6 animals, the duration of viraemia 
lasted for 21, 26, 33, 40 58 and 111 days after infection. This study used entire 
males unlike the experiments reported herein. However, EAV has also been 
isolated from blood leucocytes in two of 12 castrated male horses at days 30 and 
57 post-infection (McCollum et al., 1986). The persistent carrier state of EAV 
has been described only in the sexually mature male, in which the virus replicates 
in tissues of the urogenital tract, particularly the vas deferens and ampulla. The 
maintenance of this state appears to be dependent upon the secretion of 
testosterone. However, this does not exclude the possibility that other sites of 
persistence exist and that the male reproductive tract is a secondary persistent 
site, which has been seeded by white blood cells permanently infected with EAV. 
The male reproductive tract is an immunologically ‘privileged’ site where 
immunosupressive secretions (Anderson and Tarter, 1982) and predominance of 
CD8+ suppressor T-cells (Ritchie et al., 1984) may impede clearance of virus 
infection by the immune system. However, if anatomical sites of persistence 
existed other than the male reproductive tract, there would be several other 
potential mechanisms for immune evasion by EAV. For example, there is the 
potential for generation of CTL escape mutants, induction of CTL apoptosis or 
modification of cytokine profiles of responding lymphocytes to reduce the
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effectiveness of immune responses. Interestingly, PRRSV infections of pigs have 
been shown to persist for 3 or 4 months and they are not restricted to the male 
reproductive tract but involve lymphoid tissues of the oropharyngeal region. It is 
possible that after the onset of the VNAb response, EAV replication in the horse 
is restricted to specific cell types in lymphoid tissues until infection is finally 
cleared by CTLs. During this time, genetic variants with different biological 
properties might arise, a process already demonstrated to occur in the 
reproductive tract of stallions (Balasuriya et a/., 1999a), which could include the 
appearance of CTL escape mutants. The time required to finally control the 
infection would depend on various factors including capacity of the virus to 
infect tissues inaccessible to cells of the immune system and the genetic 
backround of the host, in particular the capacity to present EAV peptides to 
CTL’s (which depends on MHC-I. haplotype). The generation of CTL escape 
mutants is a mechanism employed by retroviruses such as equine infectious 
anemia virus (EIAV) and acquired immunodeficiency syndrome virus (AIDS) in 
humans (McGuire et al., 2002; Borrow et al., 1998).
The potential induction of apoptosis in bystander cells by EAV infection, already 
demonstrated in PRRSV infections in vivo, could result in protection from CTLs 
in infected monocytes-macrophages located in lymphoid tissues. Alternatively, 
expression of IE-10 could be upregulated in infected macrophages, as 
demonstrated in PRRSV infection of pigs (Suradhat et al., 2003), resulting in 
inhibition of inflammatory responses and diversion of the immune response from 
a Thl- towards a Th2-type regulatory response with the resulting decrease of 
CD8+ T-lymphocyte effector functions, i.e. cytolysis and IFN-y secretion.
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The new development of methods to evaluate CTL responses will increase our 
capability to understand how EAV is finally cleared from the infected horse and 
to determine the factors affecting virus persistence. CTL responses of 
persistently-infected and non-persitently-infected stallions could be compared 
directly to determine whether there is a deficit in this type of immune responses 
in the former animals. Also, nucleotide sequence analysis of isolates collected 
from long-term viraemic ponies infected with the EAVLP3A+ strain, available 
from the EAV vaccine efficacy studies, could be used to determine the 
heterogeneity of the virus populations present in the samples collected. Of 
particular interest would be the identification of differences between these and 
the original inoculated virus and to determine the speed with which new 
mutations arose. Some of these mutations could cluster around the well-known 
VNAb epitopes or CTL epitopes. Identification of the latter was an objective of 
the present project.
6.6. Identification of viral proteins serving as targets for CTL’s.
The objective of the last part of this project was the establishment of methods to 
identify proteins serving as targets for EAV specific CTLs. Target cells 
transiently expressing EAV0RF7 were used in the standard CTL assay 
previously described (Chapter 4). Unlike plasmid transfection, baculovirus 
transduction appeared to be a suitable method to achieve protein expression in a 
high proportion of EDC. The levels of expression of EAV N antigen in 
transduced EDC, which occurred without the loss of their original morphology, 
suggested a priori that this method was adequate to identify CTL targets. Time 
and resources constraints limited the number of experiments performed but
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sufficient progress was made to indicate that this expression technique has good 
potential for examining EAV CTL targets.
An interesting finding was the ease with which heterologous expression could be 
achieved using this technique. The generation of recombinant baculovirus 
required the construction of a ‘chimeric’ baculovirus shuttle vector containing a 
large fragment of the pcDNA3 / 0RF7 recombinant plasmid. This laborious 
process was also used to generate a baculovirus expressing EAV0RF5. 
However, some other experiments were performed to simplify the cloning 
strategy in order to generate recombinant baculoviruses for mammalian cell 
expression and promising results were obtained. A second ‘chimeric’ shuttle 
vector was constructed by cloning the A’ tailed Nrul-Smal fragment of the pcD / 
0RF7 plasmid into the BamHI restriction site of pVL1393 instead of the Smal 
site. This BamHI site was previously disrupted by filling the 5’ overhangs of the 
digested plasmid using Klenow polymerase and T’ tails added to the 3’ ends. By 
doing this, the only BamHI restriction sites present in the baculovirus shuttle 
vector are those flanking the EAV0RF7 allowing the quick insertion of any ORE 
containing BamHI restriction sites without the need to clone first the gene of 
interest in pcDNA3 and subclone the mammalian expression cassette into the 
pVL1393 plasmid.
The high levels of expression achieved in EDC make baculovirus transduction a 
potential effective vaccination technique for horses. Intramuscular injection of a 
recombinant baculovirus containing the pseudorabies gB gene under the control 
of the mammalian GAG promoter induced an antibody response in mice (Aoki et
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al., 1999). However, during our studies, co-infection of cells with recombinant 
vaccinia MVA / T7 was necessary for expression of the recombinant gene. 
Further work is necessary to determine why N expression was inefficient in the 
absence ofM V A / T7 co-infection.
Although it is still possible to use baculovirus transduction to determine CTL 
targets, is worth considering alternative approaches for expressing EAV genes in 
EDC. Vaccinia virus has been used extensively to express heterologous genes in 
mammalian cells and used in multitude of applications, including CTL assays. 
The use of low cytopathogenic vaccinia strains such as MVA or the use of other 
poxviruses such as fowl pox or canary pox is much preferred for generating 
targets for CTL assays. Some recombinant vaccinia viruses encoding EAV 
ORF’s have been made using the WR strain and can be made available by 
Professor Rottier to test whether these can be applied in the CTL assay. Other 
suitable expression systems include retrovirus expression vectors which have 
been used succesfully to map CTL targets of equine infectious anemia (Lonning 
et al., 1999) or alphavirus expression systems such as those based on Sindbis, 
Semliki Forest or Venezuelan Equine Enchephalitis viruses (Bennet, 1999; Hahn 
et al., 1992; Balasuriya et al., 2000).
Identification of the viral gene products that provide CTL targets will provide 
additional information about virus-host interactions during EAV infection in the 
horse. One goal would be the induction of protective immunity after in vivo 
expression of CTL epitopes using DNA or live virus vaccination. This would 
provide valuable information on the relative contribution of cellular immunity to
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protection against infection. Also, incorporation of these proteins in marker 
vaccines may increase the efficacy of such vaccination approaches. As alluded to 
earlier, identification of CTL epitopes would help to elucidate whether genetic 
mutations generated during infection represent an immune evasion mechanism of 
EAV.
For complete interpretation of data generated from CTL epitope mapping 
experiments it is essential to know the MHC-I backround of the animals from 
which effectors and targets have been obtained. This has been one of the major 
difficulties encountered during the course of these studies. MHC-I typing in 
horses has been performed by other workers using specific equine sera obtained 
from primiparous pregnant mares (since these develop antibodies against the 
paternal MHC-I antigens carried by the conceptus). These reagents are scarce 
and at the time the experiments were performed it was not possible to obtain 
them. It is essential that for this work to progress efficiently in the future, 
effectors and target cells must be derived from animals of known MHC-I 
haplotype.
In this research project two novel approaches have been used for the generation 
of marker vaccines against EAV and methods to evaluate cytotoxic T 
lymphocyte responses developed. The essential findings of the thesis provide 
new and interesting information about EAV vaccinology/immunology that now 
provide the basis for rational approaches to be undertaken to disease prevention.
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Figure 6.1. Serological responses following 6hisGLecto vaccination and subsequent 
to challenge. Vaccine doses were 0 qg (placebo), 4 qg (group 1), 8 qg (group 2) and 
32 qg (group 3).
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Figure 6.2. Responses of 3 groups of ponies vaccinated with 4 pg (Group 1), 8 
pg (Group 2) or 32 pg (Group3) of 6hisGLecto vaccine and a pony group 
injected with a placebo to EAVLP3A+ challenge. Mean rectal temperatures 
(a), mean virus titres from nasopharyngeal secretions (b) and numbers of 
ponies presenting viraemia per day (c) are shown.
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